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Noble metal nanostructures have seen a steady increase in biomedical application over the last 
several decades; new diagnostic and therapeutic modalities are under intense investigation. Many 
of these applications are possible because of post-synthetic modifications to the particle surface. 
These modifications take a variety of forms and can significantly affect the pharmacokinetics of 
these particles. In this work, various surface modifications were investigated. Particle 
agglomeration, which occurs when particle surfaces remain in contact, can significantly affect 
the toxicity and efficacy of a nanomedicine. Darkfield microscopy and single-particle ICP-MS 
were developed as complementary methods to detect agglomeration in blood, with the long-
range goal being to establish regulatory mechanisms for nanomedicine. Two novel constructs 
were developed for such theranostic applications. A hydrophobic photosensitizer was introduced 
to the surface of poly(ethylene glycol), and its potential was investigated as a photothermal 
transducer, a photoacoustic contrast agent, and as a delivery vehicle. Relative to the free drug, 
the construct was found to increase tumor accumulation of the drug in mice and to make the drug 
more effective as a photodynamic therapeutic. Further surface modification and laser irradiation 
were able to impart additional control of the release of the drug from the conjugate. Noncovalent 
interactions were also applied to load and deliver a hydrophilic antibiotic using polydopamine-
coated Au nanostructures as a platform. This construct was conjugated with a targeting agent and 
was then shown to be effective at killing methicillin-sensitive and –resistant strains of S. aureus. 
Finally, the effect of the anchoring group on AuCu3 nanorod catalysis was investigated using 
several model reactions and surface ligands, and it was determined that more strongly bound 
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Chapter I. Introduction 
Nanomaterials are typically defined as materials with some dimension in the 1-100 nm range and 
possess unique properties due to their size. These properties exist between molecular properties 
and bulk properties. Nanomaterials can be made out of a variety of components including metals, 
oxides, ceramics, polymers, lipids, organic dendrimers, and even aggregates of proteins or small 
molecules. Gold, silver, and copper nanoparticles exhibit brilliant coloration due to the localized 
surface plasmon resonance (LSPR). The conduction electrons in a small metal particle oscillate 
in resonance with particular wavelengths of light, resulting in absorption and scattering of some 
wavelengths and transmission of others. These particles were (unknowingly) used to stain glass 
for centuries, with colloids forming during the casting of the glass. The Lycurgus Cup, a fourth 
century Roman relic currently housed in the British Museum, is made of dichroic glass that 
contains Au nanoparticles, so it appears red or green depending on the direction of the incident 
light.  
Noble metals have a long history of biomedical use. Ancient Indian, Chinese, and Egyptian 
medicine treated arthritis through the oral use of a gold-salt based paste.1, 2 Ultimately the salts 
formed colloids in situ in the synovial fluid.3 More recently, intrasynovial injection of AuNPs 
has been shown to reduce inflammation and arthritis score.4 This effect has been attributed to the 
interaction between cysteines in pro-inflammatory cytokines and the Au surface. Signaling 
proteins conjugate to the particle surface, reducing the inflammatory signal and thereby the 
inflammation.4 Gold-based therapeutics were also unsuccessfully applied to treat tuberculosis, 
lupus, epilepsy, and migraines.2 Similarly, silver nitrate was used to treat wounds, as a purgative, 
and to treat ocular infections,5 and many ancient civilizations transported water in Ag containers, 
unknowingly tapping into the antimicrobial properties of the metal.  
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Modern study of Au nanoparticles began with Michael Faraday in 1857. Faraday synthesized 
extremely stable ruby-red gold colloids6 that are still on display in the Faraday Museum. The 
understanding and application of these materials has advanced significantly in the intervening 
years. Tight morphological control has been accomplished through the development of advanced 
synthetic methods. Additional metals and organic materials can be conjugated to the particles to 
increase functionality. The systems can even be engineered to respond to environmental 
changes.7 In this chapter the role of the nanoparticle surface is considered in the context of 
biomedical applications. The origin, nature, and application of the optical properties of noble 
metal nanostructures is considered in depth. Surface modification techniques are then discussed, 
with emphasis on potential avenues for drug delivery. Finally the role of the surface in toxicity, 
biodistribution, and catalysis is considered.  
The Localized Surface Plasmon Resonance (LSPR) 
When metal nanomaterials are appreciably smaller than the wavelength of incident light, the 
oscillations of the conduction electrons resonate with the incident electromagnetic wave. This 
effect is known as the localized surface plasmon resonance (LSPR),8 illustrated in Fig. 1A. 
Adjusting the solvent or the surface coating will cause a shift in the LSPR position because the 
dielectric constant around the particle has changed. This subtle shift is the basis of many 
plasmon-based sensing modalities. For biomedical applications, the various components in an 
organism cause opacity. The “tissue-transparent window” is the spectral region where light 
penetration is the greatest. The first spectral window ranges between 650 and 900 nm;9 the 
second NIR window exists between 1,000 and 1,350 nm.10 As such, shifting the LSPR to these 
regions will allow for greater optical penetration for in vivo work. 
The morphology of a nanostructure plays an important role in the LSPR position.11 Discrete 
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dipole approximation (DDA) has become a popular method for calculation of the LSPR of 
advanced geometries, which have shown remarkable agreement with experimental results.12 A 
variety of advanced Au structures exist;13 the four most commonly studied complex geometries 
are nanorods, nanocages, nanoshells, and agglomerates of spherical particles. A robust synthetic 
route for Au nanorods was developed concurrently by Murphy’s14 and El-Sayed’s15 groups. As 
the aspect ratio (length: diameter) of the rods increases, a second LSPR peak emerges (Fig. 1B). 
As the length of the rod increases, the resonant energy decreases, so the LSPR shifts to longer 
wavelengths (lower energy).16 Xia’s group developed the synthesis of gold nanocages whereby 
Ag nanocubes are synthesized as a sacrificial template; Au salt is added to the colloids, and a 
galvanic replacement occurs, which gradually leads to deposition of Au on the surface and 
dissolution of Ag resulting in a hollow structure. Increasing the amount of gold redshifts the 
LSPR and decreases wall thickness (Fig. 1C).17 Au nanoshells, first developed by Halas’s group, 
are made by coating a thin film of Au on a dielectric core nanoparticle. Increasing the deposition 
of Au increases the thickness of the shells, blueshifting the LSPR (Fig. 1D).18 This phenomenon 
is similar to AuNC wall thickness, but synthetically proceeds in the opposite direction. 
Agglomeration also results in redshifting of the LSPR as a plasmon from the ensemble of 




Fig. 1. (A) Schematic illustration of the interaction of electromagnetic wave with a metal 
nanosphere, resulting in the LSPR. Illustration and photograph of (B) Au nanorod, (C) Au 
nanocage, and (D) Au nanoshells with varying morphologies. Adapted with permission from (A) 
reference 8 and (B-D) reference 11.  
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The LSPR contains both an absorption and a scattering component. Absorption is the process by 
which the photon energy is absorbed into the nanomaterial’s overall electronic structure. Several 
interesting phenomena arise as a result of absorption. The most well-studied is photothermal 
heating, whereby the excitation energy is released as thermal energy, resulting in localized 
heating.20, 21 Additionally, absorption by the LSPR can cause quenching of nearby fluorophores, 
in a Forster type (i.e. dipole-dipole) process,22 though the process can occur directly to the metal 
surface in the absence of an LSPR.23 The quenching efficiency of plasmonic particles has been 
shown to have a 1/d6 distance dependence.24 Absorption can also result in photoluminescence 
(emission) by the particle itself, which is distinct from scattering in that the photon is absorbed 
by the LSPR and emitted after a short period of time, and the wavelength of the emitted photon 
is shifted relative to the exciting light. For metallic structures, d band holes are generated by the 
excitation. These holes recombine with sp electrons in the metal releasing a particle plasmon that 
then decays radiatively.25 A milestone efficiency of 10-4 (i.e. 1 photon emitted for every 104 
absorbed) has been achieved using nanoparticles, while emission from bulk metals is practically 
nonexistent (~10-10).26 The luminescence efficiency of this process is quite low, but the LSPR 
enhances photoluminescence by increasing the frequency of excitations.  
Scattering is the process by which the incident photon is reflected in a random direction after a 
nearly instantaneous interaction with the particle. Alternatively, plasmonic scattering generates 
regions of very high electromagnetic field strength in the local area of a nanoparticle. The 
plasmon results in scattering of resonant light, so plasmonic nanomaterials can be readily 
detected by their increased scattering at the LSPR.21 Additionally, the LSPR can enhance the 
optical properties of nearby and adsorbed dye molecules. The most-studied example is surface 
enhanced Raman spectroscopy (SERS). Raman scattering by molecules is an inelastic process 
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wherein a molecule is excited to a virtual state (between two electronic states, in nonresonance 
Raman), changes vibrational states, and relaxes by emission of a photon slightly shifted from the 
incident (Rayleigh) wavelength. 27 Raman cross sections are extremely small, but the plasmon 
acts like a two-way antenna: enabling more light flux on a single molecule thereby increasing the 
number of transient absorptions and amplifying the scattered Raman signal.28 This process is 
called electromagnetic enhancement.29 Electromagnetic enhancement30 has also been used to 
enhance fluorescence of local dye molecules.31 The LSPR enhances emission by increasing the 
excitation rate, thereby increasing the frequency of excitations; by increasing the rate of radiative 
decay, causing emission to occur more readily from the excited state of the fluorophore; and by 
engaging in far-field coupling with the emitted photon, increasing the likelihood of emission.32 
Interestingly, the LSPR can enhance both singlet and triplet state phenomena, such as 
phosphorescence,33 and singlet oxygen generation,34 by stabilizing the excited state. This 
phenomenon has also been shown to enhance the phosphorescent signal from the decay of singlet 
oxygen leading to lower detection limits.35 Various studies have further demonstrated that the 
maximum stabilization of the triplet state can be achieved by matching the LSPR with the 
wavelength of phosphorescent emission.36 
The properties of the LSPR have led to development of many sensing, imaging, diagnostic, and 
therapeutic modalities.7 Darkfield microscopy makes use of the resonance scattered light from 
nanomaterials and can be readily used to identify the location of particles in a biological 
sample.37 Similarly, multiphoton luminescence can be used to generate a signal from 
nanoparticles while reducing the background of biomolecules for easy identification.38 
Additionally, mapping the Raman signal of a sample can be used to identify SERS active 
substrates. Photoacoustic imaging results from absorption by the nanoparticle followed by 
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thermal relaxation, which generates acoustic waves that can be readily detected.39 The generation 
of heat has also been used to induce cell death in both tumors40 and bacteria.41 This heat has also 
been harnessed for a variety of drug delivery applications (vide infra). 
Particle Surface Effects on Biomedical Properties 
One of the great challenges of nanomedicine is successful delivery to the desired site. Two 
primary mechanisms can be used to deliver materials: passive targeting and active targeting; the 
primary distinction between the two is the use of targeting moieties. Passive targeting relies on 
the natural mechanisms at play within an organism to deliver the material. The best known 
example is the enhanced permeability and retention (EPR) effect observed in tumors.42 The leaky 
vasculature in a tumor allows for increased uptake of nanomaterials, while the inflammation 
associated with a tumor leads to increased retention time in the interstitium.43 Active targeting 
makes use of targeting moieties on the particle surface to provide specific interactions; small 
molecules, peptides, antigens, aptamers, and antibodies have all been used as targeting moieties 
with varying success.44 Active targeting leads to a significant increase in tumor uptake as well as 
a decrease of particle concentration in other organs.45 Because of the high local density of the 
moieties on a particle’s surface, multiple receptors can bind to a single particle, which causes 
invagination of the membrane and formation of an endosome.46 Even nontargeted particles are 
typically taken up via endocytosis and reside in small vesicles within the cytosol.47 It was 
demonstrated using MDA-MB-435 cells that 30 and 60 nm Au nanoparticles will have a 
significant increase in uptake with the use of a targeting ligand while 15 and 100 nm particles did 
not show significant changes in uptake.48 Additionally, cell penetrating peptides can be 
conjugated to the surface, which results in particles passing through the membrane to the cytosol 
without being encapsulated in a vesicle.49  
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Careful engineering of the surface, however, can be readily compromised by the formation of a 
protein corona in a biological environment, like the bloodstream. Two types of protein corona 
exist: the soft corona and the hard corona. The soft corona forms almost immediately, but is 
characterized by the rapid adsorption and desorption of proteins on the surface. Because of the 
transient nature of this binding, the soft corona tends to not disrupt the specific interactions 
engineered into a material.50 The hard corona, however, consists of relatively permanently bound 
proteins on the surface.51 The hard corona develops over an extended period of time as the 
tightly binding proteins replace proteins in the soft corona.52 The hard corona is not readily 
removed from the particle surface and it can significantly affect the particle’s fate. For instance, 
adsorbed proteins can disrupt the targeted interactions at a particle surface, leading to a loss of 
active targeting; proteins affect the surface charge and particle size, which influences cellular 
uptake.53 Additionally, adsorption of proteins like IgG and complement factors will lead to 
phagocytosis by the immune cells,54 causing the particles to be sequestered in the spleen and 
liver. The association constants for particular proteins change with particle morphology and 
surface chemistry, indicated the protein corona has a highly variable makeup.55 The variety and 
variability of the interactions between proteins and nanoparticles complicates predictions and 
generalizations. 
The particle surface also plays a significant role in the organismic toxicity of nanomaterials.56 At 
present, toxicity studies suffer from high variability across experimenters. Dosages, size 
constraints, and even initial cell counts vary widely.56 Similarly, the protein composition of the 
media used affects the corona composition, thereby affecting particle uptake and toxicity.56 As 
such, careful study of the toxicity of these materials is still needed. The surface coating may 
actually be the origin of toxicity, rather than the particle itself, as was the case with surfactant- 
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coated Au nanorods.56 It has been shown that particle toxicity can be dependent on the cell line 
used and even the ligand used to target the same receptor.57 One interesting pattern that has been 
demonstrated is the increased level of toxicity associated with nanoparticles presenting a cationic 
rather than an anionic surface.58 Similarly, heat responsive, poly(N-isopropylacrylamide) coated 
nanoparticles have shown higher toxicity than their poly(ethylene glycol) coated counterparts.59 
The presented features of the surface play a significant role in any toxicity exhibited by 
nanoparticles.60  
Agglomeration  
Particle agglomeration is an important surface consideration, as agglomeration affects the LSPR 
position and the pharmacokinetic profile of the particles. Agglomeration results from the high 
surface energy of nanoscale particles.61 Reducing the surface area of a particle is energetically 
favorable, which can be accomplished by putting the surfaces together. Agglomeration is 
prevented through the use of electrostatic and steric stabilization. Electrostatic stabilization is the 
result of charged moieties on the surface of one particle repelling the like charges on the surface 
of another particle. Steric stabilization results from the surface coating on a particle physically 
interfering with the metal surface of two particles interacting.62 Agglomeration occurs when 
these stabilization mechanisms are negated by environmental conditions.  
Agglomeration can have significant effects on nanoparticle pharmacokinetics. For instance, 
particle agglomeration was shown to decrease uptake by HeLa cells and A549 cells but increase 
uptake by MDA-MB-435 cells.63 Additionally, it has been shown that monocyte-like 
macrophages will uptake individual particles, while more mature macrophages will cause 
particle agglomeration during uptake.64 Another size dependent phenomenon is nanomaterial-
induced endothelial leakage (NanoEL). Nanomaterials bypass the cell membrane by disrupting 
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adherens junctions; agglomerates leak less efficiently from cells.65 The EPR effect is also heavily 
size dependent, with excessively large particles accumulating poorly within the tumor.66 It is 
worth noting that particles can be engineered so they function properly upon agglomeration in a 
particular environment.  
Surface Modification  
The optical properties of plasmonic nanostructures are quite robust. Particles composed of noble 
metals also exhibit high stability and robust surface chemistry. In particular, the Au-thiol bond is 
extremely strong, on the order of a hydrogen bond.67 Whitesides’s group performed much of the 
pioneering work in self-assembled monolayers on gold films using alkanethiols.68 Interestingly, 
disulfides and thioethers and even amines can also be used to functionalize the Au surface.69 
Thiol moieties can be introduced to a wide variety of molecules, enabling nearly limitless 
possibilities for ligands and functional groups (Fig. 2). The binding strength can be used to 
modulate the surface coverage and release of the ligand.70 Additionally, mixed monolayers can 
be generated that include multiple components in controllable compositions.71 PEG is one of the 
most common surface ligands because of its ability to repel proteins and increase circulation 
lifetimes.72 Heterobifunctional PEG allows the potential for a thiol to serve as an anchor to an Au 
nanoparticle and the exposed terminus to serve as a functional handle for further conjugation. 
Indeed, many fluorophores, therapeutics, markers, and targeting moieties have been conjugated 
to the surface of various nanostructures. The surface of a material is extremely important for in 
vivo and in vitro studies, as the biological response is dictated by what the cell perceives, and 




Fig.2. Illustration of molecules that can be conjugated to the surface of Au nanoparticles with 





Direct conjugation of drug molecules to the surface, without the use of a linker molecule, has 
been demonstrated in a variety of systems. Antibiotics have been directly conjugated to AuNP 
surfaces, typically through available amine groups.73 The close-packing of vancomycin on the 
AuNP surface mimicked the mechanism of action of the drug, fundamentally removing the 
entropic contribution to the activation. As such, this conjugate more readily enabled the 
antibiotic to oligomerize at the cell membrane, lowering the MIC for the antibiotic.74 Similarly, 
cefaclor,75 quinolone,76 aminoglycosides (-mycins),77 ampicillin,78 and even pyrimidines (which 
lack antibacterial activity),79 conjugated AuNPs have shown efficacy against both gram negative 
and gram positive bacteria. Photosensitizers have also been successfully conjugated and show a 
4-fold decrease in MIC relative under white light illumination.80 AuNPs conjugated with vitamin 
E derivatives have been demonstrated as a powerful radical scavengers and antioxidants.81 
Conjugation with a mimetic HIV fusion inhibitor led to a significant decrease in viral activity in 
cultures, because the high density of the peptide at the surface more effectively oligomerizes 
with the virus.82 Antigens can also be conjugated to the surface of nanoparticles and introduced 
to the immune system, which increases antibody production enabling the potential for 
immunization without the use of deactivated or live viruses.83 Rather than direct conjugation to 
the surface, a nearly limitless library of coupling techniques exist that can covalently link a 
surface bound molecule to a drug molecule of interest.84  
Noncovalent conjugation 
A number of strategies have been utilized to noncovalently tether drugs to metal nanoparticles. 
Electrostatic interactions can be used to encapsulate the drug within polyelectrolyte layers, and 
additional wrapping can lead to high loading and multiple shell layers.85 These systems utilize 
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oppositely charged polymers and ligands to incorporate the ligand between the particle surface 
and the polymer shell. Lipids can be used to encapsulate drugs through the use of vesicles86 and 
liposomes,87 though these methods suffer from limitations regarding the stability of the lipid 
structure and the loading capacity of the system. Alternatively, a “hydrophobic pocket” can be 
used to drive molecules toward the particle surface through hydrophobic interactions.88 These 
hydrophobic interactions are increased with increasing ionic strength, making these conjugates 
particularly stable in saline solutions. Au nanostructures can be embedded in heat-responsive 
matrices.89 Similarly, replacing the bulky matrix with a monolayer coating has demonstrated the 
capability for on-demand release from the interior of hollow, porous Au nanocages (AuNCs) 
with the polymers (e.g. pNIPAAm derivatives) serving as a gate at the surface pores.90, 91 
Plasmonic nanostructures also show great promise for gene delivery and gene therapy. The two 
primary conjugation strategies for genetic material are to anchor the terminus to the surface so 
the oligonucleotide is roughly perpendicular to the surface or to use electrostatic interactions 
between the anionic, phosphate backbone and cationic particles, which results in the strand being 
roughly parallel to the surface. The two most commonly delivered genetic materials are 
deoxyribonucleic acid (DNA) and small interfering ribonucleic acid (siRNA). AuNPs provide a 
significant increase in transfection efficiency relative to free DNA because they are resistant to 
DNAses92 and can be targeted to the nucleus.93 The LSPR can be used to heat a construct, 
causing melting of double-stranded DNA, which releases a single strand that can be used for 
translation.94 Alternatively, siRNAs, RNAs that help control protein expression levels by turning 
various functions off and on, and can also be delivered using AuNP conjugation.95  
Controlled release systems for drug delivery have been developed and studied for more than 
three decades.96 Many efforts have been devoted to the fabrication of “smart” delivery systems 
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that integrate responsive macromolecules with Au nanostructure platforms.97 These systems 
respond to changes of the intrinsic, physiological environment such as pH, temperature, or 
concentration of a biomolecule. Because of the LSPR, Au nanostructures enable the delivery 
systems to respond to external stimuli, particularly light. Halas’s group first demonstrated that 
the photothermal effect of Au nanoshells initiated a conformational change to a drug-loaded 
hydrogel matrix, provoking release of the payload.98 Xia’s group shrank the size of the system to 
below 100 nm by using a monolayer of heat-responsive polymer or phase-change material to 
lock the molecules inside the Au nanocage (AuNC).90, 99 The release of the molecules from the 
nanocages could be both temporally and spatially controlled by a NIR laser. Additionally, Li’s 
group photothermally released doxorubicin from poly(ethylene glycol) (PEG) coated hollow Au 
nanoshells,100 and Murphy‘s group demonstrated that release of dye molecules from layers of 
polyelectrolytes wrapped around Au nanorods could be achieved with NIR light.101 Further, a 
number of systems have utilized photothermal response of DNA to control the release of 
molecules that are grooved on the DNA strands.102 103  
In Situ catalysis 
Due to its high surface energy, the nanoparticle surface can be harnessed for catalysis of organic 
reactions in aqueous media. Stabilizing ligands can leave atomic vacancies on the particle 
surface that can be quite catalytically active.104 Noble metal nanoparticles have been 
demonstrated for a wide variety of reactions, though most of these rely on the presence of Pd or 
Pt.105 There are a handful of Au, Ag, and Cu reactions that have been demonstrated with 
nanostructures.104 Much catalytic activity derives from the crystal facets exposed at the surface, 
as such particle design is an important factor in designing nanocatalysts.106 For instance, azide-
alkyne cycloaddition, which is typically catalyzed by CuI salts, has been achieved on the Au 
15 
 
(111) surface.107Additionally, the surface ligand plays an important role in catalytic activity, with 
thiol groups having been shown to inactivate certain Au catalysts.108 Additionally, the LSPR can 
be harnessed to aid in catalysis. Aside from localized heating, which would increase reaction 
rates, the LSPR can also generate a “hot” electron, which can be a reactive partner during 
reactions such as nitro coupling to yield a di-azo group.109 Efforts are being made to use 
nanoparticle catalysts for in situ activation of prodrugs at the target site.  
Outlook 
The surface of a nanoparticle is a crucial consideration for biomedical applications. The surface 
dictates how the particle will be distributed, what cells it interacts with, and its toxicity profile. 
Additionally, the surface electrons give rise to the optical properties of noble metal materials, 
which have been harnessed for a wide range of diagnostic and therapeutic modalities. In 
particular the surface can be used to deliver chemotherapeutics. This dissertation seeks to 
understand and manipulate the surface of noble metal nanoparticles toward theranostic ends. In 
Chapter 2, a series of complementary methods are developed for the detection of particle 
agglomeration in blood. The most valuable data was provided by darkfield microscopy with 
hyperspectral imaging and single-particle inductively-coupled plasma mass spectrometry. 
Chapters 3 and 4 focus on the development, characterization, and application of Au nanocages 
coated with poly(ethylene) glycol and loaded with a photosensitizer for photodynamic treatment 
of tumors. The conjugate was found to be more effective in vivo than the free drug, and the 
release rate can be controlled with surface modification or laser irradiation. Chapter 5 covers the 
development, characterization, and application of Au nanocages coated with polydopamine, 
loaded with an antibiotic, and conjugated with a targeting molecule to treat planktonic 
Staphylococcus aureus. This system was shown to effectively kill both methicillin-sensitive and 
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methicillin-resistant strains through the synergy of photothermal and antibiotic therapy. Finally 
in Chapter 6, the catalytic properties of AuCu3 nanorods are investigated using several model 
reactions. The anchoring group of the ligand on the particle surface was found to significantly 
affect the catalytic properties of the particle. 
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Chapter II. Rapid Determination of the Agglomeration Status of Plasmonic 
Nanoparticles in Blood* 
Abstract 
Plasmonic nanomaterials as drug delivery or bio-imaging agents are typically introduced to 
biological systems through intravenous administration. However, the potential for agglomeration 
of nanoparticles in biological systems could dramatically affect their pharmacokinetic profile and 
toxic potential. Development of rapid screening methods to evaluate agglomeration is urgently 
needed to monitor the physical nature of nanoparticles as they are introduced into blood. Here, 
we establish novel methods using darkfield microscopy with hyperspectral detection (hsDFM), 
single particle inductively-coupled plasma mass spectrometry (spICP-MS), and confocal Raman 
microscopy (cRM) to discriminate gold nanoparticles (AuNPs) and their agglomerates in blood. 
Rich information about nanoparticle agglomeration in situ is provided by hsDFM monitoring of 
the plasmon resonance of primary nanoparticles and their agglomerates in whole blood; cRM is 
an effective complement to hsDFM to detect AuNP agglomerates in minimally manipulated 
samples. The AuNPs and the particle agglomerates were further distinguished in blood for the 
first time by quantification of particle mass using spICP-MS with excellent sensitivity and 
specificity. Furthermore, the agglomeration status of synthesized and commercial NPs incubated 
in blood was successfully assessed using the developed methods. Together, these complementary 
methods enable rapid determination of the agglomeration status of plasmonic nanomaterials in 
biological systems, specifically blood. 
 
*Published: Jenkins, S.V.;  Qu, H.; Mudalige, T.; Ingle, T.; Wang, R.; Wang F.; Howard, P.C.; 




Nanomaterial-containing commercial products are under intense development by the 
pharmaceutical industry for imaging, diagnosis, prevention, and treatment of disease [1]. The 
safety of these new, nanomaterial-containing products remains a concern to scientists and the 
public [2]. The toxicity of nanomaterials depends strongly on their physiochemical properties 
(e.g. size, size distribution, shape, surface charge, crystal structure, hydrophobicity, surface 
reactivity, solubility, aggregation and purity) and material composition itself [3-5]. The United 
States Food and Drug Administration (FDA) has developed a nanotechnology regulatory science 
program to enhance research in nanomaterial characterization, in vitro and in vivo modeling, and 
product-focused disposition and toxicity [6]. One priority is the development of the analytical 
tools to detect and characterize nanomaterials in commercial products, food matrices, and 
biological systems. The challenge facing biomedical research is the poor understanding of the 
agglomeration status and biological fate of nanomaterials once they are introduced into the blood 
stream. 
Gold nanomaterials (GNMs) are particularly appealing candidates as new diagnostic and 
therapeutic agents because of their relative bioinertness, tightly controllable morphology, facile 
surface functionalization, and unique optical properties [7-10]. Some GNM-based medicines are 
in clinical trials. As an example, Aurimune® is a nanomedicine with tumor necrosis factor 
(rhTNFa) covalently conjugated to PEGylated gold nanoparticles that has been approved for 
phase II clinical trials for cancer therapy [11]. AuroLase®, which is also in clinical trials, utilizes 
gold nanoshells and laser technology as a new photothermal treatment modality for refractory 
head and neck cancer [12]. In practice, GNM-based medicine is generally administered 
intravenously, i.e. directly into the blood stream. Blood is a complex fluid with significant 
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concentrations of proteins, salts, and blood cells. Nanoparticles interact with blood proteins; 
adsorption onto the materials' surface results in the formation of a protein corona [13,14]. The 
change in surface properties introduced by blood ionic strength can induce nanoparticle 
agglomeration [15], and thus significantly alter the cellular interactions, biodistribution [16], and 
toxicity profile of the particles [17]. Additionally, nanomaterials retard cell motility [18], and 
nanomaterial induced endothelial leakage (NanoEL), wherein nanomaterials bypass the cell 
membrane by disrupting through adherens junction, has also shown a strong correlation to the 
hydrodynamic size of the particle [19]. Due to their potential for agglomeration, in situ 
monitoring of nanoparticles in blood is crucial to fully understand in vivo effects of GNM-
materials targeted for human theranostics. 
There are many well-developed methods to characterize GNMs; however, characterizing GNMs 
in blood is complicated by the complex environment, e.g. plasma proteins and various blood 
cells. Electron microscopy (EM) is considered the most accurate method to measure the size of 
nanoparticles and the most widely used method of assessing nanoparticle morphology. However, 
EM requires considerable sample manipulation, which introduces artifacts; it provides only a 
static image of the GNMs, typically in thin, dry sections of tissues or matrices (e.g. 50-100 nm), 
and cannot readily distinguish agglomerates from primary particles located in close proximity 
[20-23]. Recently, cellular uptake of 30 nm, spherical AuNPs has been visualized using scanning 
transmission electron microscopy (STEM) imaging of liquids, yet at this point the technique 
suffers from low resolution [24]. Chromatographic techniques, such as size-exclusion 
chromatography, ultracentrifugation, and electrophoresis, have been shown to separate primary 
and agglomerated nanoparticles based on shape, size, or charge [25]. One considerable 
disadvantage is that these techniques often require extensive sample preparation, which may 
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affect particle agglomeration status. Dynamic light scattering (DLS) has been used to estimate 
particle concentration in blood [26]; however, DLS is limited due to (1) its requirement that the 
blood cells to be lysed prior to measurement, which could affect the agglomeration status of 
nanomaterials; (2) the presence of proteins and cells in blood interferes with nanoparticle signal; 
and (3) larger particles which are overrepresented in polydisperse samples [27]. UV-Vis and 
Raman spectroscopy can readily distinguish primary and agglomerated plasmonic nanoparticles 
[28,29], but the signal is compromised by the extremely high optical density and opacity of 
blood. Accordingly, we are unable to find a simple and robust methodology for in situ 
characterization of nanoparticle agglomeration in blood and other complex biological 
environments. 
In this work, complementary and rapid in situ methods have been developed to monitor the 
agglomeration status of plasmonic nanoparticles in ex vivo blood. These methods include 
darkfield microscopy with hyperspectral imaging (hsDFM), confocal Raman microscopy (cRM), 
and single particle inductively-coupled plasma mass spectrometry (spICP-MS). The first two 
methods are based on the optical properties of GNMs, that is, the localized surface plasmon 
resonance (LSPR) [30]. The LSPR is extremely sensitive to particle morphology with 
agglomeration of GNMs resulting in a shift of the LSPR to lower energy [31]. The hsDFM can 
monitor this shift of scattered photons from GNMs, thereby distinguishing light scattered by the 
cellular environment from that scattered by nanoparticles [32-36], and this instrument has been 
used to distinguish macrophage maturity based on silver nanoparticle (AgNPs) uptake [37]. 
Scattering also gives rise to enhancement of the fluorescence and Raman scattering properties of 
molecules close to the GNMs [38]. The areas of high curvature or between adjacent AuNPs at 
agglomeration sites create localized “hot spots” that enhance Raman signals, similar to a 
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roughened metal surface [38], with enhancement factors that can be 108 or greater [39]. 
Surface enhanced Raman spectroscopy (SERS) has been used to identify circulating tumor cells 
in blood [40] and detect tumor cells in vivo [41], as well as a wide-range of other chemical 
detection and sensing applications [42,43]. We have applied SERS via cRM to directly monitor 
nanoparticle agglomeration as a label-free detection method in this study. 
In addition to the optical techniques, spICP-MS provides a high-resolution technique to detect 
individual particle events for characterization of a variety of engineered nanomaterials [44]. 
Unlike traditional ICP-MS, which provides bulk elemental analysis of homogenized metallic 
species, spICP-MS provides a measure of individual particles in suspension. At sufficiently low 
particle concentrations, particles are introduced individually for atomization and ionization in the 
plasma, creating a packet of ions that are detected as a discrete signal. This quantifiable spike in 
intensity due to single particle events enables individual nanoparticles to be distinguished from 
the background ionic current [45]. The signal intensity is proportional to the number of atoms in 
an individual event, so larger particles produce higher signal intensity. Similarly, particle 
agglomeration can be detected by monitoring the increase in signal intensity [46]. By collecting a 
large number of data points, the particle size and distribution can be determined [44,46-48]. 
In this report, we have validated and applied the spICP-MS technique to analyze the 
agglomeration status of nanoparticles in blood as a complement to the optical methods. AuNPs 
and agglomerates were synthesized and characterized using well-developed methods like UV-
Vis, Raman spectroscopy, TEM, DLS, nanoparticle tracking analysis (NTA), and discrete dipole 
approximation (DDA) calculations. Detection of particle agglomeration was validated in a 
variety of simple biological media. The promising methods were then used to detect 
agglomerates in blood, with hsDFM and spICP-MS as the primary methodologies. Finally, 
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citrate-capped NPs were incubated in blood, and their agglomeration was monitored using the 
developed methods. Together, hsDFM, cRM, and spICP-MS provide a rapid and robust means to 
analyze nanoparticle agglomeration in biological systems with minimal sample preparation. 
These diverse, label-free methods can distinguish primary particles from agglomerates in blood. 
Identification of the interactions between nanoparticles and components in biological systems is, 
in turn, critically important for rational design and implementation of nanomedicine. 
Results and discussion 
 Synthesis and characterization of nanoparticles and agglomerates 
The AuNPs synthesized via the citrate reduction method (AuNP-cit) [49] had a diameter of 44.5 
± 9.2 nm from TEM measurements (Fig. 1A inset, Fig S1). Based on DLS, the dH was 50.1 ± 0.7 
nm and the zeta potential was -35.2 ± 0.9 mV. NTA indicated a mode diameter of 51.3 ± 2.3 nm. 
The size difference between TEM and DLS/NTA measurements is expected because TEM is 
used to determine the size of the metal core, while DLS and NTA measure dH, which reflects the 
size of the metal particle and the citrate stabilizer in solution. AuNP-cit exhibited an LSPR 
maximum at 537 nm (Fig. 1A) and appeared wine-red in color. The simulated spectrum of a 45 
nm diameter Au nanosphere showed an extinction peak at 534 nm, similar to that of the 
measured spectrum (Fig. 1E). 
Citrate-capped AuNPs have long been known to agglomerate following an increase in the ionic 
strength in the suspensions [50]. Agglomerates of increasing size were generated by addition of 
increasing volumes of saturated NaCl to AuNP-cit suspensions. After 10 min reaction, BSA 
solution (40 mg/mL) was added to the suspension to arrest agglomeration as described 
previously [17], and the samples in various agglomeration states were collected via 
centrifugation. The transmitted color of the suspension visibly changed from its initial wine-red 
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to purple and then purple-black. The UV-Vis spectra of primary, BSA-coated AuNPs and 
agglomerates showed that as the NaCl concentration increased the LSPR red-shifted from 539 to 
545 nm and a shoulder, red-shifted from the LSPR, emerged and resolved to a peak in the NIR 
(Fig S2). The morphology of the agglomerates was assessed with TEM (Fig S3). 
From these BSA-coated samples, “primary AuNPs,” “small agglomerates,” and “large 
agglomerates” were defined as the samples agglomerated with 0, 2.5, and 7.5 μL of saturated 
NaCl, respectively. These samples were used as standards for further experiments. Primary 
AuNPs (Fig. 1B) showed no agglomeration and had an LSPR maximum at 539 nm. Small 
agglomerates (Fig. 1C) consisted of trimers to pentamers with an LSPR peak at 541 nm and a 
visible shoulder at ~600 nm. Large agglomerates (Fig. 1D) were typically composed of between 
10 and 25 AuNPs per agglomerate and showed LSPR peaks at 545 and 780 nm. The emergence 
and separation of these two peaks is often observed during controlled agglomeration of 
nanoparticles and results from the plasmon resonance of the particle ensembles, while the peak 
attributed to individual particles remains [53]. The particle size, orientation, and interparticle 
distance can all affect the position of the LSPR that results from the ensemble of particles 
[29,31,54]. 
The discrete dipole approximation (DDA) method was used to simulate the optical spectra of 
primary AuNPs and their agglomerates. The simulated spectra of a BSA-coated primary AuNP 
shows an extinction peak at 543 nm (Fig. 1F), slightly red-shifted from that of a citrate-coated 
particle (534 nm) due to the increase of refractive index from 1.33 for citrate to 1.46 for BSA. 
For small agglomerates, spectra of several configurations were simulated according to 
visualization in TEM, as shown in Fig S4. These spectra were averaged and plotted in Fig. 1G, 
indicating an extinction peak at ~540 nm and a shoulder at ~670 nm, which is comparable to the 
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measured spectrum. In the case of large agglomerates, a representative configuration was chosen 
for simulation (Fig. 1H) because it was not practical to integrate all the configurations that 10-25 
particles could stochastically adopt in the sample. The simulated spectrum shows two peaks at 
~550 nm and ~750 nm with a board shoulder in between, which indicates a similar trend as the 
measured spectrum despite the discrepancy due to different configurations in the actual sample. 
It is important to note that the scattering efficiency increases in the order of primary AuNPs, 







Fig. 1. Characterization of AuNPs and agglomerates synthesized as described in the methods: 
(left) UV-Vis spectra of samples with inset TEM images (200 nm scale bar) and (right) 
corresponding spectra simulated by discrete dipole approximation with inset geometric 
illustrations: (A, E) citrate-capped AuNPs; (B, F) BSA-capped primary AuNPs, (C, G) small 
agglomerates; and (D, H) large agglomerates. The spectra in (G) are averages from six possible 




The trend of increasing agglomeration was further confirmed by DLS, NTA, and zeta potential 
measurements (Table 1). A rapid increase of hydrodynamic diameter (dH) was observed by DLS 
during the progression from primary AuNPs (53.7 ± 0.4 nm) to small agglomerates (142.3 ± 0.4 
nm), and large agglomerates (176.5 ± 3.1 nm). This result was further confirmed by NTA with 
respective mode diameters of 63.0 ± 1.0, 86.0 ± 13.0, and 177.0 ± 27.4nm. Additionally, the zeta 
potential changed from -19.5 ± 1.5mV for primary AuNPs to -20.8 ± 1.1 and -28.3 ± 1.2mV, 
suggesting that the primary AuNPs and agglomerates were coated with BSA, in agreement with 
other studies under similar conditions [55,56]. The initial discrepancy between DLS and NTA 
can be ascribed to the different measurements of the instrument. DLS is weighted by signal 
intensity, so a greater contribution to the dH is made by larger components than smaller 
components, which can artificially inflate dH values; NTA measures many particles individually 
but produces a diameter based on population intensity, rather than signal intensity, which may 
artificially deflate dH values. Further, agglomerates of 3-5 particles can be expected to show high 
variability, as their overall geometry can be expected to change the most from the stochastic 
arrangement (see Fig. S4 for some examples). Both of these techniques rely on the velocity of 
particles in solution, and indicate that as the agglomerates become larger, they travel more 

















537 50.1 ± 0.7 51.3 ± 2.3 -35.2 ± 0.9 AuNP-Cit 
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539 53.7 ± 0.4 63.0 ± 1.0 -19.5 ± 1.5 Primary AuNPs 
3-5 
 
542 142.3 ± 0.4 86.0 ± 13.0 -20.8 ± 1.1 Small agglomerate 
10-25 545, 
780 





Establishment of the hsDFM method for identification of agglomeration 
The hsDFM has been used as analytical tool to detect certain nanomaterials in cells [57,58]. For 
instance, a recent study demonstrated the combination of the plasmonic Au dimer probes and 
hyperspectral imaging is capable of quantitatively imaging single mRNA splices in live cells 
[59]. In this study, primary AuNPs and their agglomerates can be easily seen using hsDFM 
because of their large scattering cross-sections. Primary AuNPs appeared green on the 
microscope (Fig. 2A) and moved around extremely quickly due to Brownian motion (i.e. 
diffusion). The agglomerates appeared yellow and the particle motion decreased substantially 
(Fig. 2, C and E). Hyperspectral maps were acquired for the various samples. From these 
spectra, the most intense spectra were accumulated to represent typical spectral output. The 
scattering peak of primary AuNPs appeared at ~550-560 nm (Fig. 2B). For small agglomerates, 
the peak shifted to ~580 nm (Fig. 2D); for large agglomerates, the peaks were observed at ~550 
nm and ~660-700 nm (Fig. 2F). Importantly, the signal intensity increased from primary AuNPs 
to small and large agglomerates, as would be expected for a scattering-based process. The signal 
from agglomerates is significantly brighter than that of primary AuNPs, therefore the presence of 
agglomerates can be readily detected by the relative intensity difference of their scattering 
spectra. Agglomeration can be qualitatively monitored based on the color of the scattered light as 
seen in the microscope and by the particle diffusion velocity, which can then be further 





Fig. 2. Darkfield images of typical hyperspectral scattering spectra of (A, B) primary AuNPs; (C, 
D) small agglomerates; and (E, F) large agglomerates, which correspond to the samples in Fig. 1.  
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Having demonstrated the capacity to distinguish agglomerates, hsDFM was applied to identify 
the status of AuNP-cit in different media (i.e. H2O, PBS, cell-culture medium (CCM), and 
serum) and compared with UV-Vis spectra as shown in Fig. 3. In Fig. 3 A and D, the hsDFM 
showed scattering maxima at ~550-560 nm for H2O, and the true color images show mainly 
green, fast-moving particles, suggesting that the AuNP-cit did not agglomerate in these media. In 
agreement with these results, the UV-Vis spectra showed no significant changes in either 
medium. In contrast, hyperspectral plots of AuNP-cit incubated in PBS and CCM showed two 
typical peaks, one located in the 550-580 nm region and the other in the 630-700 nm region. 
True color, darkfield imaging displayed primarily bright yellow, slow-moving spots, suggesting 
that AuNP-cit agglomerates detectably in PBS and CCM. This result was confirmed by UV-Vis 
spectroscopy, which showed the emergence of a second peak ~680 nm, suggesting the formation 
of medium to large agglomerates (Fig. 3 B and C). These results clearly demonstrate that the 





Fig. 3. The agglomeration behavior of citrate-capped AuNPs in four aqueous media: (A) H2O; 
(B) phosphate-buffered saline; (C) cell-culture medium; and (D) fetal bovine serum (black) with 
and (gray) without AuNPs. (Left) UV-Vis spectra; (Center) darkfield image; and (Right) typical 




Raman studies of agglomeration 
The cRM has been applied as a fast and label-free analytical approach to detect carbon-based 
nanomaterials in biological system [60]. GNMs' use as an agent for SERS has attracted much 
attention in recent years [61]. In this study, cRM was used to characterize agglomeration as a 
compliment to hsDFM. The surface coatings, citrate and BSA, can serve as indicators of the 
agglomeration of AuNPs because the gaps between agglomerated AuNPs can enhance Raman 
signal by up to 108-fold relative to primary particles [62]. Fig. 4A shows this same trend with 
large agglomerates having more intense spectral features than small agglomerates. BSA-coated, 
primary AuNPs produced the same spectrum as pure H2O with Raman shift at ~1640 cm-1 [63]. 
As the size of the agglomerates increased, the Raman shift of H2O was replaced by several 
informative peaks. The peak at ~225 cm-1 may be the result of Au-N bond stretching [64] from 
the protein adsorbed to the particle surface. Additionally, a number of peaks emerge in the range 
of 1000-1600 cm-1 that are likely associated with stretching of the citrate carbonyls or aromatic 
vibrations and carbonyl stretching within the protein structure [65]. The strongest peak to 
emerge, however, is ~2900 cm-1 and can be attributed to C-H stretching [65]. Monitoring for the 
emergence of these peaks, particularly the C-H stretch, can be used to track the degree of 
agglomeration. Interestingly, the intensity of the peaks begins to decrease at higher 
agglomeration levels (Fig. S5), which could be the result of the agglomerate not being 
completely irradiated, thereby producing less signal [66], LSPR shift reducing the resonant 
absorption needed for enhancement [67], or the structure of the agglomerate resulting in less 
enhancement [68]. 
Raman spectroscopy was used to complement the study of the various media, and the response of 
AuNP-cit to incubation in H2O, PBS, CCM, and serum was measured (Fig. 4B). Similar to the 
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hsDFM and UV-Vis results, no significant change was seen between solvent spectra and Au 
containing spectra for water or serum, suggesting that the AuNP-cit remains nonagglomerated. 
On the other hand, incubation of AuNP-cit in CCM or PBS leads to the emergence of several 
Raman peaks attributed to citrate, particularly the C=O and C-H stretches. The emergence of 
these peaks further confirms the agglomeration of AuNP-cit in both of these media, and 





Fig. 4. Raman spectra taken from (A) (i) H2O and albumin-capped (ii) primary AuNPs, (iii) 
small agglomerates, and (iv) large agglomerates and (B) (i) H2O and citrate-capped AuNPs after 
10 min incubation in (ii) H2O, (iii) phosphate-buffered saline, (iv) cell-culture medium, and (vi) 
fetal bovine serum with (v) normal fetal bovine serum as a reference.   
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Detection and evaluation of Au particle agglomeration in blood by hsDFM 
The primary AuNPs and their agglomerates were added to whole rat blood to model the behavior 
of the particles following intravenous injection. The optical density of blood limited the use of 
Raman and UV-Vis spectroscopy to monitor agglomeration, and the medium's complexity 
additionally ruled out the use of many traditional characterization methods such as electron 
microscopy and light scattering [69]. Fig. 5 shows darkfield images and typical hyperspectral 
plots (hsDFM) of primary AuNPs and large agglomerates following 5 min incubation in blood 
prior to slide preparation. The primary AuNPs and agglomerates can be visually distinguished 
using the hsDFM as they appear green and yellow, respectively, as shown by the respective 
spectra, and with different levels of brightness. The peak does not identically match the peaks 
observed in simpler media, which may be attributed to the optical interference by the blood. The 
peak location ~600 nm for primary particles shifts to ~800 nm for agglomerates. These data 
clearly demonstrate primary AuNPs can be distinguished from agglomerates amongst the blood 





Fig 5. Characterization of prepared AuNPs in the blood: (A) darkfield image and (B) typical 
hyperspectral scattering spectra of primary AuNPs; (C) darkfield image and (D) typical 
hyperspectral scattering spectra of large agglomerates.   
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The hsDFM method was further used to monitor the agglomeration status of AuNP-cit in blood, 
as shown in Fig. 6. AuNP-cit were incubated in blood for 5 min and 18 h. After 5 min 
incubation, the hyperspectral plots showed maxima primarily ~600 nm, indicating the presence 
of primary AuNPs. A slight red-shift to ~620 nm was observed after 18 h incubation, suggesting 
there may be some slight modification of the particles. This agglomeration could be the result of 
restructuring of the protein corona during incubation [70] or an artifact of the incubation itself. 
The typical blood half-life for AuNPs is on the order of hours, though with proper surface 
coating it can be extended to days [71]. As such, it is likely that the sanguine concentration of 
AuNPs in vivo would be low after 18 h, which would reduce the likelihood of agglomeration. 
Nonetheless, the power of hyperspectral imaging of individual particles using darkfield 
microscopy is demonstrated and can be further explored to identify changes in the surface of the 
nanoparticles (i.e. agglomeration). 
For the most part, AuNP-cit did not agglomerate during incubation in blood, and cell 
morphology appeared unperturbed, though several anomalies should be remarked upon. First, 
once the blood sample is prepared, the sample must be imaged quickly to observe an accurate 
representation of the blood cell morphology. As the specimen remains on the microscope stage, 
the blood cells begin to deform over the course of 30 min. Presumably this cell disfiguration is 
the result of evaporation, leading to an increase in salinity and deformation of the blood cells. 
Blood cells presented typical morphology immediately following sample preparation even after 
the blood had been stored in a refrigerator for several days. Additionally, slides that had been 
prepared 30 min prior to imaging began to show evidence of the formation of opalescent 





Fig. 6. The agglomeration behavior of the citrate-capped AuNPs in the blood after incubation for 
different time periods: (A) darkfield image and (B) typical hyperspectral scattering spectra at 5 
min; (C) darkfield image and (D) typical hyperspectral scattering spectra at 18 h.   
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Detection of Au nanoparticle agglomeration in blood by single particle ICP-MS 
The spICP-MS was applied to discriminate the size of various primary AuNPs in whole rat 
blood. Whole rat blood was used as a matrix blank to monitor the background counts, and the 
results showed that majority of the events exhibited counts smaller than 20. Typical pulse 
intensity versus time output can clearly distinguish primary AuNPs, small agglomerates and 
large agglomerates in blood (Fig. 7A). Citrate-capped NIST AuNP reference materials with 30 
nm and 60 nm diameter were coated with BSA (NIST-30 and NIST-60, respectively) and used as 
standards against which to compare to the primary AuNPs. The measurements for each sample 
were performed three times and the results were reported as a summation. Fig. 7B clearly shows 
that a large population of events from our primary AuNPs fell between NIST-30 and NIST-60, 
consistent with the size of the primary AuNPs (45 nm diameter) obtained from TEM studies. 
Previous studies have suggested that in spICP-MS, signal intensity is proportional to particle size 
for diameters <80 nm [44]. Since the intensity of each event is proportional to the number of 
detected ions, the intensity ratio of different particle sizes should be the same as their volume 
ratio. To simplify the process, samples were normalized to the bin with maximum number of 
events. As a result, the intensity ratio between our primary AuNPs and the NIST standards were 
3.40 for NIST-30 and 0.42 for NIST-60, which are very close to their volume ratios using 45 nm 
particles (V45/V30 = 3.38; V45/V60 = 0.42). 
The capability of spICP-MS to distinguish primary AuNPs, small agglomerates and large 
agglomerates in blood was further examined. Typical measurements of primary particles, small 
agglomerates, and large agglomerates after incubation in blood are shown in Fig. 7C. Relative to 
primary AuNPs, small agglomerates presented a broader intensity range; a large portion of 
events had counts higher than 400/event. There were also a considerable number of events with 
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even higher pulse intensities, suggesting a range of agglomerate masses. When large 
agglomerates were analyzed, the intensity distribution broadened further. As the intensity 
increased, the frequency of events decreased relative to small agglomerates, further indicating a 
much greater degree of agglomeration. These results demonstrate that spICP-MS can be readily 





Fig. 7. Single particle ICP-MS analysis of various AuNPs in whole rat blood: (A) Typical pulse 
intensity versus time output from ICP-MS in single particle mode for blood without AuNPs 
(black), or incubated with primary AuNPs (blue), small agglomerates (red), or large 
agglomerates (green), (B) primary AuNPs in whole rat blood using 30 nm (red) and 60 nm (gold) 
diameter NIST standard citrate-capped AuNPs stabilized with albumin and in-house synthesized, 
albumin stabilized primary AuNPs (blue), small agglomerates (red), and large agglomerates 
(green) in whole rat blood.   
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Evaluation of Ag nanoparticle agglomeration status in blood by hsDFM 
Similar to AuNPs, AgNPs are also in development as potential therapeutics with strong 
plasmonic properties [72]. To test the robustness of the hsDFM method, AgNPs were subjected 
to similar analysis as AuNPs. Citrate-capped AgNPs were agglomerated by NaCl resulting in a 
change in LSPR. BSA-capped primary and agglomerated AgNPs were introduced to blood and 
imaged using darkfield microscopy (Fig. 8, A and B). Primary AgNPs scattered a cyan color 
associated with rapidly moving particles, while agglomerates appeared as slow-moving yellow 
spots. Due to either the size of the AgNPs (~75 nm) or the optical properties of AgNPs, the 
signal is significantly brighter than that of AuNPs. Hyperspectral plots confirm this change in 
color and intensity with primary AgNPs scattering ~500 nm and agglomerates scattering ~600-
700 nm, sometimes displaying multiple peaks. Having demonstrated that agglomeration of 
AgNPs can be detected, citrate-capped AgNPs were incubated in isolated, heparinized rat blood 
for 5 min and 18 h. After 5 min, the signal returned is primarily between 500 and 540 nm, with 
the typical spectrum of the primary particles (Fig. 8, C and D). There appears to be some 
background signal from the blood, though it presents less interference than for AuNPs, which is 
attributable to the increased signal intensity of the AgNPs. After 18 h in blood, a mixture of 
signals was obtained (representative signals shown in Fig. 8 E and F) with agglomerated AgNP 
showing emissions at 550-600 nm (upper two spectra) and primary particles at 500-540 nm 
(lower three spectra). Interestingly, the increased brightness of the AgNPs mitigated some of the 





Fig. 8. Characterization of Ag nanomaterials in isolated, whole rat blood with typical 
hyperspectral scattering spectra with inset darkfield image of albumin-stabilized (A) primary Ag 
nanoparticles and (B) agglomerates. The agglomeration behavior of citrate-capped nanoparticles 
in isolated whole rat blood after incubation for different time periods: (C) darkfield image and 
(D) typical hyperspectral scattering spectra at 5 min; (E) darkfield image and (F) typical 




Three complementary methods, hsDFM, cRM, and spICP-MS, have been demonstrated for the 
first time for rapid characterization of plasmonic nanomaterials in blood with minimal sample 
preparation. These methods were capable of distinguishing primary nanoparticles and 
agglomerates in simple media, which was validated by the standard methods such as TEM, UV-
Vis, DLS and NTA. More importantly, hsDFM and spICP-MS demonstrated the unique 
capability to distinguish primary particles and agglomerates in blood. As a test, AuNPs and 
AgNPs were incubated in whole rat blood and these methods were used to monitor for the 
agglomeration of particles. The methods are anticipated to be adaptable to a wide variety of 
particle morphologies, surface coatings, and biological matrices. Furthermore, these methods 
could be applicable to blood and tissue extracted from animals following in vivo nanomedicine 
administration. These methods provide biological and pharmacokinetic information important for 
the development of nanomedicine, as well as analytical approaches for the assessment of 
nanomaterial-based products. 
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Materials and methods 
Chemicals 
Tetrachloroauric acid trihydrate (HAuCl4•3H2O) and trisodium citrate heptahydrate (Na3-Cit; 
Na3C6H5O7•7H2O) were acquired from Alfa Aesar (Ward Hill, MA). Phosphate buffered saline 
(PBS), fetal bovine serum (FBS), and Eagle medium were acquired from Corning Cellgro 
(Manassas, VA). The reference AuNPs with nominal diameters of 10 nm (RM8010), 30 nm 
(RM8012), and 60 nm (RM8013), were purchased from the National Institute of Standards and 
Technology (NIST). Citrate-capped 75-nm AgNPs were obtained from NanoComposix (San 
Diego, CA). Sodium chloride (NaCl) and bovine serum albumin (BSA) were obtained from 
Sigma Aldrich (St. Louis, MO). All chemicals were used as received. 
Synthesis of AuNPs and agglomerates 
Citrate-capped AuNPs (AuNP-cit) were synthesized via the Turkevich method as previously 
described [49]. Briefly, 10.6 mg HAuCl4 was dissolved in 99 mL 18 MΩ H2O and heated to 
boiling. To this solution, 0.9 mL of 10 mg/mL Na3Cit was quickly injected. After 20 min, a deep 
wine-red color was observed, indicating the formation of AuNPs. The suspension was removed 
from heat and allowed to cool to room temperature. Prior to use, the excess precursors were 
removed by centrifuging at 20,800 g for 20 min at 20 °C, and the AuNP-cit was redispersed in 
18 MΩ H2O. 
Agglomerates were generated by adding 0, 2.5, 5, 7.5, 10, 20, or 50 μL of saturated NaCl 
solution to 1 mL of the AuNP-cit suspension, immediately followed by thoroughly mixing for 5 
s. After 10 min, 50 μL BSA (40 mg/mL, 18 MΩ H2O) was added to arrest agglomeration [50]. 
The solution was immediately mixed and allowed to incubate without further mixing for 30 min 
at room temperature. Agglomerates were isolated by centrifugation at 20,800 g for 20 min at 20 
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°C. The pellet was redispersed in 18 MΩ H2O, centrifuged a second time (20,800 g, 20 min, 20 
°C), redispersed in 18 MΩ H2O, and stored at room temperature. Samples were redispersed by 
brief (<2 s) bath sonication (Branson 5510, Branson Ultrasonics, Danbury, CT) prior to use. No 
appreciable changes in the UV-Vis spectra or hydrodynamic diameter of agglomerates used were 
observed after 1 month of storage at room temperature in the dark. 
Introduction of nanoparticles into blood 
Adult Fisher 344 rats were obtained from the National Center for Toxicological Research 
(NCTR) Breeding Colony (Jefferson, AR). Whole blood samples from the rats were collected via 
cardiac puncture into plastic whole blood collection tube (Becton, Dickinson, Franklin Lakes, 
NJ) for the study. The animal procedures followed the guidelines of the “Guide for the Care and 
Use of Laboratory Animals” and were approved by the NCTR Institutional Animal Care and Use 
Committee. AuNP-cit (100 μL; 80 ppm) was incubated directly with 1.5 mL fresh whole blood 
in a blood collection tube. Alternatively, primary AuNPs and agglomerates (80 ppm) were 
redispersed by bath sonication (~2 s) prior to use. A 20 mL sample was added to 200 mL of 
fresh, nanoparticle-free blood, followed by mixing for 2 s (final concentration ~8 ppm). To 
prepare samples for imaging, 3 mL of blood was applied to a clean-room-grade glass microscope 
slide (Schott, Elmsford, NY), smeared, and a coverslip applied immediately prior to acquisition 
of hsDFM images. An identical process was followed to introduce AgNPs to blood. 
Transmission electron microscopy (TEM) 
TEM images were recorded using a JEOL JEM-1400 (JEOL, Tokyo, Japan) with accelerating 
voltage of 80 keV. Samples (3 mL) were applied onto a 200 mesh carbon-coated copper grid, 
followed by addition of 3 mL isopropyl alcohol and air dried. Images were acquired using XR41 
4mp TEM CCD system (AMT, Woburn, MA) and the particle size was then measured using 
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ImageJ software (National Institute of Health, Bethesda, MD). 
Dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) 
Hydrodynamic diameter (dH) and zeta potential were determined using a ZetaPALS instrument 
(Brookhaven, Holtzville, NY). The sample was prepared by diluting 20 mL of primary AuNPs or 
agglomerates to 2 mL with 1 mM of KCl after brief sonication (<5 s) of the sample (~800 ppb). 
AuNP-cit was diluted 100-fold in 18 MΩ H2O. The dH was measured by performing three 
consecutive 60 s runs while the zeta potential was measured at 10 runs of 5 cycles each. Average 
hydrodynamic size was determined using nanoparticle tracking analysis (NTA), and was 
performed using NanoSight LM-10 (Malvern Instruments Inc, MA, USA). The sample was 
prepared by diluting 10 mL of sample to 10 mL with 18 MΩ H2O (80 ppb) after brief sonication 
(<5 s) of the sample. The diameter corresponding to the mode of the sample was used to 
represent the most prominent nanoparticle size in solution. Triplicate measurements were 
acquired for each sample. 
UV-Vis spectroscopy 
Extinction spectra were acquired on an Agilent HP8453 UV-Vis spectrometer (Agilent 
Technologies, Santa Clara, CA) using a quartz cuvette with 1-cm path length and 18 MΩ H2O as 
a blank. Samples were sonicated for <5 s and diluted 10-fold to 8 ppm with 18 MΩ H2O prior to 
measurement. 
Confocal Raman microscopy (cRM) 
Raman spectra were acquired using a Horiba Jobin Yvon high-resolution LabRam Raman 
microscope system (Horiba, Edison, NJ) equipped with a charge-coupled detector and a 
spectrometer with a grating of 600 lines/mm. The systems were set up with a 150-mm entrance 
slit and a 400-mm pinhole. The 633-nm laser excitation was provided by a HeNe laser operating 
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at 5 mW. Raman shift calibration was performed using the 521 cm-1 line of a silicon wafer. 
Raman samples were prepared by diluting 100 mL of AuNPs, or agglomerates, to 1 mL with 18 
MΩ H2O (8 ppm) after brief sonication (<5 s) of the sample. The diluted sample was then 
transferred to a 50 mL, 10 mm path length quartz cuvette. Signal was acquired for 10 s and three 
acquisitions were averaged per spectrum to improve signal-to-noise ratio. 
Darkfield microscopy with hyperspectral detection (hsDFM) 
Darkfield microscopy images and hyperspectral plots were acquired using enhanced darkfield 
transmission optical microscope (Olympus BX41) equipped with hyperspectral imaging 
spectrophotometer (Headwall, CytoViva Inc, Auburn, AL). This system is capable of recording 
high quality spectra (high signal-to-noise ratio) in the visible and near infrared wavelength range 
(400-1000 nm). Hyperspectral images were acquired using a 0.25 s collection time and a white 
light source. Images were acquired using a 100x oil immersion lens. 
Single particle inductively-coupled plasmon mass spectrometry (spICP-MS) 
The nanoparticles or agglomerates were stored at 4 °C in the dark prior to analysis. Samples 
were warmed to room temperature, then mixed and sonicated briefly prior to dilution to ensure 
full dispersion without disrupting agglomeration. Nanoparticles or agglomerates (0.1 mg/mL) 
were briefly incubated with fresh blood, and then diluted into 10 mL 18 MΩ water. Single 
particle analysis was performed using an Agilent 7700X ICP-MS (Agilent, Santa Clara, CA) 
which was tuned daily to optimal sensitivity and resolution. A MicroMist glass concentric 
nebulizer was used with nickel composite sample and skimmer cones. Argon was used as a 
carrier gas at a flow rate of 1.05 mL/min. Peristaltic pump speed was set at 0.1 rpm. Samples 
were analyzed in selected time resolved analysis (TRA)/full quantification mode with a sampling 
period of 0.01 s and an acquisition time of 180 s. Between each acquisition, the instrument was 
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first flushed with a solution containing 10% HNO3 and 10% HCl in water at a pump speed of 0.5 
rpm for 3 min to eliminate the AuNPs that were trapped inside the sampling tube from prior 
measurement. Then the system was rinsed with water for another 3 min to purge the acid. Every 
sample was measured in triplicate. Agilent's MassHunter Workstation software was used for data 
analysis. 
Calculation of optical properties 
The optical properties were calculated according to the discrete dipole approximation (DDA) 
using the DDSCAT 7.3 program [51]. In this formalism, the particles are represented by an array 
of dipole moments residing within the volume of the nanoparticles. The nanoparticles were 
represented as a dielectric continuum with the complex dielectric response function of bulk Au 
[52]. The optical efficiency, Q, is reported as the ratio of the respective optical cross section to 
π*αeff2, where the effective radius, αeff, is defined as the radius of a sphere whose volume is equal 
to that of the nanoparticle. The optical cross sections were averaged over two orthogonal 
polarization directions of the incident light. 
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Citrate 537 50.1 ± 0.7 50.4 ± 0.8 51.3 ± 2.3 -35.2 ± 0.9 
Citrate-
capped 
1 539 53.7 ± 0.4 53.2 ± 0.9 63.0 ± 1.0 -19.5 ± 1.5 Primary 
1-3 541 72.6 ± 2.0 76.1 ± 2.1 N/A -21.2 ± 1.2  
3-5 542 142.3 ± 0.4 144.1 ± 0.6 86.0 ± 13.0 -20.8 ± 1.1 Sm. Agg 
5-10 545, 732 165.8 ± 2.9 164.1 ± 2.9 114 ± 5.2 -27.4 ± 1.2  
10-25 545, 780 176.5 ± 3.1 181.2 ± 1.7 177 ± 27.4 -28.3 ± 1.2 Lg. Agg 
>25 546, 848 216.8 ± 1.9 212.1 ± 3.3 N/A -29.9 ± 1.0  





Figure S1. Histogram of particle diameter of citrate-capped AuNPs based on transmission 




Figure S2. (A) Photograph of isolated AuNPs at various agglomeration states from left to right 
corresponding to A-F in Figure S3. From left to right, agglomerates were generated by addition 
of 0, 2.5, 5, 7.5, 10, 20, or 50 μL saturated NaCl to 1 mL of citrate-capped gold nanoparticles. 
(B) UV-Vis spectra of agglomerates in (A). The spectra were normalized to LSPR maximum and 






Figure S3. (A-F) TEM characterization of agglomerates shown in Figure S2. Agglomerates 
were generated by addition of 0, 2.5, 5, 7.5, 10, or 20 μL saturated NaCl to 1 mL of citrate-
capped gold nanoparticles. The scale bar is 200 nm. (G) Hydrodynamic diameter as measured by 
dynamic light scattering (black, left axis) and nanoparticle tracking analysis (blue, left axis) and 







Figure S4. Simulated extinction, absorption, and scattering spectra of small agglomerates of 







Figure S5. (A) Raman spectra of H2O (cyan) and increasingly agglomerated AuNPs 
corresponding to Figure S2. Agglomerates were generated by addition of 0, 2.5, 5, 7.5, 10, or 20 





Chapter III. Gold Nanocage-Photosensitizer Conjugates for Dual-Modal Image-Guided 
Enhanced Photodynamic Therapy*  
Abstract 
We have demonstrated that gold nanocage-photosensitizer conjugates can enable dual 
image-guided delivery of photosensitizer and significantly improve the efficacy of photodynamic 
therapy in a murine model. The photosensitizer, 3-devinyl-3-(1’-
hexyloxyethyl)pyropheophorbide (HPPH), was noncovalently entrapped in the poly(ethylene 
glycol) monolayer coated on the surface of gold nanocages. The conjugate is stable in saline 
solutions, while incubation in protein-rich solutions leads to gradual unloading of the HPPH, 
which can be monitored optically by fluorescence and photoacoustic imaging. The slow nature of 
the release in turn results in an increase in accumulation of the drug within implanted tumors due 
to the passive delivery of gold nanocages. Furthermore, the conjugate is found to generate more 
therapeutic singlet oxygen and have a lower IC50 value than the free drug alone. Thus the 
conjugate shows significant suppression of tumor growth as compared to the free drug in vivo. 
Short-term study showed neither toxicity nor phenotypical changes in mice at therapeutic dose of 
the conjugates or even at 100-fold higher than therapeutic dose of gold nanocages. 
 
*Published: Srivatsan, A.;† Jenkins, S.V.;† Jeon, M.;† Wu, Z.; Kim, C.; Chen J.; Pandey, R. 




Gold nanostructures are an emerging class of promising multifunctional platforms for cancer 
theranostics due to their superior optical properties, chemically modifiable surface, and 
biological inertness.(1-3) They strongly scatter and absorb light at a tunable resonance 
frequency, known as localized surface plasmon resonance (LSPR). The LSPR enables enhanced 
contrast for a variety of optical imaging modalities including optical coherent tomography 
(OCT),(4-7) multi-photon photoluminescence imaging,(8-11) and photoacoustic tomography 
(PAT).(12-16) Furthermore, they can act directly as therapeutic agents by converting the light 
into heat for photothermal treatment of diseases.(17-19) When combined with drug molecules, 
Au nanostructures are widely applicable carriers for delivery of therapeutics to the target region, 
both passively and actively.(20-22) Drug molecules can be conjugated to the surface of Au 
nanostructures covalently or non-covalently via chemical bonds or intermolecular interactions, 
respectively. The latter is particularly appealing because the drug molecules remain unmodified, 
thereby minimizing the potential for alterations in drug efficacy and pharmacokinetics.(23) 
Hydrophobic interactions are an effective strategy to noncovalently incorporate lipophilic drug 
molecules within nanoparticle surface coating for drug delivery. Different types of surface 
coating have been demonstrated for this purpose including amphiphilic molecules(24) and 
polymers containing non-polar groups (e.g. poly(ethylene glycol), PEG).(25-27) Herein, we 
incorporate a hydrophobic photosensitizer, 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide 
(HPPH), into PEG covered on Au nanocages (AuNCs) as a theranostic agent for enhanced 
photodynamic therapy (PDT). 
Photodynamic therapy is a known therapeutic modality that relies on the use of light to excite a 
photosensitizer molecule which in turn transfers the energy to local O2 molecules, changing 
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them from the ground, triplet state to an excited, singlet state (1O2). The 1O2 molecules are highly 
sensitive to the environment and have an intracellular lifetime on the order of 3 μs.(28, 29) At the 
therapeutic dosage, their reaction with biomolecules leads to apoptosis and necrosis of cells.(30) 
Because of its transient nature, effective generation of 1O2 at the target site is important for the 
success of PDT. Several methods to improve PDT efficacy have been developed that use 
nanocarrier-based delivery, including liposomes,(31) polymeric micelles,(32, 33) pure 
nanocrystal forms,(34) silica nanoparticles,(35, 36) and polymeric nanoparticles.(37, 38) 
Recently, PEGylated Au nanoparticles have been demonstrated as nanocarriers to efficiently 
deliver photosensitizers for PDT.(25, 27) The hydrophobic photosensitizers were entrapped 
inside the PEG monolayer close to the surface of the Au nanoparticles and released rapidly at the 
tumor site within hours. In this case, the Au nanoparticles were used only as delivery vehicles 
because their LSPR peak was located in the visible region where light penetration is relatively 
superficial. By replacing spherical particles with nanorods, the LSPR maximum was shifted to 
the near-infrared (NIR) region where light penetrates deeper into biological tissue, enabling PDT 
to be coupled with photothermal therapy (PTT) to enhance the cancer treatment efficacy.(39, 40) 
More recently, multi-modal imaging has been demonstrated to monitor the delivery and 
treatment of particle-assemblies loaded with photosensitizers for cancer theranostics.(41) The 
loading efficiency was double that of nanorods because the hollow nature of the assemblies 
overcomes the limitation of the surface loading. The size of the particle-assemblies, however, 
was around 280 nm, which may be unfavorable for in vivo delivery. 
In this work, we develop AuNC-HPPH conjugates that incorporate the hydrophobic HPPH 
into the PEG monolayer on the AuNC surface. The size of the AuNC is relatively small with 
edge length of ~50 nm and hollow interior. The LSPR peak of AuNCs has been tuned to the 
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NIR region, which enables in vivo tracking of the conjugate delivery by both fluorescence (FL) 
and photoacoustic (PA) imaging modalities. A “see and treat” approach has been established 
with the dual-modal imaging capability that provides complementary features to guide PDT. The 
FL imaging monitors the release of HPPH from the AuNC surface by distinguishing the 
aggregated (quenched) and non-aggregated (fluorescent) states of HPPH. The PA imaging 
reveals the volumetric distribution of AuNC in the tumor and monitors the therapeutic response 
of the treatment. More importantly, the efficacy of the PDT has been significantly improved by 
the presence of AuNCs because of local electromagnetic field enhancement of 1O2 generation 
and efficient delivery of the drug. Additionally, no observable toxicity of the conjugates at 
therapeutic dose was found in the short-term study. 
Results and Discussion 
The multifunctional platform consists of AuNCs coated with a PEG layer (AuNC-PEG) in which 
HPPH is noncovalently loaded (AuNC-HPPH) (Fig. 1A). The AuNCs were synthesized using 
galvanic replacement between Ag nanocubes and HAuCl4, resulting in a composition of 91% Au 
and 9% Ag by mass. The average edge length of the AuNCs was 52.6 ± 8.2 nm, and the LSPR 
maximum was at 801 nm after PEGylation (Fig. 1B). The hydrodynamic diameter of the as-
prepared AuNC coated with PVP was 91.8 ± 7.1 nm and the zeta potential was -16.7 ± 1.4 mV in 
1 mM KCl aqueous solution. PEGylation was accomplished using heterobifunctional PEG with a 
thiol group at one terminus and an amine at the other (HS-PEG-NH3+). The HS-PEG-NH3 was 
anchored to the surface of AuNC through the Au-thiol bond, while the exposed amine formed a 
cationic surface that can be further functionalized. The hydrodynamic diameter of AuNC-PEG 
was 98.6 ± 0.9 nm and the zeta potential was positive (+4.79 ± 0.23 mV) in 1 mM KCl aqueous 
solution, indicating the success of PEGylation. The loading mechanism is based on the 
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hydrophobic interaction between the porphyrin and the -CH2-CH2- group of PEG.(46) After 
incorporation of HPPH, the LSPR peak was redshifted to 829 nm (Fig. 1C) due to the refractive 
index change of the surface layer.(47) The peaks at 517, 550, 624, and 684 nm, as well as the 
shoulder at 669 nm, were attributed to absorption by the HPPH molecules, and the slight 
redshifting can be attributed to a change in electron density as a result of conjugation. The 
hydrodynamic diameter of the HPPH incorporated AuNC-PEG (AuNC-HPPH) remains 
unchanged (100 ± 1.1 nm), while the zeta potential of the conjugates became negative (-25.73 ± 
1.23 mV) in 1 mM KCl aqueous solution. The discrepancy in the zeta potential before and after 
loading of HPPH could be due to the influence of the negatively-charged carboxylate group on 
the HPPH at neutral pH. Quantification of AuNC concentration has been well established in our 
previous publications.(48, 49) The concentration of AuNCs is estimated from an extinction-
concentration curve derived from measurement of the average size and the atomic Au and Ag 
concentration of AuNCs (Supplementary Material: Fig. S1). The final HPPH loading 
concentration was determined to be approximately 1 × 105 HPPHs per AuNC based on the 
recovered fluorescence after dissolution of a known amount of AuNCs using KCN (Fig. 1D and 






Figure 1. (A) Schematic illustration of AuNC-HPPH conjugate. The UV-Vis-NIR spectra of the 
AuNCs with an LSPR peak at 801 nm and an edge length of 52.6 ± 8.2 nm before (B) and after 
(C) loading with HPPH. Inset of (B) shows the TEM image of the AuNCs with a scale bar of 50 
nm. (D) Fluorescence spectra of AuNC-HPPH before (red) and after KCN etching (black).   
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The release of HPPH from the AuNC-HPPH was studied in serum to better understand the 
conjugate’s interaction with blood and interstitial environments. The AuNC-HPPH suspensions 
were incubated in serum or PBS over 24 h. Fluorescence was gradually recovered in the protein-
containing serum (Supplementary Material: Fig. S3A) but barely recovered in PBS. The lack of 
fluorescence in PBS primarily results from HPPH aggregation.(34) For this reason, the release in 
PBS was also monitored by measuring the absorption spectra of the supernatant at various times 
(Supplementary Material: Fig. S3B). It was found that while over 80% of the drug was unloaded 
by the serum within 24 h, only 3% of the payload was released in PBS (Fig. 2A). 
The release profile can also be monitored using PA amplitude since both AuNC and HPPH can 
function as exogenous PA contrast agents.(13, 50) As the amplitude of PA signal is proportional 
to the light absorption,(44) extinction spectra were acquired and compared with the change of 
PA signal during the release. The extinction spectrum of AuNC-HPPH initially included two 
convoluted peaks at 665 and 685 nm (Fig. 2B) which could be attributed to the high local 
concentration of HPPH,(51) metalation of the pheophorbide ring,(52) metal-HPPH 
interactions,(53) or a combination thereof. During release, the peak at 685 nm disappeared 
while the peak at 665 nm was augmented. Figure 2, C and D, shows the changes of PA signals 
over the period of 30 h at 665 and 685 nm in serum. As expected, the PA signal at 685 nm 
decreased as a function of time due to the decrease of light absorption at this wavelength. 
Surprisingly, the PA signal decreased over time at 665 nm in contrast to the increase of 
absorbance. This discrepancy is attributed to the fluorescence recovery of HPPH, which offers a 
competitive relaxation pathway (i.e. emission) to the nonradiative decay. At close proximity to 
AuNC, the fluorescence of HPPH was quenched through energy transfer to the metal surface. As 
a result, the energy dissipated nonradiatively as heat whose conversion efficiency was linearly 
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proportional to the amplitude of the PA pressure waves. During the release of HPPH from the 
metal surface, the recovery of quenched fluorescence led to the reduction of the nonradiative 
energy decay, and thus the decrease of PA signal. After 30 h, the signal at 685 nm decreased to 
less than 50%, while the signal at 665 nm leveled off at 60%. The slower decay rate of PA signal 







Figure 2. (A). Comparison of 24 h release kinetics of AuNC-HPPH in serum (diamonds) and 
PBS (squares). Inset depicts photograph of vials containing AuNC-HPPH as PBS (left) and 
serum (right) under UV light illumination. (B) UV-Vis-NIR spectra of AuNC-HPPH in serum at 
different time periods, with PA wavelengths marked. Spectra are normalized to the AuNC LSPR 
peak. (C) plot of normalized PA signal amplitude of AuNC-HPPH in serum as a function of time 




Photodynamic therapy relies on photoexcited molecules to generate reactive oxygen species, 
mainly 1O2, for destruction of malignant cells. To investigate the potential efficacy of AuNC-
HPPH for PDT, SOSG was used to qualitatively measure the 1O2 generation.(54) Interestingly, 
73% enhancement of 1O2 signal was observed for the AuNC-HPPH conjugates as compared to 
the same amount of free HPPH upon light irradiation at 665 nm with a fluence of 15 J/cm2 (Fig. 
3A). As control experiments (Supplementary Material: Fig. S4A), SOSG in absence of drugs 
shows no change in the fluorescence signal following irradiation, confirming that the sensor 
alone does not directly respond to the light. On the other hand, the 1O2 generation from AuNC 
alone is negligible upon light irradiation at the 1 pM concentration. The results implied that the 
HPPH in proximity to AuNCs could enhance the probability of 1O2 generation upon irradiation 
as compared to free HPPH. This enhancement is possibly due to the overlap between the 
LSPR of AuNCs (~800 nm) and the phosphorescence emission of HPPH (750-800 nm).(55, 56) 
Replacing the aqueous solution with MeOH, the enhancement fell to 26% as compared to free 
HPPH (Supplementary Material: Fig. S4B). The decrease of 1O2 signal is attributed to the near-
complete release of HPPH from the AuNC-HPPH conjugate in methanol. Interestingly, the 1O2 
signal of AuNC-HPPH and a combination of AuNC and HPPH was nearly identical; suggesting 
that the prescence of the AuNCs in the tumor would continue to enhance 1O2 generation after 
HPPH is released. 
The efficacy of PDT was evaluated in vitro using Colon-26 cell line. The cells were incubated 
with the free drug and the AuNC-HPPH at equimolar HPPH concentrations. After 24 h 
incubation, the cells were irradiated with 665 nm light at a fluence of 0.25 J/cm2, followed by 
incubation for another 48 h. Cell viability was then assessed by MTT assay. Figure 3B shows 
the plot of cell viability as a function of HPPH concentration under different conditions. The 
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dose response curves were fitted by the method of least squares. The estimated IC50 
concentrations were 57 and 27 nM for HPPH and AuNC-HPPH, respectively (p < 0.05). The 
relatively-high potency of the AuNC-HPPH could be the result of the increased 1O2 generation 






Figure 3. (A) Fluorescence spectra of SOSG in PBS/D2O after different treatments: in the dark 
as a control (black dashes), and after light irradiation at 665 nm with a dose of 15 J/cm2 and 
treatment with AuNC-HPPH (red) or HPPH (green). (B) Plot of cell viability as a function of 
concentration after treatment with free HPPH (black) and AuNC-HPPH (red), followed by light 
irradiation at a fluence of 0.25 J/cm2. The dose response curves were fitted using the method of 
least squares (p < 0.05).  
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The delivery of HPPH to the tumor was further monitored by fluorescence imaging in vivo using 
a Colon-26 tumor-bearing mouse model. Two groups of Colon-26 tumor-bearing BALB/c mice 
(3 mice per group) were intravenously administered with free HPPH and AuNC-HPPH using 
equal HPPH amounts (0.3 µmol/kg). The fluorescence intensity of the tumor region was 
monitored up to 48 h post-injection. Figure 4, A-F and G-L show the fluorescence images of 
representative mice injected by AuNC-HPPH and HPPH, respectively. In either case, the 
fluorescence at the tumor region increased with time and reached a peak at 24 h post-injection. 
The strong fluorescence signal was mainly localized at the tumor region for the AuNC-HPPH 
treated mouse whereas the fluorescence intensity was relatively weak at the tumor site and 
elevated in other organs for the HPPH treated mouse. The fluorescence intensity of the tumor 
region was further plotted as a function of post-injection time for the two groups (Fig. 4M). A 
linear model is fitted to the fluorescence data, resulting in p < 0.05 for all time points. At 2 h 
post-injection, the fluorescence intensity for the HPPH was higher than that for the AuNC-
HPPH. This discrepancy could be attributed to two factors: different accumulation rates for small 
molecules and nanoparticles and/or fluorescence quenching of HPPH at close proximity to the 
AuNC surface. At 8 h post-injection, the fluorescence intensity for the HPPH was significantly 
lower than that of the AuNC-HPPH, suggesting that the HPPH gradually released from the 
conjugates in agreement with the release profile in serum discussed earlier. At the same time, 
the AuNC-HPPH was accumulated more efficiently within the tumor as compared to the HPPH 





Figure 4. In vivo whole-body fluorescence images of Colon-26 tumor-bearing mice acquired 
after intravenous injection of 0.3 μmol/kg of HPPH as AuNC-HPPH (A-F) and HPPH (G-L). 
(M) Plot of fluorescence intensity of the tumor region as a function of time for two groups of 
mice (3 mice per group) intravenously administered with AuNC-HPPH (red) and HPPH (black). 
The mean values and the standard errors were obtained by fitting the raw data using a linear 
model (p < 0.05). The measurements at each time point were labeled for AuNC-HPPH (triangles) 




The PDT efficacy was evaluated in vivo using Colon-26 tumor-bearing mouse model. Two 
groups of tumor-bearing mice (5 mice per group) were intravenously injected with HPPH (0.3 
µmol/kg) as free HPPH or AuNC-HPPH. As a control group, 5 mice were intravenously injected 
with PBS. Guided by FL imaging, the mice were treated with 665-nm laser irradiation for 30 
min with a total light dose of 135 J/cm2 at 24 h post-injection when the accumulation of the 
conjugates reached the peak. After the PDT treatment, tumor growth was monitored by 
measuring the tumor size for up to 60 days. The mice were euthanized when the tumor grew to 
400 mm3. Figure 5 shows the Kaplan-Meier plot (percent survival versus time) that compares 
the in vivo PDT efficacies of three groups treated with different conditions. Of the mice treated 
with free HPPH, only 1 of the 5 mice remained alive with tumor size < 400 mm3 (20% survival) 
at 60 days post-treatment. Of the mice treated with AuNC-HPPH, 3 of 5 mice survived with 
tumor size remained < 400 mm3 (60% survival) at 60 days post-treatment. In contrast, no mouse 
in the control group with PBS injection survived beyond 15 days post-treatment. These results 
suggest that the survival rate of the AuNC-HPPH treated mice is higher than the HPPH-treated 
mice under the same irradiation condition, indicating the higher potency of AuNC-HPPH as 





Figure 5. Kaplan-Meier plot of percent survival of Colon-26 tumor-bearing mice after 
intravenous injection of PBS (green), HPPH (0.3 μmol HPPH/kg, black), and AuNC-HPPH (0.3 
μmol HPPH/kg, red), followed by light irradiation with a fluence of 135 J/cm2.  
87 
 
The high potency of the AuNC-HPPH formulation could be attributed to the increased 
accumulation of HPPH to the tumor region through the EPR effect of the nanocarriers, as well 
as the enhanced 1O2 generation in the presence of AuNC. Due to the high HPPH loading per 
AuNC (1 × 105 HPPHs per AuNC), the AuNC dose is on the order of 30 pM which is nearly 
three orders of magnitude lower than that of PTT (10 nM).(58) Under PDT conditions (75 
mW/cm2 for 30 min), the temperature rise of ~0.1 nM AuNC-HPPH was negligible 
(Supplementary Material: Fig. S5A). In this case, the photothermal effect on the PDT efficacy 
could be ruled out. Additionally, the entrapped HPPH has essentially no influence on the 
photothermal capability of the AuNCs (Supplementary Material: Fig. S5B). Potentially, the PDT 
and PTT can be combined to further improve the survival rate of cancer. 
Photoacoustic imaging was used to further assess the PDT efficacy in vivo. This method was 
demonstrated on a tumor-bearing BALB/c mouse which was imaged before and after 
intratumoral injection of AuNC-HPPH, followed by PDT treatment. Figure 6, A-E, shows 
photographs of the tumor taken before and over nine days following PDT post injection of 
AuNC-HPPH. Prior to intratumoral injection of AuNC-HPPH, a control PA image was acquired 
at an optical wavelength of 829 nm (Fig. 6F). The tumor boundary and tumor-feeding 
vasculature were clearly visualized. After injection of AuNC-HPPH, the distribution of AuNC-
HPPH within the tumor was clearly mapped (Fig. 6G) and served as background signal of 
AuNCs. After PDT, a series of PA images were obtained at 3, 7 and 9 days post-treatment (Fig. 
6, H-J). The PA amplitude increased significantly after PDT treatment, suggesting that the 
contrast mainly resulted from the necrotic effect due to the draining of AuNCs from the tumor 
region over a long period of time. Thus, mapping of the PA signal provides information about 
the necrotic region after PDT treatment. At 7 days post-treatment, the PA signal amplitude 
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further increased in the tumor necrotic region whose boundary matched well with the 
corresponding photograph. Figure 6, K-O, shows the respective depth-sensitive cross-sectional 
PA B-scan images of Figure 6, F-J. The imaging depth information of Fig 6, K-O, was further 
mapped using pseudo color as shown in Figure 6, P-T, respectively. The bottom of the tumor 





Figure 6. (A-E) Photograph of the tumor taken before and after PDT with an injection of AuNC-
HPPH at various time points up to 9 days. PA images acquired (F) before intratumoral injection 
of AuNC-HPPH, (G) after injection, and (H-J) 3, 7, and 9 days post-treatment. (K-O) Depth-
resolved PA B-scan images cut along the dotted lines in (F-J), respectively. (P-T) Depth-encoded 




In order to translate the conjugate to clinic, the biocompatibility of AuNCs is important from a 
clinical perspective. The biosafety of AuNCs has yet to be understood or well studied in animals, 
although several studies have been performed on therapeutic Au-based nanoparticles such as 
spherical particles,(59) SiO2@Au core-shell particles,(60) and nanorods.(61) In this study, we 
investigate the biodistribution and short-term toxicity of AuNC-PEG at therapeutic or higher 
dose. AuNC is an excellent exogenous contrast agent for PA imaging with a detection limit of 
4.5 pM (or ~9 × 10-21 mol of AuNCs per imaging voxel). We have demonstrated the use of PA 
to quantify the accumulation of AuNC-PEGs ex vivo 24 h post-injection.(13) Three groups of 
BALB/c mice (n = 3 per group) were intravenously injected with a dose of 100 µL AuNCs with 
three different concentrations, 10, 30, and 100 nM (1, 3, and 10 pmol). For comparison, the 
corresponding organs from untreated mice were used as controls. Figure 7A shows the 
photograph of the four excised spleens with injections of 0, 1, 3, and 10 pmol of AuNCs, and 
their corresponding PA images (Fig. 7B). The PA signal of the spleen increases with the 
injection dose. The PA amplitude of the spleen collected from the mouse after injection of AuNC 
at a dose of 10 pmol was ~740 % stronger than that from a non-treated mouse. The PA 
amplitude from the different organs was plotted in Figure 7C. The PA signal intensity is dose-
dependent, and the change of signal was low at the therapeutic dose (1 pmol) as compared to the 






Figure 7. Biodistribution study of mice that were intravenously injected with 100 μL of AuNC-
PEGs at different concentrations for 24 h. (A) Photographs of excised spleens, (B) ex vivo PA 
images of excised spleens acquired at 700 nm, and (C) biodistribution of AuNCs in different 
excised organs.   
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The short-term toxicity was also performed for both the therapeutic dose of AuNC-HPPH and 
high dose of AuNC-PEG. In this study, mice were monitored for 28 days after injection of 
therapeutic dose of AuNC-HPPH (0.3 µmol/kg HPPH) and three different doses of AuNC-PEG 
(1, 3, and 10 pmol) to examine any phenotypical changes. During the course of the 
experiment, neither weight loss nor abnormal behavior was observed in any of the mice. After 
28 day post-treatment, histological analysis was performed on five organs including spleen, liver, 
kidney, lung, and heart (Fig. 8). No tissue toxicity or visible differences were found with 
therapeutic dose of AuNC-HPPH compared to the control mice without treatment. Similar result 
was found in 7 day post-treatment without any observable difference (Supplementary Material: 
Fig. S6). When the dose of AuNC-PEG (10 pmol) was increased to ~100 times of the therapeutic 
dose (~0.1 pmol), scattered macrophages with multiple dark granules in the cytoplasm were 
found, indicating the presence of AuNCs in the spleen of the mice. Macrophages are known sites 
for nanoparticle accumulation and actively take up various nanoparticles.(63) Similar uptake by 
the macrophages was observed in the liver, however, no dark granules were found in the Kupffer 
cells in the same mouse. No dark granules were found in the kidney, lung, and heart of the 
mouse at the dose of 10 pmol. These results suggest that there was no observable toxicity at the 
therapeutic dose of AuNC-HPPH or even at 100-fold higher than therapeutic dose of AuNC-PEG 





Figure 8. Photographs of representative H&E staining tissue sections of mice after 28 days of 
different treated conditions: Control mouse without treatment (left column), AuNC-HPPH 
treated at 0.3 μmol/kg of HPPH (middle column), and AuNC treated at a dose of 10 pmol (right 





We have demonstrated AuNC-HPPH conjugates as a multifunctional agent for enhanced PDT. 
HPPH entrapped within a PEG layer can be delivered more effectively to the tumor as compared 
to free HPPH. The presence of the AuNCs enhances the 1O2 generation and the phototoxicity of 
the HPPH in vitro. The growth of the tumor in vivo was suppressed possibly due to the 
combination of the effective delivery and the enhanced phototoxicity of the AuNC-HPPH 
conjugates. In addition, the FL and PA imaging were demonstrated as an informative tool to 
monitor the progression of delivery and tumor treatment following PDT. A short-term study 
showed a relatively-low toxicity of the therapeutic-dose conjugates and high-dose AuNCs. This 
AuNC-HPPH system could potentially be translated from bench-top research to preclinical and 
clinical trials. 
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Materials and Methods 
Synthesis and PEGylation of AuNCs: The AuNCs were synthesized by a two-step process using 
Ag cubes as a sacrificial template in the galvanic replacement reaction.(42) The LSPR peak of 
the AuNCs was tuned to 798 nm as monitored using a UV-Vis-NIR spectrometer (Agilent 





composition of the AuNCs was measured by atomic absorption spectrometer (GBC 932). The 
surface of the AuNCs was then derivatized with amine-terminated PEG thiol (HS-PEG-NH3 
M.W. = 5,000, JenKem). Briefly, 4 mg HS-PEG-NH3 was dissolved in 4 mL water in a 20 
mL vial. The solution was placed in an ice bath with stirring for 5 min. To this solution, 8 
mL of 1 nM AuNC suspension was added dropwise over 5 min. The vial was flushed with argon 
for 10 min and allowed to stir overnight in the dark. After conjugation, the excess PEG was 
removed by washing the PEGylated AuNCs (AuNC-PEG) with water 3 times. The AuNC-PEG 
were redispersed in phosphate buffered saline (PBS) at a concentration of ~3 nM. The 
hydrodynamic diameter and zeta potential were determined using dynamic light scattering 
instrument (Brookhaven ZetaPALS). 
Entrapment of photosensitizers to AuNC-PEGs: The photosensitizer, 3-devinyl-3-(1’-
hexyloxyethyl) pyropheophorbide (HPPH) which was prepared in Dr. Pandey’s laboratory,(43) 
was used in this study. The HPPH (7 mg, 11 μmol) was dissolved in 2.5 mL DMSO at a 
concentration of 4.5 mM as a stock solution. This stock solution (0.25 mL) was diluted in 4 mL 
of PBS to a concentration of ~0.3 mM. The diluted HPPH solution was flushed with Ar for 5 min 
and allowed to mix for an additional 5 min. The AuNC-PEG solution (3 nM, 2 mL) was added 
dropwise to the HPPH solution, and the reaction was allowed to stir overnight under the 
protection of argon in the dark. The product, containing noncovalently-incorporated HPPH on 
AuNC-PEG (AuNC-HPPH), was then washed with PBS three times and redispersed in PBS at a 
concentration of 6 nM with a loading efficiency of ~1 × 105 HPPHs per AuNC. 
The release of HPPH was monitored by fluorescence (Horiba FluoroLog3), optical absorbance, 
and PA amplitude in serum. The PA measurement was performed using a home-made PA 
imaging system.(44, 45) Briefly, a tunable OPO laser (Surelite OPO PLUS, Continuum) 
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pumped by a Q-switched Nd:YAG laser (SLII-10, Continuum) produced laser pulses with 5 ns 
pulse widths at a rate of 10 Hz. The illumination was focused on a Tygon tube filled with an 
aqueous suspension of AuNC-HPPH conjugates with serum. The resultant PA waves were 
detected by a 5 MHz ultrasound transducer (V308, Panametrics-NDT). For each data point, the 
PA signals were averaged from 10 B-scan images of the same solution at multiple positions at 
wavelengths of 665 and 685 nm. 
Measurement of singlet oxygen generation: The production of 1O2 was monitored with singlet 
oxygen sensor green® (SOSG, Invitrogen). Measurements were carried out in D2O (Cambridge 
Isotope Laboratories) to increase 1O2 lifetime. Briefly, SOSG was dissolved in MeOH at a 
concentration of ~5 mM as a stock solution and then diluted in 2 mL of PBS in D2O to give a 
final concentration of ~10 µM. Equimolar HPPH as free HPPH or AuNC-HPPH was added 
to the SOSG solution. Each sample was irradiated for 20 min by a Xenon lamp (Newport) with 
a 650-680 nm filter and a fluence of 15 J/cm2. After irradiation, AuNCs were digested by 
addition of 10 µL of 0.5 M KCN for 10 min to advoid interference. Fluorescence spectra of 
SOSG were acquired using λex = 488 nm. 
Cell line and animal model: The Colon-26 cell line was cultured in RPMI medium 
(Invitrogen) supplemented with 10% fetal bovine serum (FBS, Hyclone) at 37 °C with 5% CO2. 
BALB/c mice, aged 6-8 weeks, were obtained from the National Cancer Institute (NCI). The 
Colon-26 tumor model was generated by subcutaneous injection of ~1 × 106 Colon-26 cells in 
100 µL PBS into the right rear flank. Animals used in the studies had a tumor volume of 50-60 
mm3 (typically 5-7 days after inoculation). All animal experiments were conducted in 
compliance with the guidelines for the care and use of research animals established by the 




Evaluation of PDT efficacy in vitro: The Colon-26 cells were reseeded in 96-well plates at a 
density of 3 × 103 cells/well. After overnight incubation, equimolar HPPH as free HPPH or 
AuNC-HPPH were added to the wells and incubated at 37 °C with 5% CO2 for 24 h in the dark. 
Before PDT treatment, the medium was replaced with fresh drug-free medium. The cells were 
then illuminated by the argon-pumped dye laser at a wavelength of 665 nm and a fluence of 
0.25 J/cm2. After PDT treatment, the cells were incubated for another 48 h at 37 °C with 5% 
CO2 in the dark. The cell viability was assessed by 3-[4, 5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazoliumbromide (MTT) assay. Briefly, 10 µL of 4 mg/mL MTT in PBS was added to 
each well and incubated for 4 h. After incubation, the solution was completely removed, and then 
100 µL DMSO was added to dissolve the formazan crystals in each well. The absorbance at 570 
nm was read using a microplate reader (BioTek ELx800). Each experiment was performed with 
three replicates. 
Fluorescence imaging in vivo: Six tumor-bearing mice (~ 20 g) were randomly divided into two 
groups (n = 3). The mice were anesthetized by inhalation of isoflurane (2% in 100% oxygen). 
The mice in Groups 1 and 2 were injected intravenously with 0.3 µmol/kg HPPH as free HPPH 
and AuNC-HPPH, respectively. Prior to fluorescence imaging, the hair at the tumor region was 
depilated using a hair-removal lotion. The mice were imaged using a Nuance optical imaging 
system (Cambridge Research) with excitation wavelength at 665 nm. Fluorescence images were 
acquired using a 700 nm long pass filter. The fluorescence intensity of the region of interest 
(ROI) encompassing the tumor was analyzed for each image using the Image J (NIH) software. 
Evaluation of PDT efficacy in vivo: Fourteen tumor-bearing mice (~ 20 g) were randomly 
divided into three groups. The mice in Groups 3 (n = 4) and 4 (n = 5) were intravenously injected 
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with 0.3 µmol/kg HPPH as AuNC-HPPH and free HPPH, respectively. The mice in Group 5 (n 
= 5) were administered with 100 µL of PBS as a control. At 24 h post-injection, each mouse 
was positioned in a specially-designed mouse holder and exposed to laser irradiation at a 
wavelength of 665 nm with a fluence of 135 J/cm2 at a rate of 75 mW/cm2 under the non-
anesthetic condition. After irradiation, the tumor regrowth of each mouse was monitored. Mice 
were monitored up to 60 days post-treatment and euthanized once the tumor volume reached 
400 mm3. The results were plotted as Kaplan-Meier curve using Graphpad Prism software. 
PA monitoring of PDT in vivo: The in vivo PA experiments were carried out using the same 
system as described previously for monitoring the release kinetics. To enhance the spatial 
resolution, a 10-MHz-single-element ultrasound transducer was used with the resolutions of 125 
μm and 140 μm in the axial and transverse directions, respectively. Each volumetric image with 
a field of view (FOV) of 1.4 × 1.4 cm2 took ~25 min with a fluence of 1 mJ/cm2. The mice 
were initially anesthetized by intraperitoneal injection of a mixture of ketamine (85 mg/kg) of 
body with hematoxylin and eosin (H&E) for histology studies. 
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Appendix A: Supporting Information  
 
 
Figure S1. Plot of AuNC concentration against extinction intensity at 802 nm. The particle 
concentration of AuNCs was estimated from the size and composition of AuNCs directly 
measured from the TEM and AA analyses. Based on Beer-Lambert law, a linear fit to the data 





Figure S2. Plot of HPPH concentration against emission intensity at 670 nm as a calibration 





Figure S3. (A) Fluorescence spectra of AuNC-HPPH at different time points of incubation in 
serum. Spectra were taken after incubation for 20 s, 10, 20, 30, 45, 60, 75, 90, 120 min, 4, 6, 8, 
12, and 24 h, as well as post-KCN digestion with λex = 605 nm. (B) UV-Vis absorbance spectra 
of supernatants of AuNC-HPPH incubated in serum for 5 min and 24 h after 15 min 





Figure S4. (A) Fluorescence spectra for PBS/D2O solution of only SOSG before (black) and 
after (green) irradiation, as well as for PBS/D2O dispersion of 10 pM AuNC and SOSG before 
(dashed) and after (red) irradiation. (B) Fluorescence spectra of SOSG in methanol with 
equimolar HPPH (green), AuNC-HPPH conjugate (red), and mixture of AuNC-PEG and HPPH 





Figure S5. The temperature profile of AuNC and AuNC-HPPH that were irradiation under 
different conditions: (A) 0.1 nM AuNC irradiated with 665-nm laser at 75 mW/cm2 (PDT 





Figure S6. Photographs of representative H&E staining tissue sections of mice after 7 days post-




Appendix B: Unpublished Data 
A covalent conjugate between AuNC-PEG and HPPH was synthesized. Briefly, 1 mg of N-
hydroxysuccinimide and 1 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide were 
incubated in DMSO with 0.17 mM HPPH for 30 min. To this solution, AuNC-PEG with NH2 
terminus was added dropwise to a final concentration of 1 nM. The reaction was allowed to 
proceed overnight and the product was isolated by centrifugation. No significant change was 
observed in the UV-Vis spectrum (Fig. B1A) of the product, but following KCN digestion, the 
fluorescent signal (Fig. B1B) indicated that that ~5×103 HPPH/AuNC had been conjugated. 
Assuming 2×104 PEG/AuNC,[1] the conjugation efficiency was ~25 %. This conjugate was then 
tested for its photodynamic efficacy in vitro using Colon-26 tumor cells (Fig. B1C). This 
construct was found to be significantly less effective than free HPPH, which was presumably due 
to excited state quenching by the AuNC. The IC50 for the conjugate was ~400 µM, while the IC50 
for free HPPH was 57 µM.[2] This result stands in contrast to the noncovalent conjugate, 




Figure B1. (A) Extinction spectrum and (B) post-KCN digestion fluorescence spectrum of 
covalently-conjugated AuNC-HPPH as well as (C) Viability plot of tumor cells treated with 
(squares) HPPH, (triangles) 10 nM AuNC-HPPH, and (circles) 30 nM AuNC-HPPH at 




The role of the AuNC’s LSPR in 1O2 generation was investigated further. AuNCs were 
synthesized with LSPR at 660 nm. The edge length of AuNCs were found to be 18 ± 2.5 nm (Fig 
B2A). These AuNCs were treated with HS-PEG-NH2 similar to AuNCs with LSPR at 800 nm[2] 
before they were noncovalently conjugated with HPPH. The loading was found to be ~105 
HPPH/AuNC. The LSPR peak did not shift significantly (Fig B2B), but the absorbance peaks 
from HPPH emerged, resulting in a strong peak at 685 nm, the wavelength of 1O2 generation. 
The generation of 1O2 was then measured using SOSG and compared to free HPPH and AuNC-
HPPH with LSPR at 800 nm (Fig. B2C). Interestingly, AuNC665 conjugate showed reduced 1O2 
generation relative to free HPPH and the AuNC800 conjugate. The AuNC800 conjugate showed 
improved 1O2 generation relative to free HPPH. This discrepancy can be attributed to two 
phenomena. First, the AuNC665 LSPR overlaps with the absorbance of HPPH, thereby resulting 
in a lowered light dose to the photosensitizer. Second, the AuNC800 LSPR overlaps with the 
phosphorescent emission of porphyrins.[3] The LSPR has been shown to stabilize the triplet state 
of nearby molecules in a manner similar to its enhancement of fluorescence.[4] Stabilization of 
the triplet state allows for a longer lifetime, increasing the likelihood of collision with ground O2 
to allow triplet-triplet annihilation to generate 1O2. These results demonstrate the importance of 








Figure B2. (A) TEM of AuNC with LSPR maximum at 665 nm and (B) extinction spectrum of 
AuNCs in A (black) before and (green) after loading of HPPH and (C) singlet oxygen generation 
of equimolar HPPH as measured by SOSG for (green) free HPPH, (blue) AuNC-HPPH with 
LSPR maximum at 665 nm, and (red) AuNC-HPPH with LSPR maximum at 800 nm. Dashed 
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Chapter IV.  Understanding the Interactions between Porphyrin Photosensitizers and 
Polymer-Coated Nanoparticles in Model Biological Environments* 
Abstract 
 Non-covalent incorporation of hydrophobic drugs into polymeric systems is a commonly-used 
strategy for drug delivery because non-covalent interactions minimize modification of the drug 
molecules, and their efficacy is retained upon release. The behaviors of the drug-polymer 
delivery system in the biological environment it encounters will affect the efficacy of treatment. 
In this report, we have investigated the interaction between a hydrophobic drug and its 
encapsulating polymer in model biological environments using a photosensitizer encapsulated 
polymer-coated nanoparticle system. The photosensitizer, 3-(1’-hexyloxyethyl)-3-
devinylpyropheophorbide-a (HPPH), was non-covalently incorporated to the poly(ethylene 
glycol) (PEG) monolayer coated on Au nanocages (AuNCs) as AuNC-HPPH conjugates. The 
non-covalent binding was characterized by Scatchard analysis, fluorescence lifetime, and Raman 
experiments. The dissociation constant (Kd) between PEG and HPPH was found to be ~35 µM 
with a maximum loading of ~2.5 × 105 HPPHs/AuNC. The release was studied in a serum 
mimetic environment and in vesicles that models human cell membranes. The rate of the drug 
release mediated by proteins decreased with negatively-charged terminus of surface modified 
PEG or cross-linking of the terminus. Furthermore, the photothermal effect of AuNC can initiate 
burst release, and thus control of the release kinetics, demonstrating on-demand drug release.   
 
*Submitted: Jenkins, S.V.; Srivatsan A.; Reynolds, K.Y.; Gao, F; Zhang, Y.; Heyes, C.D.; 





Controlled release systems for drug delivery using nanocarriers have been developed and studied 
for more than three decades.[1] Gold nanostructures have been used as drug delivery vehicles in 
chemotherapy because of their biocompatibility, facile surface modification, and robust optical 
properties.[2-8] While drug molecules can be covalently immobilized on the nanoparticles’ 
surface,[2, 8-10] noncovalent interactions are particularly appealing because they minimize 
modification of the drug molecules, whose efficacy is then largely retained upon release. Several 
strategies have been developed to noncovalently tether molecules through electrostatic and 
hydrophobic interactions to polymer-coated nanoparticles by wrapping into layer-by-layer 
assembled polyelectrolytes,[11] entrapping in a polymer monolayer,[12-14] encapsulating into 
phospholipid bilayer,[15] or absorbing into a hydrogel.[16] Among these methods, poly(ethylene 
glycol) (PEG) coated nanoparticles are advantageous because PEG is generally nontoxic and 
possesses antifouling properties well suited for increasing circulation half-life and minimizing 
immunological clearance.[17]  Hydrophobic phthalocyanine photosensitizers[18-20] or anti-cancer 
drugs[21, 22] could be delivered within the surface PEG layer or inside the hydrophobic pocket for 
photodynamic therapy or chemotherapy. We have recently applied a similar system to deliver a 
hydrophobic porphyrin-derivative (3-(1’-hexyloxyethyl)-3-devinylpyropheophorbide-a, HPPH) 
for image-guided photodynamic therapy with enhanced efficacy.[14]  
In this work, we systematically investigate the binding affinity and the release kinetics of HPPH 
from PEG-coated AuNCs to further elucidate the behavior of the drug-polymer delivery system. 
The induced-dipole/induced-dipole interactions between the pheophorbide and the PEG 
backbone serve as the driving force to load molecules within the PEG layer.[23] HPPH is stably 
integrated within the PEG coating of AuNC-HPPH in saline solution. The release itself is 
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mediated by either serum proteins (specifically albumin in our model) or cell membranes 
(modelled here with vesicles). The serum proteins unloaded the drug over several hours and the 
release of entrapped molecules can be endogenously controlled by the charge and functionality 
of the PEG terminus. Additionally, the release rate can be exogenously controlled by utilizing the 
photothermal (PT) effect of Au nanostructures which allows external and temporal control of the 
drug release by non-invasive near-infrared light.[11, 24-27]  By manipulating these variables, we are 
able to demonstrate on-demand unloading of the drug with minimal premature loss and were able 
to suggest the relative affinity of the drug for soluble proteins versus cell membranes.  
Results and Discussion 
The AuNC-HPPH conjugates were prepared according to the method previously reported[14] by 
covalently attaching HS-PEG-X to the nanoparticle surface and subsequently encapsulating 
HPPH into the PEG monolayer. AuNCs with an average exterior edge length of 52.6 ± 8.2 nm 
and interior edge length of 41.2 ± 6.2 nm were synthesized for this study. After their surface was 
coated with HS-PEG-NH3+, the LSPR of the AuNCs was centered at 801 nm (Fig. 1A), slightly 
redshifted from the LSPR of the “bare” AuNCs at 798 nm (Fig. S1A). This LSPR maximum falls 
within the tissue-transparent window and overlaps the 808 nm wavelength of the diode laser 
utilized for PT release. Figure 1B shows the spectral changes after loading; the LSPR of AuNCs 
was further redshifted to 829 nm, which can be attributed to a change in the refractive index of 
the local surface environment.[28] The peaks at 512, 545, 617, and 669 nm are attributed to 
absorption by the HPPH molecules (Fig. S1B). The fluorescence was quenched after loading due 
to static/contact quenching in the HPPH, nanometal surface energy transfer, light being absorbed 
by the AuNCs, or a combination thereof.[29-32] After the AuNCs were digested by KCN, the 
fluorescence was recovered, and then quantified by comparison to the calibration curve (Figs. 
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1C, S2A). The AuNC concentration was initially determined by flame atomic absorbance 







Figure 1. Normalized UV-Vis-NIR spectra (A) AuNC before and (B) after loading with HPPH. 
Inset shows TEM image of AuNCs with a 50 nm scale bar. (C) Fluorescence spectra of HPPH-
loaded AuNCs, before (green) and after (red) KCN digestion of AuNCs.   
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The loaded concentration of HPPH increased to a maximum on the order of 105 HPPHs per 
AuNC. As the loading increased, the hydrodynamic diameter (dH) slightly increased from 98.7 ± 
0.9  to 105.3 ± 2.8  nm while the zeta potential decreased from +6.4 ± 0.5 to -26.3 ± 0.8 mV 
(Fig. 2A). The dH remained more or less constant, suggesting that HPPH was mostly entangled 
within the PEG monolayer on the nanocage surface rather than aggregating on top of the 
monolayer. Earlier theoretical work simulated that the addition of PEG to a solution of 
hematoporphyrin resulted in concentration-dependent porphyrin deaggregation and association 
with the PEG chains through strong interaction between the –CH2CH2– region of the PEG chain 
and the porphyrin ring.[23] The decrease of zeta potential is likely due to the increasing amount of 
negatively-charged HPPH in the conjugates.  
The hydrophobic interaction between PEG and HPPH was further confirmed by studying the 
binding affinity. Increasing amounts of HPPH were introduced to phosphate buffer (10 mM, pH 
7.4) with 0 or 135 mM NaCl at constant AuNC-PEG concentration. After incubation overnight, 
the unbound HPPH concentration was determined by the absorbance at 669 nm upon removal of 
AuNCs by centrifugation. The bound HPPH (Lb) was taken to be the difference between the total 
(Lt) and the unbound HPPH (Lu) concentration. No loss of HPPH was seen in the absence of 
AuNCs. A saturation binding isotherm (Fig 2B) was developed, and Scatchard analysis results in 
a plot that is both hyperbolic and concave up, consistent with nonspecific binding between PEG 
and HPPH.[33] The data were fit to the equation Lb = N × Lu / (Kd,ns + Lu), where Kd,ns is the 
dissociation constant for nonspecific binding and N is a constant loosely related to the number of 
available binding sites.[34] Based on the fitting, the Kd,ns was determined to be  3.2 x 10-5 M and 
3.7 x 10-5 M for 0 mM and 135 mM NaCl, respectively, which is similar to simulation results on 
similar molecules;[23] the respective N values increased from ~100 to ~180. These data suggest 
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that the NaCl does not enhance binding between HPPH and PEG, but makes available additional 
binding sites, increasing the packing density of HPPH. The presence of aqueous ions 
significantly increased the available binding sites of PEG and HPPH due to a further exposure of 
–CH2CH2– of PEG to the porphyrin ring of HPPH, which ultimately caused a near doubling the 
N value. Moreover, the loaded HPPH reached a maximum at ~2.5 × 105 HPPHs/AuNC, 





Figure 2. (A) Zeta potential (diamonds) and hydrodynamic diameter (squares) as measured by 
DLS for AuNC-HPPH at varying ratios of HPPH to AuNC. (B) Saturation binding isotherm 
between HPPH and the PEG monolayer on AuNC surface, AuNC concentration (1 nM) using 0 
mM (squares) or 135 mM (circles) NaCl in 10 mM phosphate buffer (pH = 7.4). The red line 






The fluorescent properties of HPPH inside the PEG layer on the AuNCs was examined by the 
fluorescence lifetimes of the conjugates (Fig. 3A). Due to quenching, the quantum yields were 
very low, but a weak signal was present. The HPPH lifetime (τavg) for AuNC-HPPH was 
measured to be 1.39 ns, comparable to that in PBS (1.51 ns) and appreciably shorter than in 
methanol (6.55 ns) or BSA (7.21 ns). Even when the loading concentration was reduced to 5 × 
103 HPPHs per AuNC, the lifetime increased only slightly to 2.69 ns. These data suggest that the 
HPPH molecules in AuNC-HPPH are in close proximity to each other, similar to the small 
aggregates that have been generated in PBS.[35] The proximity of HPPH to the AuNC surface 
was characterized by Raman spectroscopy (Fig. 3B). Raman spectra were acquired at excitation 
wavelength of 488 nm and the signal intensities were compared for different forms of HPPH at a 
concentration of 100 nM. The samples include free HPPH, AuNC-HPPH (5 × 103 HPPHs per 
AuNC), and AuNC-HPPH (1 × 105 HPPHs per AuNC). The peak at 1641 cm-1 was assigned to 
the weak Raman signal from water. The C-H peaks at ~2950 cm-1 in these spectra likely 
originate from the PEG as the intensity does not change with the HPPH concentration. The broad 
Gaussian region from 2000 to 2500 cm-1 (540-555 nm) in the free HPPH was attributed to weak 
fluorescence of HPPH. The high loading concentration gave rise to a typical Raman peak at 1590 
cm-1 that corresponds to the vibration of aromatic bonds in the macrocycle[36], suggesting that the 
pheophorbide ring is oriented somewhat perpendicularly to the surface of the metal.[37]  At low 
concentration, the Raman signature disappeared and was replaced by a broad fluorescence peak 
centered at 2340 cm-1. These data suggest that HPPH may be driven deeper in the monolayer and 
closer to the metal surface at higher concentrations. These results suggest HPPHs were densely 





Figure 3. (A) Fluorescence lifetime measurements of HPPH under various conditions: dispersed 
in methanol (violet), 4% w/w BSA solution (blue), PBS (green) and as AuNC-HPPH in PBS 
loaded at 5000 HPPHs/AuNC (red) and 105 HPPHs/AuNC (cyan). (B) Raman spectra of 100 nM 
HPPH under various conditions: (a) free HPPH, (b) AuNC-HPPH (~5000 HPPHs/AuNC, 20 pM 
AuNC), and (c) AuNC-HPPH (~105 HPPHs/AuNC, 1 pM AuNC); spectra were acquired over 




The release of the drug was monitored in a serum-mimetic environment to simulate intravenous 
injection (Fig. 4A).[38] Fluorescence gradually recovered over 32 h when incubated in 4 wt % 
BSA (~600 µM, 37 °C, pH = 7.4).[39] As a control, AuNC-HPPH was also incubated in PBS, and 
release was monitored using supernatant absorbance at various times compared to the maximum. 
It was found that 86.3 ± 7.6 % of HPPH had been unloaded in the BSA solution within 24 h, but 
only 4.7 ± 2.1 % of the payload had unloaded in PBS. PEG monolayers are known to resist 
formation of a “hard” (nonremovable) protein corona,[40, 41] therefore the release is attributable to 
the formation of a “soft” protein corona, which entails rapid adsorption and desorption of serum 
proteins on the PEG surface.[42, 43] During this transient event, BSA presumably binds HPPH, 
which then desorbs with the protein. The Kd,ns of PEG-HPPH complexes is on the order of 10-5 
M, much larger than the typical Kd values of BSA-porphyrin complexes (~10-9 M),[44, 45] ergo it 
would be energetically favorable for BSA to bind HPPH, releasing it from the PEG.  
The PEG terminus was changed by conjugating AuNCs to either amine- or carboxylate- 
terminated PEG prior to HPPH loading (AuNC-HPPH and AuNCCOO-HPPH, respectively), 
which was found to significantly affect the kinetics of HPPH release. Replacing the cationic 
(NH3+) with anionic (COO-) termini, resulted in slower unloading kinetics with only 50.1 ± 6.8 
% release within 24 h. Because the isoelectric point of BSA is 4.7, it is negatively charged at pH 
= 7.4, and should therefore be repelled by the carboxylate terminus of the PEG,[46] which in turn 
retards the unloading of HPPH. The release rate could be further slowed by cross-linking the 
termini of the PEGs on the surface (Fig. 4B). Amide coupling between the cross-linker, HOOC-
PEG250-COOH (3-4 repeating units), and the NH3+ terminus of the PEG resulted in steric 
hindrance that blocked protein binding. Cross-linking with PEG250 resulted in a dramatic 
reduction of the HPPH release to only 31.1 ± 8.7 % within 32 h as compared to the release of 
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Figure 4. (A) Comparison of HPPH release kinetics at pH = 7.4, 37 °C for AuNC-HPPH using 
PEG-NH3+ (squares) and PEG-COO- (diamonds) with 4% w/w BSA in PBS, and in  only PBS 
(triangles). (B) Comparison of HPPH release kinetics from AuNC-HPPH without (squares) and 
with (triangles) cross-linking of the polymer terminus (-NH2) by HOOC-PEG-COOH. Maximum 
(100%) values were determined by the recovered fluorescence signal after the AuNCs were 




Ideally, AuNC-HPPH is anticipated to unload the HPPH in the tumor cell membrane for 
maximal photodynamic effect due to the short lifetime of singlet oxygen. Vesicles were prepared 
with a 3:1 mole ratio of DMPC and DMPG to mimic the composition of human cell membranes. 
Incorporation of HPPH in the vesicle membrane (1 mM lipid solution) leads to recovery of its 
fluorescence; therefore the release could be monitored similarly to BSA solutions. The release of 
HPPH to the vesicle solution was compared for free HPPH and AuNC-HPPH (Fig 5). Similar to 
the BSA solution, ~90 % of the HPPH unloaded from the AuNC-HPPH after 24 h. It is worth 
noting that unlike tumor cells, the vesicles were free in solution and able to interact freely with 
suspended particles, which would artificially inflate the kinetics of the process. Interestingly, free 
HPPH did not reach its maximum signal until between 2 and 4 h incubation in the vesicle 
solution, whereas the BSA solution of free HPPH reached a maximum within 10 min. These 
results imply that kinetics of HPPH adsorption are much higher for BSA than for the cell 
membrane. However, the release from AuNC-HPPH is comparable for both systems, which 
suggests that diffusion of the conjugate is a major determining factor in release. As such, 
following intravenous injection HPPH would be less likely to be bound by BSA when delivered 
as AuNC-HPPH than free HPPH. Additionally, because of its accumulation in tumors,[14] AuNC-











The release could be further controlled with PT heating by the AuNCs (Fig. 6). Under NIR 
irradiation by a diode laser (1 W/cm2 at 808 nm) that overlaps with the LSPR, the solution 
temperature was held at 46 oC for 2 h.[47, 48] In the dark, only 26.2 ± 6.7 % of the payload was 
released from the PEG monolayer after two hours. The slow release profile should provide 
enough time for the AuNC-HPPH to accumulate in the tumor prior to unloading, as 
demonstrated in our previous in vivo study.[14] Irradiation led to localized heating, which 
presumably increased the fluidity of the PEG layer and enabled HPPH to rapidly diffuse to the 
interface and interact with BSA. A linear burst release (69.2 ± 5.0 %) in the first 45 min was 
observed, after which the release proceeded gradually, only reaching ~75 % when the study 
terminated after two hours. The remaining HPPH may have been buried too deeply within the 





Figure 6. Comparison of HPPH release kinetics from AuNC-HPPH under irradiation by 808 nm 
diode laser at 1 W/cm2 (triangles), and from AuNC-HPPH at 37 °C in the dark (squares). 
Maximum (100%) values were determined by the recovered fluorescence signal after the AuNCs 





A finer measure of control was achieved using brief pulses of irradiation, and little release was 
observed during the dark time. The controlled release profiles are shown in Figure 7A, and the 
change in temperature of equimolar AuNCs in PBS is shown in Figure 7B. The suspension 
temperature rose from 37 °C to 46 °C during the 5 min irradiation period and returned to 37 °C 
during the 10 min dark time. AuNCCOO-HPPH and AuNC-HPPH were separately incubated in 
BSA for 5 min prior to the first irradiation. During the first laser pulse roughly 20 and 30 % of 
the respective payload was released, and only a further 5 % of the payload released in the dark 
time that followed. The second pulse resulted in 15 and 20 % of the respective payloads being 
released, and the final pulse released ~10 % of the payload. Ultimately, ~60 % and ~80 % of the 
payload was released from AuNCCOO-HPPH and AuNC-HPPH, respectively, during the three 
laser pulses. Faster release was observed for AuNC-HPPH than AuNCCOO-HPPH, similar to the 
dark release (Fig. 7A). Both samples demonstrated similar capacity for on-demand release, 
though AuNCCOO-HPPH seemed to be more responsive to the irradiation. The slow release 
observed in the absence of irradiation suggests that little premature leakage would occur during 
transport from the injection site to the tumor, but the extensive, controllable release of the 
payload suggests that extensive unloading can be accomplished quickly within the tumor. 
Further, release was achieved using photothermal temperatures, suggesting that added 





Figure 7. (A) On-demand release of HPPH from AuNC-HPPH as triggered by NIR irradiation at 
808 nm (1 W/cm2). Maximum (100%) values were determined by the recovered fluorescence 
signal after the AuNCs were digested by KCN. (B) Temperature change of sample solutions for 






PEG-monolayer-covered Au nanoparticle platforms are a robust system for delivery of such 
hydrophobic drugs, particularly photosensitizers, in part because noncovalent conjugation 
minimizes changes to drug pharmakokinetics. HPPH was incorporated into such a system, 
characterized thoroughly, and the response to biomimetic environments investigated. The 
Raman, fluorescence, and physical properties of these conjugates were investigated to elucidate 
the nature of the binding. The loading capacity was found to be ~2x105 HPPHs/AuNC, the Kd 
was determined to be ~35 μM, and the drug was found to pack tightly within the monolayer. 
Release from this delivery system was studied in albumin-containing media to mimic in vivo 
delivery following intravenous injection. To mimic unloading the cell membrane, release into 
vesicles was also investigated. The terminus of the PEG chain significantly affected the release 
profile. Significantly faster release was observed from amine-terminated (cationic) PEG than 
carboxylate terminated (anionic) PEG. Cross-linking these termini was used to introduce steric 
hindrance that blocked binding of the protein with the embedded HPPH. Controllable burst 
release could be accomplished by using irradiation to induce the PT effect. This PEG-monolayer-
covered AuNC system can potentially serve as a multifunctional platform for controlled delivery 





Exterior incorporation of HPPH to AuNC-PEG (AuNC-HPPH). HPPH (7 mg, 11 μmol) was 
dissolved in 2.5 mL DMSO at a concentration of 4.5 mM as stock solution. This stock solution 
(0.25 mL) was diluted in 4 mL of PBS via dropwise addition in ice bath to a concentration of 
~183 µM. The diluted HPPH solution was flushed with Ar for 5 min and allowed to mix for 5 
additional min. The AuNC-PEG suspension (3 nM, 2 mL) was added dropwise to the HPPH 
solution. The reaction was allowed to stir overnight under the protection of Ar in the dark. The 
product containing non-covalently-incorporated HPPH on AuNC-PEG was then washed three 
cycles of centrifugation (14,000 RPM, 15 min, 20 °C) and redispersion in PBS with a final 
AuNC concentration of 6 nM. The conjugated HPPH can be fully released from conjugates by 
methanol. UV-Vis-NIR spectroscopy was used to determine the concentration of non-covalently 
incorporated HPPH (extinction coefficient in methanol εHPPH ≈ 4.0 × 104 M-1cm-1). The 
concentration of AuNCs was calculated by the metal concentration from elemental analysis and 
size information from TEM analysis. The loading efficiency was calculated as ~1 × 105 
HPPHs/AuNC. The incorporated HPPH per AuNC is readily changed by adjusting the ratio of 
HPPH to AuNC in the reaction. To determine the Kd, 1 nM AuNC-PEG was incubated with 
varying concentrations of HPPH overnight with stirring in 10 mM phosphate buffer (pH = 7.4) 
with 0, 135, or 1000 mM NaCl. The suspension was centrifuged and the supernatant HPPH 
concentration was quantified by absorbance at 665 nm. These data were used to develop a 
saturation binding isotherm, and fit to the equation Lb = N*Lu/(Lu + Kd). 
Cross-linking of AuNC-HPPH. AuNC-PEG-NH3+ was incorporated with HPPH to a 
concentration of ~2.5 × 104 HPPHs/AuNC using the above procedure. PEG250, a diacidic cross-
linker, was dispersed in borate buffer (pH = 9) in an ice bath with stirring to a concentration of 
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2.0 mM (4.2 µmol, 1.0 mg). To this solution, EDC (7.8 µmol, 1.2 mg) and NHS (10.4 µmol, 1.2 
mg) were added. The solution was then flushed with Ar for 20 min. AuNC-HPPH solution (0.2 
mL) was added dropwise into the solution. The reaction was allowed to stir overnight in the dark 
under the protection of Ar. The product was recovered by two centrifugation cycles (14,000 
RPM, 15 min, 20 °C) and redispersion in PBS. 
Preparation of Lipid Vesicles. 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, 75 μmol) 
and 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DMPG, 25 μmol) were dissolved in 
5 mL chloroform to yield a 20 mM lipid solution. The solvent was removed under high vacuum 
overnight. The lipids were hydrated in 5 mL PBS with vigorous shaking for 2 h, following by 2 h 
in the bath sonicator, until the solution was no longer turbid. Lipid vesicles were stored at 4 °C 
under Ar.   
Study of HPPH release kinetics. Recovered fluorescence was used to monitor the release 
kinetics of HPPH from AuNC-HPPH conjugates. Typically, AuNC-HPPH was diluted in PBS or 
BSA in PBS (4 % w/w, ~575 μM) at a final concentration of 0.1 nM. Fluorescence 
measurements were acquired after the dilution at various intervals throughout a 32 h period using 
λex = 605 nm and λem = 668 nm. Samples were kept at room temperature, in the dark, without 
stirring or unnecessary agitation between measurements. At the end of the data acquisition, 10 
µL of 0.5 M aqueous KCN was added to dissolve AuNCs and the fluorescence spectrum was 
acquired to determine the maximum (100%) HPPH signal for the sample. PBS samples were 
monitored using supernatant absorbance at various times following centrifugation. After 
measurement, the pellet was redispersed in the original supernatant. 
To test the PT effect on the release kinetics, an 808-nm diode laser (Power Technology) was 
used to irradiate the suspension of AuNC-HPPH conjugates.  The laser intensity was adjusted to 
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a power density of 1 W/cm2 by changing the spot size, so the temperature of the sample was 
maintained at ~46 oC. The fluorescence measurement was taken at different time periods over the 
course of 2 h irradiation, and irradiation began within 10 s of introduction of sample into BSA. 
On-demand release was demonstrated using 5 min irradiation pulses followed by 10 min without 
irradiation. 
Acknowledgement: This work was supported in part by the pilot project funds from the 
Arkansas Biosciences Institute, the National Institutes of Health (NIH P30 GM103450), the 
Ralph E. Powe Jr. Faculty Enhancement Award, and startup funds from the University of 
Arkansas, to J.C.; the financial support from Roswell Park Alliance to R.K.P; and an 
appointment to S.V.J. to the Summer Student Research Program at the National Center for 
Toxicological Research administered by the Oak Ridge Institute for Science and Education 
through an interagency agreement between the U.S. Department of Energy and the U.S. Food 
and Drug Administration.. K.Y.R. thanks the support from Student Undergraduate Research 
Fellowship (SURF).  
References 
[1] D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer Nat Nano. 2007, 2, 
751-760. 
[2] P. Ghosh, G. Han, M. De, C. K. Kim, V. M. Rotello Adv. Drug Del. Rev. 2008, 60, 1307-
1315. 
[3] P. R. Gil, W. J. Parak ACS Nano. 2008, 2, 2200-2205. 
[4] O. C. Farokhzad, R. Langer ACS Nano. 2009, 3, 16-20. 
[5] R. Bardhan, S. Lal, A. Joshi, N. J. Halas Acc. Chem. Res. 2011, 44, 936-946. 
[6] Y. Xia, W. Li, C. M. Cobley, J. Chen, X. Xia, Q. Zhang, M. Yang, E. C. Cho, P. K. Brown 
Acc. Chem. Res. 2011, 44, 914-924. 
[7] E. C. Dreaden, A. M. Alkilany, X. Huang, C. J. Murphy, M. A. El-Sayed Chem. Soc. Rev. 
2012, 41, 2740-2779. 
138 
 
[8] S. Rana, A. Bajaj, R. Mout, V. M. Rotello Adv. Drug Del. Rev. 2012, 64, 200-216. 
[9] J. Xie, S. Lee, X. Chen Adv. Drug Del. Rev. 2010, 62, 1064-1079. 
[10] A. M. Alkilany, S. E. Lohse, C. J. Murphy Acc. Chem. Res. 2012, 46, 650-661. 
[11] J. Huang, K. S. Jackson, C. J. Murphy Nano Lett. 2012, 12, 2982-2987. 
[12] C. K. Kim, P. Ghosh, C. Pagliuca, Z.-J. Zhu, S. Menichetti, V. M. Rotello J. Am. Chem. 
Soc. 2009, 131, 1360-1361. 
[13] F. Ren, S. Bhana, D. D. Norman, J. Johnson, L. Xu, D. L. Baker, A. L. Parrill, X. Huang 
Bioconjugate Chem. 2013, 24, 376-386. 
[14] A. Srivatsan, S. V. Jenkins, M. Jeon, Z. Wu, C. Kim, J. Chen, R. K. Pandey Theranostics. 
2014, 4, 163-174. 
[15] N. C. M. Tam, B. M. T. Scott, D. Voicu, B. C. Wilson, G. Zheng Bioconjugate Chem. 2010, 
21, 2178-2182. 
[16] S. R. Sershen, S. L. Westcott, N. J. Halas, J. L. West J. Biomed. Mater. Res. 2000, 51, 293-
298. 
[17] K. Knop, R. Hoogenboom, D. Fischer, U. S. Schubert Angew. Chem. Int. Ed. 2010, 49, 
6288-6308. 
[18] Y. Cheng, A. C. Samia, J. D. Meyers, I. Panagopoulos, B. Fei, C. Burda J. Am. Chem. Soc. 
2008, 130, 10643-10647. 
[19] Y. Cheng, A. C. Samia, J. Li, M. E. Kenney, A. Resnick, C. Burda Langmuir. 2009, 26, 
2248-2255. 
[20] Y. Cheng, J. D. Meyers, A.-M. Broome, M. E. Kenney, J. P. Basilion, C. Burda J. Am. 
Chem. Soc. 2011, 133, 2583-2591. 
[21] P. Ghosh, G. Han, M. De, C. K. Kim, V. M. Rotello Advanced Drug Delivery Reviews. 
2008, 60, 1307-1315. 
[22] F. Ren, S. Bhana, D. D. Norman, J. Johnson, L. Xu, D. L. Baker, A. L. Parrill, X. Huang 
Bioconjugate Chemistry. 2013, 24, 376-386. 
[23] Y.-C. Li, S. Rissanen, M. Stepniewski, O. Cramariuc, T. Róg, S. Mirza, H. Xhaard, M. 
Wytrwal, M. Kepczynski, A. Bunker J. Phys. Chem. B. 2012, 116, 7334-7341. 
[24] M. S. Yavuz, Y. Cheng, J. Chen, C. M. Cobley, Q. Zhang, M. Rycenga, J. Xie, C. Kim, K. 
H. Song, A. G. Schwartz, L. V. Wang, Y. Xia Nat. Mater. 2009, 8, 935-939. 
[25] G. D. Moon, S.-W. Choi, X. Cai, W. Li, E. C. Cho, U. Jeong, L. V. Wang, Y. Xia J. Am. 
Chem. Soc. 2011, 133, 4762-4765. 
139 
 
[26] J. You, G. Zhang, C. Li ACS Nano. 2010, 4, 1033-1041. 
[27] S. R. Sershen, S. L. Westcott, N. J. Halas, J. L. West Journal of Biomedical Materials 
Research. 2000, 51, 293-298. 
[28] K. A. Wilets, R. P. V. Duyne Ann. Rev. Phys. Chem. 2007, 58, 267-297. 
[29] C. S. Yun, A. Javier, T. Jennings, M. Fisher, S. Hira, S. Peterson, B. Hopkins, N. O. Reich, 
G. F. Strouse J. Am. Chem. Soc. 2005, 127, 3115-3119. 
[30] T. L. Jennings, M. P. Singh, G. F. Strouse J. Am. Chem. Soc. 2006, 128, 5462-5467. 
[31] X. Xia, M. Yang, L. K. Oetjen, Y. Zhang, Q. Li, J. Chen, Y. Xia Nanoscale. 2011, 3, 950-
953. 
[32] L. Biczok, P. Valat, V. Wintgens Physical Chemistry Chemical Physics. 1999, 1, 4759-
4766. 
[33] C. M. Mendel, D. B. Mendel Biochem J. 1985, 228, 269-272. 
[34] E. J. van Zoelen Biochem J. 1989, 262, 549-556. 
[35] K. Baba, H. E. Pudavar, I. Roy, T. Y. Ohulchanskyy, Y. Chen, R. K. Pandey, P. N. Prasad 
Mol. Pharm. 2007, 4, 289-297. 
[36] T. M. Cotton, S. G. Schultz, R. P. V. Duyne J. Am. Chem. Soc. 1982, 104, 6528-6532. 
[37] X. Gao, J. P. Davies, M. J. Weaver J. Phys. Chem. 1990, 94, 6858-6864. 
[38] S. V. Jenkins, H. Qu, T. Mudalige, T. M. Ingle, R. Wang, F. Wang, P. C. Howard, J. Chen, 
Y. Zhang Biomaterials. 2015, 51, 226-237. 
[39] J. P. Doweiko, D. J. Nompleggi J. Parenteral Enteral Nutrition. 1991, 15, 207-211. 
[40] P. Harder, M. Grunze, R. Dahint, G. M. Whitesides, P. E. Laibinis J. Phys. Chem. B. 1998, 
102, 426-436. 
[41] E. Ostuni, R. G. Chapman, R. E. Holmlin, S. Takayama, G. M. Whitesides Langmuir. 2001, 
17, 5605-5620. 
[42] C. D. Walkey, J. B. Olsen, H. Guo, A. Emili, W. C. W. Chan J. Am. Chem. Soc. 2011, 134, 
2139-2147. 
[43] C. D. Walkey, W. C. W. Chan Chem. Soc. Rev. 2012, 41, 2780-2799. 
[44] M. Rotenberg, R. Margalit Biochem. J. 1985, 229, 197-203. 
[45] A. Mahammed, H. B. Gray, J. J. Weaver, K. Sorasaenee, Z. Gross Bioconjugate Chem. 
2004, 15, 738-746. 
140 
 
[46] R. A. Hartvig, M. van de Weert, J. Østergaard, L. Jorgensen, H. Jensen Langmuir. 2011, 27, 
2634-2643. 
[47] J. Chen, C. Glaus, R. Laforest, Q. Zhang, M. Yang, M. Gidding, M. J. Welch, Y. Xia Small. 
2010, 6, 811-817. 
[48] J. Chen, M. Yang, Q. Zhang, E. C. Cho, C. M. Cobley, C. Kim, C. Glaus, L. V. Wang, M. J. 






Appendix A: Supporting Information 
Experimental Details: 
Materials. Silver trifluoroacetate (AgCF3COO), tetrachloroauric acid (HAuCl4), poly(vinyl 
pyrrolidone) (PVP, M.W.~55,000), sodium hydrogen sulfide (NaSH), dimethylsulfoxide 
(DMSO), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and N-
hydroxysuccinimide (NHS) were purchased from Alfa Aesar.   Ethylene glycol (EG), potassium 
cyanide (KCN), and sodium chloride (NaCl) were purchased from JT Baker. Hydrochloric acid 
(HCl, 99.999%), phosphate-buffered saline (PBS), O-(3-Carboxypropyl)-O’-[2-(3-
mercaptopropionylamino)ethyl] polyethylene glycol(PEG-COO-, M.W.=5,000), and 
poly(ethylene glycol) bis(carboxymethyl) ether (PEG250, M.W.=250) were purchased from 
Sigma Aldrich. Amine-terminated PEG thiol TFA salt (PEG-NH3+, M.W.=5,000) was purchased 
from JenKem. Acetone and methanol (MeOH) were purchased from EMD. Bovine serum 
albumin was purchased from Rockland Inc. All water used in the procedures was 18 MΩ H2O 
unless specified. 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide (HPPH, marketed as 
Photochlor) was prepared based on the previously reported method in Dr. Pandey’s laboratory.[1] 
All chemicals were used as received.  
Synthesis of AuNCs. AuNCs were synthesized by a two-step process using Ag cubes as a 
sacrificial template for the galvanic replacement reaction. Briefly, Ag nanocubes were 
synthesized with edge length of ~40 nm and LSPR peak at 443 nm.[2] The as-prepared Ag 
nanocubes (96 pmol, ~8 nM) were then titrated with  1 mM HAuCl4 aqueous solution at a rate of 
45 mL/h at 100 °C under vigorous stirring until the LSPR of the reaction mixture reached ~800 
nm.[3]  The mixture remained on heat for 5 min, before being cooled to room temperature. The 
AuNCs were further purified with saturated NaCl solution to remove AgCl precipitate. The 
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product was washed twice with H2O and redispersed in H2O for future use. Atomic absorption 
data indicate that the AuNCs are 91% Au by mass with the remainder being Ag. 
Conjugation of PEG to AuNCs. Details regarding AuNC synthesis can be found in the 
supporting information. AuNCs were synthesized with LSPR of ~800 nm to overlap with the 
laser used for photothermal experiments. To conjugate thiol-terminated PEG (i.e., PEG-NH3+, 
PEG-COO-) to AuNCs, based on a previously published procedure,[4] 0.4 µmol of PEG was 
dissolved in 4 mL H2O in a 20 mL vial. The solution was placed in an ice bath with stirring for 5 
min. Next, 8 mL of 1.0 nM AuNC suspension was added dropwise over 5 min. The vial was 
flushed with Ar for 10 minutes and allowed to stir overnight in dark. After conjugation, the 
excess PEG was removed by three cycles of centrifugation (14,000 RPM, 15 min, 20 °C) and 
redispersion in H2O, and finally redispersed in PBS with a concentration of ~3 nM. 
Instrumentation. Transmission electron microscrope (TEM) images were obtained using JEOL 
100cx with an acceleration voltage of 100 kV. The specimens were prepared by dropping the 
samples onto carbon-coated copper grid and allowing the solvent to evaporate in air. UV-Vis-
NIR spectra were obtained using spectrophotometer (Agilent HP8453). Fluorescence spectra 
were obtained using fluorimeter (Horiba FluoroLog3). The concentrations of Au and Ag were 
determined using atomic absorption (AA) spectrometer (GBC 932). Hydrodynamic diameter (dH)  
and ζ potential of the conjugated AuNCs were determined using dynamic light scattering 
(Brookhaven ZetaPALS).  Fluorescence lifetime measurement were acquired using MicroTime 
200 microscope (PicoQuant GmbH) with λex = 640 and λem = 670; the data were fitted using 
SymPhoTime software. Raman spectra were obtained using Raman Microscope (Horiba). 
Spectra were acquired in a 50 µL quartz cuvette using 488 nm laser with a He/Ar source and an 









Figure S2. Calibration curves for AuNC extinction at 801 nm (A) and HPPH fluorescence at 669 
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Chapter V. Drug-Loaded Immuno-Gold Nanoconstructs for Synergistic Photothermal 
and Antibiotic Killing of Staphylococcus aureus* 
Abstract 
Resistance to conventional antibiotics is a growing public health concern that is quickly out-
pacing the development of new antibiotics. This has lead the Infectious Disease Society of 
America to define Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species as the ESKAPE 
pathogens based on the alarming lack of antibiotics useful for the treatment of infections caused 
by these species. This emphasizes the need for alternative therapeutic strategies to combat 
infections caused by these and other bacterial pathogens. In this report, we used Staphylococcus 
aureus as a proof-of-principle ESKAPE pathogen to demonstrate that therapeutic levels of an 
appropriate antibiotic (daptomycin) can be incorporated into polydopamine-coated gold 
nanocages (AuNC@PDA) and that daptomycin-loaded AuNC@PDA can be conjugated to 
antibodies targeting a species-specific surface protein (staphylococcal protein A) as a means of 
achieving selective delivery of AuNCs directly to the bacterial cell surface. We also demonstrate 
that laser irradiation at levels within the current safety standard for use in humans can then be 
used to achieve both a lethal photothermal effect and controlled release of antibiotic, thus 
resulting in a degree of therapeutic synergy capable of eradicating viable bacteria.  
 
*Submitted: Jenkins, S.V.;† Meeker, D.G.;† Miller, E.K.; Beenken, K.E.; Loughran, A.J.; 






The treatment of bacterial infections has been dramatically compromised by the persistent 
emergence of antibiotic resistant strains.1-3 This has lead the Infectious Disease Society of 
America (IDSA) to designate Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species as 
the ESKAPE pathogens based on the rapidly decreasing availability of useful antibiotics against 
these pathogens.4 Although new antibiotics have been developed, the pace of development is 
slow by comparison to the emergence of resistant strains, and past experience has proven that the 
use of any conventional antibiotic will ultimately lead to the emergence of such resistance.1 In 
addition, many forms of bacterial infection, specifically those associated with biofilm formation, 
are intrinsically resistant to antimicrobial therapy irrespective of the acquired resistance status of 
the offending bacteria.5 These factors have created an urgent need for the development of 
alternative antibacterial strategies that would be less subject to the selective forces that drive the 
emergence of acquired antibiotic resistance. 
Two alternatives that have been explored are photodynamic therapy (PDT) and photothermal 
(PT) therapy.6 PDT utilizes a photosensitizer and visible light in the presence of oxygen to 
produce reactive oxygen species (ROS) capable of killing pathogenic microorganisms.7-9 
However, it is challenging to destroy the number of bacteria required to achieve the desired 
effect of eliminating the infection without damaging host tissues due to the short lifetime and 
thus limited potency of the ROS generated by this approach.10 Instead, we and others have 
explored the use of PT therapy using light-absorbers such as gold nanoparticles and carbon 
nanotubes to generate laser-assisted PT effects capable of the targeted physical destruction of 
bacterial cells.11-13 Indeed, in an experimentally amenable murine model, we confirmed that this 
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approach can be combined with photoacoustic (PA) flow cytometry to detect and eradicate 
bacterial cells in the blood.14-15 While PT killing has great potential to treat bacteremia and 
potentially other forms of bacterial infection including those involving formation of a biofilm,13 
the combined use of PT with controlled antibiotic release has the potential to dramatically 
improve treatment efficacy compared to either therapeutic approach alone.  This combined 
approach of using gold nanoparticles to achieve PT-mediated effects and controlled drug release 
has been explored to great effect in the context of cancer,16 but to date it has not been explored in 
the context of infectious disease. As with cancer, this synergistic approach has tremendous 
potential in that the therapeutic synergy of PT-mediated killing and controlled antibiotic release 
has the potential to reduce both the degree of laser irradiation and the amount of antibiotic 
required to achieve the desired clinical effect. Evaluating this hypothesis was the focus of the 
experiments we report.  
To this end, we examined the killing efficacy of a novel pathogen-targeted nanotherapeutic 
approach that allowed for both the physical, PT-mediated destruction of bacterial cells and 
concomitant release of an antibiotic in relatively high concentrations and in the immediate 
environment of the offending bacterial cells. We chose to focus on Staphylococcus aureus (S. 
aureus) as a proof-of-principle pathogen because it is one of the most prominent ESKAPE 
pathogens owing to the frequency and severity of the infections it causes, its antibiotic resistance 
status,3 and its prominence as a cause of biofilm-associated infections.17 The nanoconstruct we 
investigated consisted of a plasmonic hard core of gold nanocages (AuNC) and a polymer soft 
shell of polydopamine (PDA) assembled as a core-shell structure. This construct was loaded with 
the antibiotic daptomycin (Dap), which was chosen because it is active against MRSA18 and has 
relatively good efficacy in the context of a biofilm.19 Daptomycin-loaded AuNCs were 
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functionalized for targeting to S. aureus by conjugation to antibodies against staphylococcal 
protein A (anti-SPA), thereby creating a photoactivatable, highly selective nanodrug. As 
illustrated in Figure 1, the underlying concept is that when this nanodrug attaches to the S. 
aureus cell surface, irradiation with near-infrared (NIR) light will activate plasmonic AuNCs to 
convert photon energy to thermal energy resulting in an increase in temperature20-21 of sufficient 
magnitude for the simultaneous generation of localized PT effects and expansion of the PDA 





Figure 1. Schematic illustration of the working mechanism of the photoactivatable 





Results and Discussion 
The AuNCs were synthesized using a galvanic replacement reaction between Ag nanocubes and 
chloroauric acid as described in previous reports.23-24 The initial AuNCs were found to contain 
74.3% Au and 25.7% Ag by mass corresponding to 61.3% Au and 38.7% Ag by atomic number. 
The outer and inner edge lengths of the AuNCs were 54.5 ± 5.0 nm and 38.4 ± 5.3 nm, 
respectively, and they exhibited an extinction maximum of localized surface plasmon resonance 
(LSPR) at 753 nm (Fig. S1). The desired nanoconstruct was then prepared in three sequential 
steps following the reaction scheme in Figure 2 with details described in supporting information: 
i) in situ polymerization of dopamine to deposit a layer of PDA on the AuNCs forming an 
intermediate core-shell structure (AuNC@PDA);25-27 ii) loading of Dap to the PDA shell through 
intermolecular interactions to obtain a Dap-loaded intermediate (AuNC@Dap/PDA); and iii) 
covalent conjugation of anti-SPA through catechol chemistry to yield the final nanoconstruct 
(AuNC@Dap/PDA-anti-SPA). The intermediates obtained during synthesis were isolated, 





Figure 2. (A) Three-step scheme for synthesis of the nanoconstruct: (i) in situ polymerization of 
dopamine to form AuNC@PDA; (ii) loading of Dap to obtain AuNC@Dap/PDA; and (iii) 




After self-polymerization of dopamine on the surface of AuNCs, a layer of PDA with a thickness 
of 20-50 nm was confirmed by TEM (Fig. 3A). The hydrodynamic diameter was increased from 
~90 nm for AuNCs to ~200 nm for AuNC@PDA (Fig. S2). The LSPR peak was shifted to 824 
nm (Fig. 3B) which is attributed to the changes in the refractive index of the medium from 1.33 
for water to 1.55 for PDA as the PDA coating becomes thicker.28-29 The PDA coating process 
was monitored by UV-Vis spectral analysis of the reaction solution (Fig. S3, A and C). During 
the deposition of PDA, the LSPR maxima of the AuNCs gradually shifted from 753 nm to 824 
nm. Additionally, a peak at 410 nm attributable to quinone was progressively increased, 
indicating the oxidation of dopamine to dopamine quinone.30  The product of AuNC@PDA was 
further characterized by Fourier transform infrared (FTIR) spectroscopy (Fig. S3D). The peak at 
1611 cm-1 can be assigned to C-C stretching of indole or indoline structures while the peaks at 
1729, 2846/2916, and 3600 cm-1 can be attributed to C=O, C-H, and N-H stretching on the 
heterocyclic molecules.31  
The photothermal effect of AuNC@PDA suspension was measured under in vitro conditions 
used for antimicrobial studies. AuNC@PDA suspensions (200 µL) with an LSPR at ~820 nm 
was added to each well of a 96-well microtiter plate at concentration ranging from 0.04 to 0.4 
nM (2.4×1010-2.4×1011 AuNC@PDA/mL). Samples were sealed by a transparent film to prevent 
evaporation and irradiated using a diode laser centered at 808 nm with a power of 0.75 W and a 
spot size of 0.30 cm2 covering the entire surface area of the well. Through the transparent film, 
the actual power that reached the samples was reduced to 0.50 W corresponding to 1.67 W/cm2. 
Temperature changes as a function of time were recorded by an infrared thermal sensor. The 
results confirmed a temperature increase with increased concentration of AuNC@PDA and laser 
fluence that reached a plateau after 5 min (Fig. 3, C and D).  This photo-responsive 
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AuNC@PDA was used for Dap loading and anti-SPA conjugation in consecutive steps to 





Figure 3. (A) TEM image of AuNC@PDA; (B) UV-Vis spectra of AuNC@PDA aqueous 
suspension. (C, D) Temperature profile of AuNC@PDA suspension in PBS as a function of time 




Daptomycin is a cyclic lipopeptide consisting of a cyclic moiety of a 10 amino acid peptide with 
an N-terminal three amino acids protruding with an N-terminus containing a decanoyl fatty acyl 
side chain.32 It can be loaded to AuNC@PDA through intermolecular interactions such as ionic 
(or electrostatic) interactions, hydrogen bonding, and dispersion forces (hydrophobic 
interactions). Dap has an isoelectric point (pI) of ~3.8,33 and thus it carries a net positive charge 
at a pH < 3.8 while at a higher pH it carries a net negative charge. The zeta potential of 
AuNC@PDA is neutral at a pH ~3.0 and changes from negative to positive as pH decreases (Fig. 
4A). At a pH above 3.0 but below 3.8, the cationic Dap and anionic PDA may form an ionic 
complex. On the other hand, Dap was found to aggregate via reversible “self-association” and 
the critical aggregation concentration (CAC) depends on pH.34 At pH > 6.5, Dap remains a 
monomer while it forms aggregates of 16-20 molecules at a pH ≤ 5.0 with a CAC between 0.12 
and 0.20 mM. Therefore, it is expected that the loading capacity increases at low pH due to the 
additional driving force of self-association as the concentration of Dap is higher than its CAC.  
At a fixed concentration of 0.6 mM, Dap was loaded to 4 nM AuNC@PDA at pH of 7.8 or 2.2. 
After Dap loading, the PDA surface was functionalized with anti-SPA through catechol 
chemistry by conjugate addition of primary amine to the oxidized product of catechol (o-
quinone).35 The loading capacities of Dap were found to be 4 and 12 µg/mL of Dap in 0.4 nM of 
AuNC@PDA-anti-SPA using ultra-performance liquid chromatography (UPLC) (Fig. S4A). 
These values correspond to 6.2 × 103 and 1.9 × 104 Dap molecules per AuNC@PDA denoted as 
AuNC@DapLo/PDA-anti-SPA and AuNC@DapHi/PDA-anti-SPA, respectively. The UV-Vis 
spectra were essentially unchanged after Dap loading and anti-SPA conjugation with LSPR 
maxima at 819, 818, and 821 nm for AuNC@PDA-anti-SPA, AuNC@DapLo/PDA-anti-SPA and 
AuNC@DapHi/PDA-anti-SPA, respectively (Fig. S4B). The number of anti-SPA molecules on 
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the particle surface was quantified using a dye-labeled secondary IgG antibody. After dissolution 
of AuNCs with KCN, the fluorescence intensity was measured and compared to a calibration 
curve (Fig. S4C). The number of anti-SPA per AuNC was estimated to be 19, 28, and 13 for 
AuNC-anti-SPA, AuNC@DapLo/PDA-anti-SPA and AuNC@DapHi/PDA-anti-SPA, respectively. 
The efficiency of antibody conjugation averaged ~20% under the reaction conditions used. The 
binding affinity was further analyzed by Scatchard plot and the disassociation constant (Kd) was 
determined (Fig. S4D). The nonspecific interactions of Dap to AuNC@PDA are likely due to a 
high affinity binding motif with Kd of 4.9 µM and a low affinity binding site with Kd of 230 µM. 
Since the ionic complex of Dap and AuNC@PDA is unlikely to form at either pH, the increase 
in loading capacity at low pH is likely attributable to self-association of Dap. Such aggregation is 
reversible at elevated temperature, thus facilitating the photothermal release of Dap.34, 36 
The light-triggered release of Dap was then examined under in vitro conditions. The Dap release 
profile was established at a 0.4 nM concentration of AuNCs (Fig. 4B). When the laser was on, 
the amount Dap released from the nanoconstructs gradually increased over time and reached 
~2.6 and ~4.8 µg/mL at 10 min after irradiation at power density of 1.67 W/cm2 for 
AuNC@DapLo/PDA-anti-SPA and AuNC@DapHi/PDA-anti-SPA, respectively. In contrast, the 
release of Dap without irradiation was <1 µg/mL for AuNC@DapLo/PDA-anti-SPA and ~1 
µg/mL for AuNC@DapHi/PDA-anti-SPA. Additionally, the nanoconstructs were stable for at 
least two months at 4oC with Dap released < 1 µg/mL. The corresponding temperature profiles of 
the samples showed that the suspension temperature rapidly increased above 37 oC within 1-2 
min of irradiation and reached a plateau at ~55oC 5 min after irradiation. Within the first two 
minutes, the amount of Dap released was ~1 µg/mL. To rule out leakage at physiological 
temperature, the samples were incubated at 37oC for 24 h and the amount of Dap released was 
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remained to be ~ 1 µg/mL, suggesting that this amount was likely due to background signal of 





Figure 4. (A) Zeta potential of AuNC@PDA and loading capacity of Dap as a function of pH. 
(B) Release profiles of Dap upon irradiation by a diode laser at 808 nm with a power density of 
1.67 W/cm2 at a concentration of 0.4 nM AuNCs with different Dap loading: 4 µg/mL or 6.2 × 






Specific binding of the anti-SPA functionalized nanoconstructs was confirmed by two-photon 
luminescence imaging of S. aureus cells exposed to AuNC@PDA-anti-SPA by comparison to 
those exposed to AuNC@PDA and unexposed cells. S. aureus cells stained with 4’,6-diamidino-
2-phenylindole (DAPI) appeared blue, while AuNCs emitted light in the visible region when 
excited at the plasmon resonance (~800 nm) and appeared red.37 These studies were done with 
the methicillin-sensitive S. aureus (MSSA) strain UAMS-1 and the MRSA strain LAC, which 
were chosen for these studies because they are distinct by comparison to each other at both the 
genetic and phenotypic levels, one example of the latter being that UAMS-1 produces protein A 
at high levels by comparison to LAC.38-40 
For both UAMS-1 and LAC, the results confirmed co-localization of red and blue signals 
with S. aureus cells exposed to AuNC@PDA-anti-SPA (Fig. 5, A and D), suggesting that the 
AuNC@PDA-anti-SPA were attached to the cell surface. No co-localization was observed with 
S. aureus cells exposed to AuNC@PDA (Fig. 5, B and E). As an additional control, isogenic 
spa mutants that do not produce protein A were also examined in these experiments (Fig. 5, C 
and F). Quantitative analysis was performed by comparing the ratio of the pixel intensity from 
AuNC image (800 nm laser, red channel) to the pixel intensity of the DAPI image (700 nm laser, 
blue channel). The ratio intensities of fifty individual cells were averaged for each sample (Fig. 
S5). Significant differences were confirmed by comparing AuNC@PDA-anti-SPA to 
AuNC@PDA for both strains consistent with the qualitative visualization. Albeit at reduced 
levels, co-localization of blue and red signals was also observed in the spa mutants, which 
suggests additional biomarkers on the cell surface that bind anti-SPA. This was confirmed by 
western blot of conditioned medium using the same anti-SPA antibody used to produce our 
nanoconstructs (Fig. S6). In this respect it should be emphasized that SPA is an IgG-binding 
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protein and that S. aureus produces other such proteins, one example being Sbi.41 More 
importantly, in the context of the therapeutic approach we propose, this could be viewed as an 
advantage as it would further enhance antibody targeting even in strains that produce relatively 






Figure 5. Two-photon fluorescence images of S. aureus cells treated at different conditions: (A) 
UAMS-1 exposed to AuNC@PDA-anti-SPA; (B) UAMS-1 exposed to AuNC@PDA; (C) 
UAMS-1 spa mutant exposed to AuNC@PDA-anti-SPA; (D) LAC exposed to AuNC@PDA-
anti-SPA; (E) LAC treated with AuNC@PDA; and (F) LAC spa mutant exposed to 
AuNC@PDA-anti-SPA;. Cells were stained with DAPI colored in blue. Luminescence of 




Killing efficacy of different AuNC nanoconstructs was assessed using a 96-well microtiter plate 
format. In control experiments carried out to establish a baseline for these studies, the S. aureus 
strain UAMS-1 was grown in tryptic soy broth (TSB) and diluted to an optical density (OD560) of 
0.05, which corresponds to 1 × 107 bacterial cells. As a control for the number of viable bacteria, 
expressed as colony-forming units or CFU, 180 µL of this suspension was placed in each well of 
a microtiter plate (1.8 × 106 CFU per well) without exposure to any nanoconstruct or laser 
irradiation. To make the volume in each well consistent with our other experiments, 20 µl of 
sterile TSB was then added to bring the total volume to 200 µL. A sample was then removed, 
appropriately diluted in TSB, and plated on tryptic soy agar (TSA) to determine the number of 
CFU. These studies confirmed the initial concentration of bacteria, while a sample taken after 24 
h incubation at 37°C confirmed a concentration of 109 CFU/mL (Fig. 6, group 1). When S. 
aureus cells were exposed to Dap at a concentration of 5 µg/mL, which corresponds to 5 times 
the breakpoint minimum inhibitory concentration (MIC) that defines a daptomycin-sensitive 
strain of S. aureus,19 the number of CFU remained unchanged at the immediate time point but 
decreased below the limit of detection after 24 h (Fig. 6, group 2). 
Bacterial cells were also exposed to seven different nanoconstructs corresponding to the 
following experimental groups: 3) AuNC, 4) AuNC@PDA (no Dap loaded), 5) 
AuNC@DapLo/PDA (4 µg/mL Dap loaded), and 6) AuNC@DapHi/PDA (12 µg/mL Dap loaded), 
and 7-9) nanoconstructs 4-6 conjugated to anti-SPA antibody. The number of AuNCs used was 
4.8×1010, which corresponds to a ratio of ~2.7×104 AuNCs per bacterial cell. Replicate samples 
(n = 3) confirmed little or no bacterial cell killing when S. aureus cells were exposed to any 
formulation of AuNC in the absence of laser irradiation (Fig. 6, groups 3-9). This confirms the 
absence of bacterial cell killing in the absence of irradiation even with the AuNC@DapHi/PDA-
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anti-SPA constructs. This is consistent with our results confirming that Dap release in the 
absence of laser irradiation (i.e. “dark release”) was <1.0 µg/mL in the low Dap samples and 
~1.0 µg/mL in the high Dap samples (see above), thus confirming minimal release of Dap in the 
absence of the temperature increase associated with laser irradiation. Based on these collective 
results, our interpretation of the studies described below in which irradiation was employed is 
that bacterial cell death observed immediately after exposure is indicative of PT-mediated 
effects, while those observed after 24 h is indicative of Dap release. 
To assess bacterial cell killing as a function of laser irradiation, bacterial cells were exposed to 
the alternative nanoconstructs using the same concentration of bacterial cells and nanoconstructs. 
Replicate samples were then irradiated as detailed above in the context of assessing Dap release 
(10 min, 1.67 W/cm2).  Immediately after irradiation, a sample was taken to determine the 
relative number of CFU. The remainder of each sample was then incubated at 37°C for 24 h 
before taking a second sample. Significant reductions in bacterial viability were observed in all 
nanoconstruct-exposed cells with laser irradiation. This includes cells exposed to AuNC@PDA 
even without Dap loading or antibody conjugation (Fig. 6, group 10). However, in the absence 
of Dap loading, bacterial counts in one of three samples rebounded to those observed in the 
control group after 24 h incubation (Fig. 6, group 1). These results confirm a PT-mediated effect 
that reduced bacterial counts below the level of detection but did not completely clear all 
samples of viable bacteria. Support for this hypothesis comes from the observation that this 
rebound effect was not observed with AuNCs loaded with even the lower concentration of 
daptomycin (AuNC@DAPLo/PDA) (Fig. 6, group 11).   
These results demonstrate a significant degree of bacterial cell killing even without antibody-
mediated targeting. However, this must be interpreted in the context of the confined environment 
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of the wells of a microtiter plate. This is particularly true when considering the transition to in 
vivo use in which antibody-mediated localization is likely to be required to achieve selective 
targeting of bacterial cells within the complex milieu of the host. Based on this, we examined 
AuNC@PDA conjugated to anti-SPA antibodies (AuNC@PDA-anti-SPA). Based on CFU 
counts at the immediate time point, we achieved a 2-3 log reduction in CFU (Fig. 6, group 12), 
which for the reasons discussed above we attribute to PT-mediated effects. While significant, 
this reduction was less than that observed with unconjugated AuNC@PDA (Fig. 6, groups 10 
and 11), suggesting antibody conjugation reduces bacterial cell killing due to PT effects. This is 
consistent with the observation that the temperature increase associated with laser irradiation was 
less with anti-SPA conjugated AuNCs by comparison to unconjugated AuNCs (Fig. S7A). As 
would be expected based on this, in the absence of daptomycin loading CFU counts rebounded in 
some samples to maximum levels after 24 hr incubation (Fig. 6, group 12). In contrast, this 
rebound effect was eliminated by daptomycin loading even at the lower concentration (Fig. 6, 
groups 13 and 14), thus confirming the therapeutic synergy of our approach.   
These same trends were also observed with the methicillin-resistant S. aureus strain LAC, but 
LAC appeared to be even more sensitive to PT-mediated killing than UAMS-1. Specifically, a 
decrease in CFU of 3-4 logs was observed immediately after irradiation (AuNC@PDA-anti-
SPA) (Fig. 6, group 15), while with daptomycin loading the number viable bacteria was below 
the level of detection at both the immediate and 24 hr time points (Fig. 6, groups 16-17). These 
results suggest that LAC is thermally more sensitive than UAMS-1 in the relevant temperature 
range of 50-55 oC. This was subsequently confirmed in experiments in which each strain was 
exposed to 50 or 55 oC and samples removed at 2 minute intervals to assess the decrease in CFU 




Figure 6. Viability of S. aureus cells exposed to different AuNC formulations without (black, 
groups 1-9) and with (red, groups 10-17) irradiation with a diode laser at 808 nm at a power 
density of 1.67 W/cm2 for 10 min (right in red). CFU values were determined by plating samples 
0 h and 24 h after treatment exposure to the indicated nanoconstructs and, where appropriate, 
laser irradiation. Group 1-14 were UAMS-1 cells exposed to (1) no treatment; (2) 5 µg/mL Dap; 
(3) AuNCs; (4) AuNC@PDA; (5) AuNC@DapLo/PDA; (6) AuNC@DapHi/PDA; (7) 
AuNC@PDA-anti-SPA; (8) AuNC@DapLo/PDA-anti-SPA; (9) AuNC@DapHi/PDA-anti-SPA; 
(10) AuNC@PDA; (11) AuNC@DapLo/PDA; (12) AuNC@PDA-anti-SPA; (13) 
AuNC@DapLo/PDA-anti-SPA; and (14) AuNC@DapHi/PDA-anti-SPA. Group 15-17 were LAC 






We have demonstrated our ability to successfully synthesize antibiotic-loaded immuno-
plasmonic nanoconstructs for use as novel antimicrobial agents. These AuNC-based 
nanoconstructs were effectively shown to convert NIR light into heat for PT killing of bacterial 
cells as well as thermally-controllable PDA expansion and antibiotic release. The therapeutic 
synergy of the nanoconstructs was confirmed for both the methicillin-sensitive S. aureus 
(MSSA) strain UAMS-1 and the methicillin-resistant S. aureus (MRSA) strain LAC. Although 
its utility against MRSA is perhaps particularly noteworthy given that these strains pose a 
particular clinical problem, it is also noteworthy in that LAC is representative of the USA300 
clonal lineage of S. aureus isolates, which are characterized by high levels of expression of the 
accessory gene regulator (agr) and consequently relatively low levels of SPA production.40  This 
demonstrates that this photoactivatable nanodrug provides a new platform for therapeutic 
synergy of PT and antibiotic treatment of diverse strains of S. aureus including those most 
commonly associated with highly-invasive community-associated infections.2 Moreover, 
sensitivity and coverage for additional strains could potentially be increased even further by 
including additional antibodies either alone or in combination with each other.15 Indeed, the 
technology we describe would be applicable to other bacterial pathogens, including the other 
ESKAPE pathogens, depending only on the availability of an appropriate pathogen-specific 
antibody and the ability to incorporate appropriate antibiotics into the AuNC formulation.   
As in the treatment of cancer,16 the dual therapeutic approach we describe has the potential to 
limit the amount of laser irradiation and potentially even the amount of antibiotic required to 
achieve the desired therapeutic effect, particularly given the highly localized nature of both PT 
effects and antibiotic release directly at the bacterial cell surface. Using a murine bacteremia 
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model, we previously demonstrated that, even without antibiotic loading, we could achieve 
significant bacterial killing using anti-SPA conjugated gold nanoconstructs and transdermal laser 
irradiation in the context of bacteria in the bloodstream.15 However, this therapeutic synergy is 
likely to prove a very important consideration in the transition from in vitro studies to in vivo use 
in humans, particularly when attempting to achieve adequate laser irradiation through the skin in 
other types of infection including the deeper layers of an established biofilm. Thus, our results 
provide an important experimental foundation to pursue this transition in the context of diverse 
bacterial pathogens and diverse forms of bacterial infection, including those associated with 






Synthesis of antibiotic-loaded immuno-gold nanoconstructs. The AuNCs were synthesized by 
galvanic replacement reaction between Ag nanocubes and HAuCl4 as previously described.1 
AuNC@PDA were prepared by self-polymerization of dopamine monomer on the surface of 
AuNCs under basic conditions in the presence of O2. Briefly, 3 mL of 5 nM AuNCs were diluted 
to 200 mL using Tris-buffered saline (TBS, 20 mM Tris and 100 mM NaCl, pH = 9) in a 250-
mL, 3-neck, round-bottom flask. The reaction flask was briefly flushed with O2 and placed in a 
bath sonicator held at 4oC with ice. Dopamine hydrochloride (0.2 mmol, 36.0 mg) was added to 
the flask, the vessel was sealed under 1 atm O2, and the mixture was sonicated for 75 min until 
the LSPR had red-shifted ~50 nm. After this reaction, the product was collected by 
centrifugation at 7,000 rpm for 10 min, washed with H2O twice and recovered by centrifugation 
at 14,000 rpm for 10 min at 4oC. The AuNC@PDA were resuspended in H2O at a concentration 
of 6 nM for characterization and future use.  
Various amounts of daptomycin were loaded to the AuNC@PDA under different conditions to 
prepare daptomycin-loaded AuNC@PDA (AuNC@DAP/PDA). Briefly, 1 nM AuNC@PDA 
were incubated with 1 mg/mL of daptomycin (0.6 mM) in 10 mM citrate buffer (pH = 2.2 or 7.8) 
at various NaCl concentrations (0 mM, 150 mM, or 1 M). The reaction was allowed to stir 
overnight at 4oC in the dark. The product was collected, purified with PBS once and H2O 3 
times, and re-collected by centrifugation at 14,000 rpm for 10 min to remove free daptomycin. 
The AuNC@DAP/PDA were resuspended in H2O at a concentration of 4 nM AuNCs for 
characterization and future use.  
Anti-SPA was conjugated to the surface of AuNC@DAP/PDA through the N-terminal amine by 
Michael addition reaction to form anti-SPA conjugated AuNC@DAP/PDA nanoconstructs 
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(AuNC@DAP/PDA-anti-SPA). Briefly, AuNC@DAP/PDA were dispersed in 1 mL of 10 mM 
bicene buffer (pH = 8.5) and 0.1 nmol of anti-SPA was added to the solution. The reaction was 
allowed to proceed at 4oC for 1 h. The nanoconstructs were collected and washed 3 times with 
PBS by centrifugation at 14,000 rpm for 5 min at 4oC. The nanoconstructs were dispersed in PBS 
for future use.  
Two-photon imaging. Cultures of the S. aureus strains UAMS-1, LAC, and their isogenic spa 
mutants were grown to an optical density (OD560) of 1.0 in tryptic soy broth (TSB), which 
corresponds to ~2×108 CFU/mL. This sample (40 µL) was applied to a glass microscope slide 
demarcated with a hydrophobic pen and allowed to air dry. Bacteria were heat fixed before 
adding 90 uL of PBS and 10 uL of AuNC@PDA-anti-SPA or AuNC@PDA. After 30 min at 
room temperature, reagents were removed by soaking in PBS 3 times for 10 min each time. The 
slide was blotted dry before adding 100 uL of 40× diluted DAPI (purchased as NucBlue Fixed 
Cell ReadyProbe Reagent, Molecular Probes) in PBS and incubating for 10 min. This stain was 
removed and the slides washed by soaking in fresh PBS 3 times for 5 min each time. The slides 
were blotted dry, 10 uL of PBS was used as a mounting medium, and a #2 coverslip was applied 
and sealed with nail polish. Two-photon images were acquired using customized, four channel, 
resonant scanning multiphoton microscopy platform (Thorlabs, USA) and a 40× water 
immersion 0.8 NA objective (Nikon). Illumination was provided by a Mai Tai HP ultra-fast 
Ti:Sapphire laser (Spectra Physics). DAPI fluorescence was visualized using 10 mW excitation 
at 700 nm and collecting from blue (466/40) channel. AuNC luminescence were visualized using 
10 mW excitation at 800 nm and collecting from the red (607/70) channel. Images are the 
average of 200 frames and processed identically using ImageJ. The quantitative analysis was 
performed by comparing the ratio of the pixel intensity from AuNC image (800 nm laser, red 
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channel) to the pixel intensity of the DAPI image (700 nm laser, blue channel). The cells (n = 50) 
were analyzed and the ratio intensities were averaged for each sample.  
Antimicrobial activity analysis. The S. aureus strains UAMS-1 and LAC were grown in tryptic 
soy broth (TSB) and diluted to an optical density (OD560) of 0.05, which corresponds to 1 × 107 
bacterial cells, using TSB supplemented with 2.5 mM CaCl2, which is required for the in vitro 
bactericidal activity of daptomycin. This suspension (180 µL) was placed in each well of a 
microtiter plate (1.8 × 106 CFU per well). Prior to irradiation, the nanoconstruct suspension for 
each experimental group was sonicated (Bransonic 2800; Branson) and vortexed for 5 s to ensure 
homogenous dispersion. the appropriate nanoconstruct (20 µL) was then added to each well 
giving a final volume of 200 µL and a final AuNC concentration of 0.4 nM, which corresponds 
to 2.4 × 1011 AuNCs per mL. Thus, each well contained 4.8×1010 AuNCs, which corresponds to 
a ratio of ~2.4×105 AuNCs per bacterial cell. For irradiated groups, the contents of each well 
were mixed thoroughly and a Breathe-Easy gas permeable sealing membrane (Diversified 
Biotech) was used to seal the microtiter plate prior to irradiation, thus preventing evaporation. 
Plates containing irradiated groups were placed on ice and each treatment well was irradiated for 
10 min by diode laser at 808 nm with a power of 0.75 W and a spot size of 0.30 cm2 covering the 
surface area of a well. Immediately following irradiation, the sealing membrane was removed, 
the contents of each well were mixed thoroughly by pipetting, and a 50 µL aliquot was removed 
for bacterial quantification. For non-irradiated groups, a 50 µL aliquot was removed immediately 
after mixing of culture and the appropriate nanoconstruct for bacterial quantification. After 
removal of aliquots with or without laser irradiation, plates were re-sealed and incubated at 37 ºC 
with constant shaking (115 rpm). After 24 h, sealing membranes were removed, the contents of 
each well were mixed by pipetting, and a 50 µL aliquot was removed for bacterial quantification. 
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Bacterial quantification was performed by serial dilution and plate counts to enumerate viable 
bacteria based on colony-forming units (CFU) per well. This method allowed for simultaneous 
assessment of PT-mediated killing (quantification of samples immediately following irradiation) 
and laser-assisted daptomycin release (quantification of samples after 24 h incubation). 
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Appendix A: Supporting Information 
Experimental Details 
Chemicals and materials Silver trifluoroacetate (AgTFA), sodium hydrogen sulfide (NaSH), 
hydrochloric acid (HCl, 99.999%), tetrachloroauric acid trihydrate (HAuCl4∙3H2O), sodium 
chloride (NaCl), and dopamine hydrochloride (99%) were purchased from Alfa Aesar. 
Poly(vinylpyrrolidone) (PVP, M.W.=55,000), phosphate-buffered saline (PBS), 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), tris(hydroxymethyl)aminomethane 
(Tris), citric acid, trisodium citrate dehydrate, bicine, and anti-protein A antibody (catalog 
number P3775) were purchased from Sigma Aldrich. Ethylene glycol (EG) was purchased from 
J.T. Baker. Acetone was purchased from EMD. Daptomycin was purchased from Cubist 
Pharmaceuticals. All experiments were performed using 18 MΩ H2O unless specified otherwise. 
All chemicals were used as received. 
Synthesis of Au nanocages (AuNCs). The AuNCs were synthesized by galvanic replacement 
reaction between Ag nanocubes and HAuCl4 as previously described.1 First, Ag nanocubes were 
synthesized by the polyol method.2 Briefly, 50 mL EG was added to a 250-mL round-bottom 
flask equipped with a stirring bar and placed in an oil bath at 150oC. After the temperature 
equilibrated (30~45 min), EG solutions of 0.6 mL of 3 mM NaHS, 5 mL of 3 mM HCl, 12.5 mL 
of PVP (0.25 g), and 4 mL of 282 mM AgTFA were sequentially added to the reaction flask. 
Once the LSPR peak reached ~440 nm (~35 min after addition of AgTFA), the reaction was 
quenched in an ice bath. Upon cooling, the product was collected by adding acetone to the 
reaction solution at a ratio of 5:1 and centrifuging at 7,000 rpm for 10 min. The resulting pellet 
was purified twice with H2O and collected by centrifugation at 15,000 rpm for 10 min, and 
resuspended in 10 mL of H2O for future use.  
To synthesize AuNCs, 10 mL of H2O was heated to boiling in a 50-mL round-bottom flask 
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equipped with a stirring bar. To the boiling liquid, 1 mL of the Ag nanocubes described above 
was added and subsequently 1 mM HAuCl4 was added using a syringe pump at a rate of 45 mL/h 
until the LSPR maximum was at 750 nm. The AuNCs were purified by saturated NaCl solution 
to remove by-product AgCl, washed 3 times by centrifugation at 15,000 rpm for 10 min, and 
resuspended in H2O at a concentration of 5 nM for future use.  
Synthesis of polydopamine-coated AuNCs (AuNC@PDA). AuNC@PDA were prepared by self-
polymerization of dopamine monomer on the surface of AuNCs under basic conditions in the 
presence of O2. Briefly, 3 mL of 5 nM AuNCs were diluted to 200 mL using Tris-buffered saline 
(TBS, 20 mM Tris and 100 mM NaCl, pH = 9) in a 250-mL, 3-neck, round-bottom flask. The 
reaction flask was briefly flushed with O2 and placed in a bath sonicator held at 4oC with ice. 
Dopamine hydrochloride (0.2 mmol, 36.0 mg) was added to the flask, the vessel was sealed 
under 1 atm O2, and the mixture was sonicated for 75 min until the LSPR had red-shifted ~50 
nm. After this reaction, the product was collected by centrifugation at 7,000 rpm for 10 min, 
washed with H2O twice and recovered by centrifugation at 14,000 rpm for 10 min at 4oC. The 
AuNC@PDA were resuspended in H2O at a concentration of 6 nM for characterization and 
future use.  
Loading of daptomycin. Various amounts of daptomycin were loaded to the AuNC@PDA under 
different conditions to prepare daptomycin-loaded AuNC@PDA (AuNC@DAP/PDA). Briefly, 1 
nM AuNC@PDA were incubated with 1 mg/mL of daptomycin (0.6 mM) in 10 mM citrate 
buffer (pH = 2.2 or 7.8) at various NaCl concentrations (0 mM, 150 mM, or 1 M). The reaction 
was allowed to stir overnight at 4oC in the dark. The product was collected, purified with PBS 
once and H2O 3 times, and re-collected by centrifugation at 14,000 rpm for 10 min to remove 
free daptomycin. The AuNC@DAP/PDA were resuspended in H2O at a concentration of 4 nM 
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AuNCs for characterization and future use. Prior to quantification of daptomycin concentration, 
AuNCs were digested by KCN to avoid interference. The dissociation constant (Kd) for 
daptomycin and AuNC@PDA in PBS was determined by Scatchard plot.  
Conjugation of anti-protein A antibody (anti-SPA). Anti-SPA was conjugated to the surface of 
AuNC@DAP/PDA through the N-terminal amine by Michael addition reaction to form anti-SPA 
conjugated AuNC@DAP/PDA nanoconstructs (AuNC@DAP/PDA-anti-SPA). Briefly, 
AuNC@DAP/PDA were dispersed in 1 mL of 10 mM bicene buffer (pH = 8.5) and 0.1 nmol of 
anti-SPA was added to the solution. The reaction was allowed to proceed at 4oC for 1 h. The 
nanoconstructs were collected and washed 3 times with PBS by centrifugation at 14,000 rpm for 
5 min at 4oC. The number of anti-SPA per nanoconstruct was determined by the use of the 
secondary antibody, fluorescein isothiocyanate-labeled IgG (FITC-IgG). The nanoconstructs 
were dispersed in PBS for future use.  
Characterization of nanoconstructs. Transmission electron microscopy (TEM) images were 
captured using a TEM microscope (JEOL 100cx) with an accelerating voltage of 100 kV. The 
hydrodynamic diameters and zeta potentials of nanoconstructs were determined using a dynamic 
light scattering instrument (Brookhaven ZetaPALS). The concentration of metals was 
determined using an atomic absorption (AA) spectrometer (GBC 932). UV-Vis spectra were 
taken on a UV-Vis spectrophotometer (Agilent Cary 50). Fluorescence spectra were recorded on 
a fluorimeter (Horiba FluoroLog3). Infra-red spectra were collected on Fourier Transform infra-
red spectrometer (FTIR, Bruker Tensor 27).  
Two-photon imaging. Cultures of the S. aureus strains UAMS-1, LAC, and their isogenic spa 
mutants were grown to an optical density (OD560) of 1.0 in tryptic soy broth (TSB), which 
corresponds to ~2×108 CFU/mL. This sample (40 µL) was applied to a glass microscope slide 
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demarcated with a hydrophobic pen and allowed to air dry. Bacteria were heat fixed before 
adding 90 uL of PBS and 10 uL of AuNC@PDA-anti-SPA or AuNC@PDA. After 30 min at 
room temperature, reagents were removed by soaking in PBS 3 times for 10 min each time. The 
slide was blotted dry before adding 100 uL of 40× diluted DAPI (purchased as NucBlue Fixed 
Cell ReadyProbe Reagent, Molecular Probes) in PBS and incubating for 10 min. This stain was 
removed and the slides washed by soaking in fresh PBS 3 times for 5 min each time. The slides 
were blotted dry, 10 uL of PBS was used as a mounting medium, and a #2 coverslip was applied 
and sealed with nail polish. Two-photon images were acquired using customized, four channel, 
resonant scanning multiphoton microscopy platform (Thorlabs, USA) and a 40× water 
immersion 0.8 NA objective (Nikon). Illumination was provided by a Mai Tai HP ultra-fast 
Ti:Sapphire laser (Spectra Physics). DAPI fluorescence was visualized using 10 mW excitation 
at 700 nm and collecting from blue (466/40) channel. AuNC luminescence were visualized using 
10 mW excitation at 800 nm and collecting from the red (607/70) channel. Images are the 
average of 200 frames and processed identically using ImageJ. The quantitative analysis was 
performed by comparing the ratio of the pixel intensity from AuNC image (800 nm laser, red 
channel) to the pixel intensity of the DAPI image (700 nm laser, blue channel). The cells (n = 50) 
were analyzed and the ratio intensities were averaged for each sample.  
Release of daptomycin. The release of daptomycin from the AuNC@DAPLo/PDA and 
AuNC@DAPHi/PDA was carried out at neutral pH under the near-infrared irradiation. Briefly, 
each construct was suspended in 200 µL PBS (pH = 7.4) at a concentration of 0.4 nM on ice. 
Samples were irradiated by an 808-nm diode laser at a power density of 1.66 W/cm2 for different 
periods of time up to 10 min. After irradiation, the samples were centrifuged briefly at 14,000 
rpm for 3 min at 4oC and the supernatants were collected. The concentration of daptomycin was 
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then analyzed by ultra-performance liquid chromatography (UPLC, Waters Acquity). As 
controls, a solution containing daptomycin and, if applicable, nanoconstructs digested with KCN, 
were also evaluated by UPLC.  Elution was performed using a mobile phase consisting of a 
gradient (90:10 to 10:90) of H2O and acetonitrile (1% trifluoroacetate) through a phenyl 
stationary phase (BEH phenyl, Acquity) at a flow rate of 0.2 mL/min with ultraviolet detection at 
262 nm. Daptomycin eluted after 3.5 min and peak integral was linear over the concentrations 
tested.  
Thermal curve assessment. The temperature measurement was performed under the same 
conditions described above for assessment of daptomycin release, with temperature changes as a 
function of time recorded by a thermal couple inserted into the 200 µL suspension or an infrared 
sensor .  
Western blot analysis. Relative amounts of extracellular protein A (eSpa) was assessed using 
standardized cell-free supernatants as previously described.3  Briefly, eSpa was detected by 
Western blot using rabbit anti-Protein A (Sigma Chemical Co., St. Louis, MO) at a 1:4000 
dilution as primary antibody. Secondary antibody was horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO). Blots were developed using 
SuperSignal West Femto Chemiluminescent Substrate kit (Thermo Fisher Scientific, Rockford, 
IL). 
Antimicrobial activity analysis. The S. aureus strains UAMS-1 and LAC were grown in tryptic 
soy broth (TSB) and diluted to an optical density (OD560) of 0.05, which corresponds to 1 × 107 
bacterial cells, using TSB supplemented with 2.5 mM CaCl2, which is required for the in vitro 
bactericidal activity of daptomycin. This suspension (180 µL) was placed in each well of a 
microtiter plate (1.8 × 106 CFU per well). Prior to irradiation, the nanoconstruct suspension for 
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each experimental group was sonicated (Bransonic 2800; Branson) and vortexed for 5 s to ensure 
homogenous dispersion. the appropriate nanoconstruct (20 µL) was then added to each well 
giving a final volume of 200 µL and a final AuNC concentration of 0.4 nM, which corresponds 
to 2.4 × 1011 AuNCs per mL. Thus, each well contained 4.8×1010 AuNCs, which corresponds to 
a ratio of ~2.4×105 AuNCs per bacterial cell. For irradiated groups, the contents of each well 
were mixed thoroughly and a Breathe-Easy gas permeable sealing membrane (Diversified 
Biotech) was used to seal the microtiter plate prior to irradiation, thus preventing evaporation. 
Plates containing irradiated groups were placed on ice and each treatment well was irradiated for 
10 min by diode laser at 808 nm with a power of 0.75 W and a spot size of 0.30 cm2 covering the 
surface area of a well. Immediately following irradiation, the sealing membrane was removed, 
the contents of each well were mixed thoroughly by pipetting, and a 50 µL aliquot was removed 
for bacterial quantification. For non-irradiated groups, a 50 µL aliquot was removed immediately 
after mixing of culture and the appropriate nanoconstruct for bacterial quantification. After 
removal of aliquots with or without laser irradiation, plates were re-sealed and incubated at 37 ºC 
with constant shaking (115 rpm). After 24 h, sealing membranes were removed, the contents of 
each well were mixed by pipetting, and a 50 µL aliquot was removed for bacterial quantification. 
Bacterial quantification was performed by serial dilution and plate counts to enumerate viable 
bacteria based on colony-forming units (CFU) per well. This method allowed for simultaneous 
assessment of PT-mediated killing (quantification of samples immediately following irradiation) 






Figure S1. (A) TEM image of AuNCs synthesized by galvanic replacement of Ag nanocubes 
with chloroauric acid; and (B) UV-Vis spectrum of the AuNC aqueous suspension corresponding 




Figure S2. Histogram of hydrodynamic diameter of aqueous suspensions measured by dynamic 





Figure S3. (A) UV-Vis spectroscopic monitoring of the reaction solution during self-
polymerization process of dopamine on the surface of AuNCs; (B) LSPR shift of AuNCs as a 
function of reaction time; (C) Absorbance change at 410 nm as a function of time with the red 





Figure S4. (A) Calibration curve of Dap concentration using UPLC; (B) UV-Vis spectra of 
AuNC@PDA-anti-SPA (blue), AuNC@DapLo/PDA-anti-SPA (green) and AuNC@DapHi/PDA-
anti-SPA (red); (C) Calibration curve of dye-labeled IgG using fluorometer; and (D) Scatchard 






Figure S5. Quantitative analysis of two-photon fluorescence images by pixel intensity ratio of 
AuNCs (red channel) to DAPI (blue channel) for each sample corresponding to the images in 





Figure S6. Western blot analysis of spa mutants. Supernatants from stationary phase cultures of 
the indicated strains were resolved by SDS-PAGE, transferred to nitrocellulose, and blotted with 
anti-Spa antibody. The boxed region indicates the molecular weight range expected of protein A 
(SPA). Although protein A is an LPXTG-anchored surface protein, supernatants were used for 
this experiment because it is also known to be released into the supernatant in amounts that 






Figure S7. (A) Temperature profile of 0.4 nM suspensions of the indicated AuNC formulations 
as a function of time of irradiation with an 808-nm diode laser at power density of 1.67 W/cm2.  
(B) Relative thermal sensitivity of UAMS-1 (U1) and LAC. Bacterial cells were suspended in 
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Chapter VI. Gold-Copper Alloyed Nanorods for Metal-catalyzed Organic Reactions: 
Implication of Surface Ligands on Nanoparticle-based Heterogeneous Catalysis* 
Abstract 
Recent advances in nanoparticle synthesis have created new potential avenues for aqueous 
catalysis of organic reactions. Morphological control of metal nanoparticles often involves the 
use of surface ligands, which in turn affect the catalytic activity of nanocatalysts. This Letter 
demonstrates that surface anchoring group, chain length, and configuration of the water-soluble, 
polymeric ligands influence the catalytic properties of alloyed AuCu3 nanorods for metal-
catalyzed organic reactions. Due to the binding affinity of the surface-anchoring groups, a thiol 
anchor was found to be detrimental the Au-catalyzed reduction of p-nitrophenol while the Cu-
catalyzed azide–alkyne cycloaddition was severely inhibited by amine anchors. Furthermore, the 
catalytic activity of nanorods increased with increased dimension of the ligands with the same 
anchoring group due to the reduction of graft density. Elevated temperature facilitates the 
mobility of surface ligands in benzonitrile hydration to benzamide, resulting in the enhancement 
of catalytic activity. This work highlights the paramount importance of surface ligand selection 
in the design of nanocatalysts for catalytic organic reactions. 
 




Metal nanoparticles have received considerable attention as heterogeneous catalysts in the past 
two decades due to their extremely large surface-to-volume ratio compared to their bulk 
counterparts.1 Uniform nanoparticle suspensions are considered as the bridge between traditional 
homogenous and heterogeneous catalysis. Nanoparticle catalysts have demonstrated the capacity 
to catalyze reactions in H2O, at relatively low temperatures, under normal atmosphere.2 These 
catalysts can be readily recovered by centrifugation, therefore they can be recycled. Numerous 
efforts have been made to synthesize metal nanoparticles with controllable size and shape which, 
in turn, tune their catalytic activity.3 In order to manipulate the morphology, surface ligands are 
deployed in the synthesis and the resultant nanoparticles are capped by a monolayer of these 
ligands. The binding affinity of these ligands to the surface plays an important role in the 
catalytic activity of the nanoparticles in heterogeneous catalysis because the reactant molecules 
are activated on the nanoparticle surface.4–6 
Ligand exchange is used as the first step in many phase transfer processes designed to retain 
surface activity of nanomaterials. In this Letter, we correlate the catalytic activities of aqueous, 
surface-capped Au–Cu alloyed nanorods to polymeric ligands with different functional groups, 
molecular weights, and configurations for organic reactions. This correlation allows us to choose 
and design surface ligand to retain and further enhance the catalytic activity of the nanoparticles. 
Coinage metals, such as Au and Cu, have been demonstrated for numerous catalytic processes.1 
Alloying Au and Cu enables synergy of their catalytic properties, and thus Au–Cu alloys are 
better catalysts than Au or Cu alone for many important reactions such as CO oxidation,7 
propene epoxidation,8 and benzyl alcohol oxidation.9 
Additionally, using these alloys can defray the cost of pure Au materials and reduce the 
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reactivity of Cu with air.10 The catalytic activity can be further altered by modifying the 
morphology of the nanoparticles. For example, we have demonstrated that the rod-shaped AuCu3 
nanoparticles are approximately ten-fold more active than spherical nanoparticles with the same 
composition and surface area.11 The AuCu3 nanoparticles absorb visible or near-infrared light, 
which may generate singlet oxygen,12 which could be used in an alternative approach for organic 
syntheses developed by Prof. Harry Wasserman,13 including bipyrrole aldehyde,14 an 
intermediate in the total synthesis of prodigiosenes.15,16 Herein, we use the AuCu3 nanorods 
(AuCu3NRs) as model catalysts to study the influence of surface ligands on their catalytic 
activity. Three metal-catalyzed reactions are chosen for this study: Au-catalyzed p-nitrophenol 
reduction, Cu-catalyzed alkyne–azide ‘click’ cycloaddition, and metal-catalyzed nitrile 
hydration, all of which are important reactions for the synthesis of intermediates in drug 
discovery. The binding affinity of polymeric ligands to Au and Cu surfaces is correlated to their 
catalytic activity for these three reactions. 
Results and Discussion 
The AuCu3NRs were synthesized by alkylamine reduction as previously described.11 Briefly, 
HAuCl4 was reduced at 140 °C for 20 min in tetradecylamine under protection of Ar to generate 
Au seed particles. The reaction temperature was increased to 210 °C and copper acetylacetonate 
(4:1 mol ratio Cu–Au) dissolved in oleylamine was injected. The reaction was allowed to 
proceed for another 20 min to form AuCu3NRs. Figure 1A shows the transmission electron 
microscopy (TEM) image of typical AuCu3NRs, having an average length of 25.0 ± 2.1 nm and 
diameter of 11.2 ± 1.0 nm, equal to an aspect ratio of ~2. The powder X-ray diffraction (XRD) 
pattern verified that the AuCu3NRs adopted face-centered-cubic (fcc) crystal structure, 
suggesting a random alloy of Au and Cu (Fig. 1B). The peaks at 42.1, 48.2, and 71.3 ° were 
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assigned to (1 1 1), (2 0 0), and (2 2 0) crystallographic planes of fcc structure. The composition 
(1:3 ratio Au to Cu) of the AuCu3NRs was confirmed by analyzing the most prominent peak of 
the (1 1 1) plane using Vegard’s law. Figure 1C shows the optical spectrum of the AuCu3NRs 
with an extinction peak at 670 nm. To obtain water-soluble catalysts, ligand exchange was 
performed in CHCl3, followed by transferring into aqueous solution using ethanol as a phase 
transfer intermediary.11,17 After phase transfer, the AuCu3NRs were well-dispersed in aqueous 
solution and there was little change in their optical spectra. The concentrations of Au and Cu 









Water-soluble polymers were used to replace the alkylamines capping the surface of the 
AuCu3NRs, yielding water-soluble catalysts. Table 1 lists the water-soluble polymers including 
linear poly(ethylene glycol) (PEG) and branched poly(ethyleneimine) (PEI). PEG (M.W. = 5000) 
terminated with amine (–NH2), thiol (–SH), and carboxylic acid (–COOH) functional groups 
were chosen for the study, named as PEG-NH2, PEG-SH, or PEG-COOH. The amine group has 
a high affinity to coordinate with Cu while the thiol group strongly interacts with Au surface. 
The carboxylic acid group loosely attaches to both Cu and Au surfaces. The effect of 
multidentate binding to the surface is compared using PEI which contains multiple amino 
groups. The influence of steric hindrance is studied using PEG and PEI with different molecular 
weights. To investigate the effects of capping-ligand effects on the catalytic properties, Au-
catalyzed p-nitrophenol reduction, Cu-catalyzed alkyne–azide ‘click’ cycloaddition, and metal-




Table 1. Summary of aqueous AuCu3NRs capped by different polymeric ligands 
AuCu3NR 
sample name 




PEG-NH2 poly(ethylene glycol) -NH2 5000 0.41 
PEG750 poly(ethylene glycol) -NH2 750 0.40 
PEG-SH poly(ethylene glycol) -SH 5000 0.46 
PEG-COOH poly(ethylene glycol) -COOH 5000 0.43 
PEI10000 poly(ethyleneimine) branched, -NH2 10000 0.55 
PEI600 poly(ethyleneimine) branched, -NH2 600 0.54 
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The NaBH4 reduction of p-nitrophenol (more accurately, p-nitrophenolate) is a well-studied 
model reaction for nanoparticle-based catalysis (Scheme 1).18 Compared to Cu, Au can catalyze 
the p-nitrophenol reduction more efficiently.19 The reduction process can be monitored by the 
loss of absorbance at 400 nm corresponding to the disappearance of p-nitrophenolate.19 The 
reaction proceeds through two steps: an induction period (t0) wherein the surface of the particle 
is reconstructed to activate the adsorbed reactant molecules and a catalytic period (kcat) where the 
reaction follows first-order kinetics with respect to p-nitrophenol concentration.20 In the absence 
of metal nanoparticles the reaction had not proceeded after 2 h incubation (Fig. S1). Table 2 lists 
the results derived from the UV–Vis spectroscopic analysis. Figure 2 shows the UV–Vis 
spectroscopic monitoring of the reaction process in the presence of ligand-capped AuCu3NRs. 
The induction period was found to be 3.7, 3.9, and 17.7 min for the PEG-NH2, PEG-COOH, and 
PEG-SH and the kcat (s-1) was determined to be 0.0048, 0.0033, and 0.0022, respectively, for 1 
ppm Au samples (catalyst loading 1% by Au atom). The strong binding between the thiol and Au 
prevents access of reactant molecules to the metal surface.6 As a result, the induction time is 
increased and the kcat reduces. On the other hand, the AuCu3NRs with weakly-bound PEG-NH2 
and PEG-COOH show much shorter induction times and larger catalytic rate constants than 




Scheme 1. Au-catalyzed p-nitrophenol reduction.  
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Table 2. Catalytic efficiency of ligand-capped AuCu3NRs for p-nitrophenol reduction 
Sample [Au] 
(ppm) 
kcat (s-1)a t0 (min)b 
PEG-NH2 1.0 0.0048 3.7 
PEG-COOH 1.0 0.0033 3.9 
PEG-SH 1.0 0.0022 17.7 
PEG-NH2 2.0 0.0101 0.9 
PEG750 2.0 0.0062 1.4 
PEI10000 2.0 0.0071 2.3 
PEI600 2.0 0.0064 2.0 
adetermined by taking the slope of the linear portion of ln(Abs0/Abs) 





Figure 2. Nitrophenol reduction catalyzed by (black) PEG-NH2, (green) PEG-COOH, and (blue) 
PEG-SH monitored as (A) absorbance at 400 nm, and (B) natural log of the ratio of absorbance 
at 400 nm at time = 0 and time = t. 
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Several different polymers with amine groups were used to investigate the effects of multidentate 
binding and steric hindrance, as shown in Figure 3. Both PEG750 and PEG-NH2 provide a 
single anchor to the AuCu3NR surface, while the PEIs allow multidentate binding to the metal 
surface. Using 2 ppm Au (2% catalyst loading) the induction times were 1.4 and 0.8 min and the 
kcat were 0.0062 and 0.0101 s-1 for PEG750 and PEG-NH2 capped AuCu3NRs, respectively. This 
discrepancy can be attributed to the increased graft density of shorter polymers relative to longer 
polymers,21 thereby inhibiting the access of reactants to active sites on the surface. The PEI-
capped AuCu3NRs showed induction times of 2.3 and 2.0 min and kcat of 0.0064 and 0.0071 s-1 
for PEI600 and PEI10000, respectively. One would expect that the multidentate binding ligands 
should greatly reduce the catalytic activity; however, the catalytic activity of PEI600-capped 
AuCu3NRs is comparable to that of PEG750-capped ones. Coincidently, it was found that a blue 
supernatant was recovered during the phase transfer process with PEIs, suggesting that Cu2+ ions 
had been released from the AuCu3NRs. The FAAS results confirmed the substantial increase in 
the mole fraction of Au and Cu in the AuCu3NRs while XRD pattern revealed the composition 
remained to be AuCu3. These data imply that the PEI-capped AuCu3NRs are covered by a skin 
of pure Au, which promotes the catalytic properties of the AuCu3NRs and compensates the 
detrimental effect of multidentate binding to the surface. The PEI etching of Cu from the 
AuCu3NRs is akin to the Tumbaga processing that Native Americans used to produce alloyed 
AuCu3 pots with a pure Au surface.22 Similar to the case of PEG, the catalytic activity increased 
with increased chain length, suggesting that the bulky PEI10000 configuration wrapping around 





Figure 3. Nitrophenol reduction catalyzed by (black) PEI10000, (red) PEI600, (blue) PEG-NH2, 
and (green) PEG750 monitored as (A) absorbance at 400 nm, and (B) natural log of the ratio of 
absorbance at 400 nm at time = 0 and time = t. 
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To further elucidate the surface ligand effects on the bimetallic catalysts, the catalytic activity of 
AuCu3NRs was investigated for the Cu-catalyzed ‘click’ reaction between benzylazide and 
phenylacetylene yielding a triazole (Scheme 2).23 Pure Cu nanoparticles have been demonstrated 
for this reaction in THF;24 however, the possibility of surface oxidation of the Cu nanoparticles 
could not be ruled out. This reaction has been demonstrated on the Au (1 1 1) surface, but the Au 
acts as a two-dimensional constraint rather than as a catalytic participator.25 In this study, the 
click reaction was carried out in 1:1 t-butanol–H2O at room temperature for 0.5, 2, and 18 h with 
1 equiv. phenylacetylene, 1.2 equiv benzylazide, 0.1 equiv sodium ascorbate, and 0.005 equiv. 
Cu (as AuCu3NR or CuCl, 0.5% catalyst loading). The product was isolated by extraction with 
dichloromethane and the conversion was quantified by 1H NMR by monitoring the loss of alkyne 
peak (2.9 ppm) and the emergence of the vinyl peak (7.65 ppm), as listed in Table S1. No 
reaction was observed in the absence of Cu-based catalysts. The conversion efficiencies of the 
different ligand-capped AuCu3NRs are included in Table 3. Comparable to the CuCl salt as a 
positive control catalyst, PEG-SH and PEG-COOH capped AuCu3NRs demonstrated nearly a 
complete conversion of phenylacetylene because the weak-ligand bound surface are accessible to 
the reactants. The amine terminated PEG750 capped AuCu3NRs only demonstrated 
approximately 50% conversion and PEG-NH2 capped AuCu3NRs showed almost no catalytic 
activity. This result indicates that the strong interaction between amines and Cu prevents 
successful adsorption of the reactants to the nanoparticle, thereby inhibiting the reactions. 
Surprisingly, both PEI750 and PEI10000, which contain numerous primary, secondary, and 
tertiary amines, did not seem to interfere with the catalytic process, suggesting that the leaching 
of Cu from AuCu3NR surface weakens the binding of branched PEI to the surface and makes it 
available for reactants to adsorb over a prolonged reaction time. Similar trends for the ligand 
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Scheme 2. Cu-catalyzed alkyne-azide ‘click’ cycloaddition 
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Table 3. Catalytic efficiency of ligand-capped AuCu3NRs for azide-alkyne cycloaddition 
Catalyst 0.5 h Conversiona 2 h Conversiona 18 h Conversiona 
No Catalyst <5 % <5 % <5 % 
CuCl 5 % 20 % >98 % 
PEG-NH2 <5 % <5 % 5 % 
PEG-750 <5 % 6 % 51 % 
PEG-SH <5 % 15 % >98 % 
PEG-COOH <5 % 11 % >98 % 
PEI10000 <5 % 16 % >98 % 
PEI600 6 % 19 % >98 % 




The binding affinity of ligand to the surface is weakened as the temperature increases. To study 
the temperature effects on the ligand binding, the metal-catalyzed hydration of benzonitrile to 
benzamide was investigated (Scheme 3).26 The reaction was run at both 75 °C and 95 °C and 
catalyzed using AuCu3NRs (0.5% catalyst loading by metal atom) capped by all six different 
ligands and results are listed in Table 4. The initial concentration of benzonitrile was 1 mg/mL 
(~9.3 mM) and ultra-performance liquid chromatography (UPLC) was used to quantify the 
conversion by monitoring absorbance at 254 nm as listed in Tables S2 and S3. In the absence of 
AuCu3NRs, no reaction took place at 75 °C and complete conversion from benzonitrile was 
observed at 95 °C after 24 h. Both of PEI600 and PEG750 capped AuCu3NRs showed the 
highest turnover frequency and greatest conversion at either temperature among all catalysts 
studied. The 5000 Da PEG-capped AuCu3NRs showed roughly similar, low catalytic activity, 
suggesting steric interference preventing access to the AuCu3NR surface to catalyze the reaction. 
The elevated temperature provides surface lability, which reduced the graft density of the 
ligands. At high temperatures, the PEI10000 showed similar activity to the small ligands (i.e., 
PEG750 and PEI600) because the elevated temperature aided surface lability and fluidity of the 
ligand coating. The turnover number was found to increase by two orders of magnitude at the 
elevated temperature. After 24 h at 75 °C in the presence of only ligands (1 mg/mL) without 
AuCu3NRs, no significant conversion was observed for linear polymers, while the branched 
ligands showed slight conversion (<5 %), suggesting that the presence of the metal particles 




Scheme 3. Metal-catalyzed nitrile hydration.  
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Table 4. Catalytic efficiency of AuCu3NRs for benzonitrile hydration 
Catalyst 24 h,  











No Catalyst  <2 % <2 % N/A 20.7 % 1380 
PEG-NH2 <2 % 3.1 % 14.5 % 121 26.7 % 1780 
PEG750 <2 % 8.6 % 25.0 % 209 40.0 % 2670 
PEG-SH <2 % 2.4 % 10.1 % 84 23.1 % 1540 
PEG-COOH < 2 % <2% 12.5 % 104 21.2 % 1420 
PEI10000 3.0 % 3.0% 15.1 % 180 39.6 % 2640 
PEI600 4.6 % 6.5 % 21.7 % 126 43.3 % 2890 
aControls performed without AuCu3NRs using 1 mg/mL ligand concentration. 
bConversion determined by UPLC monitoring 254 nm. Reaction proceeded according to Scheme 
3 with 9.3 mM benzonitrile and 0.5 % catalyst loading. 
cTurnover frequency calculated based on 24 h incubation. 





In summary, we have demonstrated the effects of surface ligands on the catalytic properties of 
alloyed AuCu3NRs. The surface anchoring group, chain length and configuration of the water-
soluble, polymeric ligands were found to affect the catalytic properties of the nanoparticles. The 
Au-catalyzed reduction of p-nitrophenol was found to be detrimentally affected by thiol anchors, 
presumably due to the strength of the Au–thiol bond. In contrast, the Cu-catalyzed azide–alkyne 
cycloaddition was severely inhibited by amine functional groups because of the strong 
interaction between amine and Cu. Additionally, smaller ligands were found to have reduced 
catalytic activity relative to larger ligands owing to the decrease of graft density. From 
benzonitrile hydration to benzamide, elevated temperature was found to increase the mobility of 
ligands and result in the enhancement of catalytic activity of the ligand-capped nanocatalysts. 
This work reveals the potential of AuCu3NRs for a variety of catalytic organic reactions, yet 
underscores the paramount importance of surface ligand selection in the design of nanocatalysts. 
Acknowledgements 
This work was funded in part by Ralph E. Powe Junior Faculty Enhancement Award, Robert C. 
and Sandra Connor Endowed Faculty Fellowship, and startup funds by University of Arkansas to 
J.C. The authors thank Prof. N. Zheng and Dr. M. Govindarajan for helpful discussions and Prof. 
H. Wasserman for instilling a love of science, education, and inquiry. 
References  
1. Yan, N.; Xiao, C.; Kou, Y. Coord. Chem. Rev. 2010, 254, 1179–1218. 
2. Polshettiwar, V.; Varma, R. S. Green Chem. 2010, 12, 743–754. 
3. Wang, D.; Li, Y. Adv. Mater. 2011, 23, 1044–1060. 
4. Schrinner, M.; Ballauff, M.; Talmon, Y.; Kauffmann, Y.; Thun, J.; Möller, M.; Breu, J. 
Science 2009, 323, 617–620. 
211 
 
5. Coppage, R.; Slocik, J. M.; Sethi, M.; Pacardo, D. B.; Naik, R. R.; Knecht, M. R. Angew. 
Chem., Int. Ed. 2010, 49, 3767–3770. 
6. Biswas, M.; Dinda, E.; Rashid, M. H.; Mandal, T. K. J. Colloid Interface Sci. 2012, 368, 77–
85. 
7. Kameoka, S.; Tsai, A. P. Catal. Lett. 2008, 121, 337–341. 
8. Chimentão, R. J.; Medina, F.; Fierro, J. L. G.; Llorca, J.; Sueiras, J. E.; Cesteros, Y.; Salagre, 
P. J. Mol. Catal. A: Chem. 2007, 274, 159–168. 
9. Della Pina, C.; Falletta, E.; Rossi, M. J. Catal. 2008, 260, 384–386. 
10. Bracey, C. L.; Ellis, P. R.; Hutchings, G. J. Chem. Soc. Rev. 2009, 38, 2231–2243. 
11. Chen, S.; Jenkins, S. V.; Tao, J.; Zhu, Y.; Chen, J. J. Phys. Chem. C 2013, 117, 8924– 8932. 
12. Vankayala, R.; Sagadevan, A.; Vijayaraghvan, R.; Kuo, C.-L.; Hwang, K. C. Angew. Chem., 
Int. Ed. 2011, 50, 10640–10644. 
13. Wasserman, H. H.; Ives, J. L. Tetrahedron 1981, 37, 1825–1852. 
14. Wasserman, H. H.; Petersen, A. K.; Xia, M.; Wang, J. Tetrahedron Lett. 1999, 40, 7587–
7589. 
15. Wasserman, H. H.; McKeon, J. E.; Smith, L.; Forgione, P. J. Am. Chem. Soc. 1960, 82, 506–
507. 
16. Jenkins, S.; Incarvito, C. D.; Parr, J.; Wasserman, H. H. CrystEngComm 2009, 11, 242–245. 
17. Yang, J.; Sargent, E.; Kelley, S.; Ying, J. Y. Nat. Mater. 2009, 8, 683–689. 
18. Herves, P.; Perez-Lorenzo, M.; Liz-Marzan, L. M.; Dzubiella, J.; Lu, Y.; Ballauff, M. Chem. 
Soc. Rev. 2012, 41, 5577–5587. 
19. Pozun, Z. D.; Rodenbusch, S. E.; Keller, E.; Tran, K.; Tang, W.; Stevenson, K. J.; 
Henkelman, G. J. Phys. Chem. C 2013, 117, 7598–7604.  
20. Gu, S.; Wunder, S.; Lu, Y.; Ballauff, M.; Fenger, R.; Rademann, K.; Jaquet, B.; Zaccone, A. 
J. Phys. Chem. C 2014, 118, 18618–18625. 
21. Xia, X.; Yang, M.; Zheng, Y.; Li, Q.; Chen, J.; Xia, Y. ACS Nano 2012, 6, 512–522. 
22. Guisbiers, G.; Mejia-Rosales, S.; Khanal, S.; Ruiz-Zepeda, F.; Whetten, R. L.; José- 
Yacaman, M. Nano Lett. 2014, 14, 6718–6726. 
23. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int. Ed. 2001, 40, 2004–2021. 
24. Alonso, F.; Moglie, Y.; Radivoy, G.; Yus, M. Tetrahedron Lett. 2009, 50, 2358–2362. 
212 
 
25. Díaz Arado, O.; Mönig, H.; Wagner, H.; Franke, J.-H.; Langewisch, G.; Held, P. A.; Studer, 
A.; Fuchs, H. ACS Nano 2013, 7, 8509–8515. 





Appendix A: Supporting Information 
Materials and Methods 
Chemicals 
Tetrachloroauric acid trihydrate (HAuCl4∙3H2O), copper acetoacetonate (Cu(acac)2), oleylamine 
(70%), branched poly(ethyleneimine) (m.w. 10,000, PEI10000), branched poly(ethyleneimine) 
(m.w. 600, PEI600), sodium borohydride (NaBH4), benzonitrile, benzylbromide, sodium 
ascorbate, trifluoroacetic acid, and dimethylsulfoxide (DMSO) were purchased from Alfa Aesar. 
Choloroform (CHCl3), dichloromethane, diethyl ether, hexanes, toluene, acetonitrile, and t-
butanol were purchased from EMD. Sodium azide (NaN3), methoxypolyethyleneglycol 5000 
acetic acid (m.w. 5000, PEG-COOH), poly(ethylene glycol) monomethyl ether thiol (m.w. 5000, 
PEG-SH), and phenylacetylene were purchased from Sigma Aldrich. Methoxypolyethylene 
glycol amine (m.w. 5000, PEG-NH2), O-(2-aminoethyl)-O’-methylpolyethylene glycol (m.w. 
750, PEG750), and p-nitrophenol were purchased from Fluka. Tetradecylamine was purchased 
from TCI. Octadecylamine was purchased from Acros. Ethanol (EtOH, 200 proof) was 
purchased from Koptec. Deuterated chloroform (CDCl3) was purchased from Cambridge Isotope 
Labs. Ultrapure H2O (18 MΩ) generated with an Elga PurelabUltra was used in all experiments. 
All chemicals were used as received. 
Synthesis of AuCu3 Nanorods (AuCu3NRs) 
To a 25 mL 3-neck round-bottom flask, 17.9 mg HAuCl4∙3H2O was added directly, followed by 
addition of 2.1 g tetradecylamine and 2.7 g octadecylamine. The flask was placed on a heating 
mantle at 80 °C with magnetic stirring and purged with Ar for 5 min. The temperature was then 
increased to 140 °C and the reaction allowed to proceed for 20 min. In a separate vial, 47.6 mg 
Cu(acac)2 was added and dissolved in 2 ml oleylamine. The reaction temperature was increased 
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to 210 °C and the Cu precursor solution was quickly injected. The reaction was allowed to 
proceed for an additional 20 min. The reaction was removed from heat and allowed to cool. Once 
the temperature had reached ~120 °C, the reaction mixture was separated into two 2 dr. vials, 
and the vials were then filled with toluene. The mixture was centrifuged at 3,300 g for 2 min and 
the supernatant removed quickly. The pellet was redispersed in ~0.1 mL toluene via sonication, 
and the remaining volume of the vial was filled with EtOH, and centrifuged for 3 min at 3,300 g. 
The AuCu3NRs were redispersed in toluene, washed with ethanol, and centrifuged 3 additional 
times. The product was finally dispersed in 4 mL toluene.  
Phase Transfer of AuCu3NRs 
To a 20 mL scintillation vial, 10 mg of ligand (see Table 2 in main text) was added and 
dissolved in 10 mL CHCl3. This solution was placed in an ice bath under magnetic stirring. To 
this solution, 0.5 mL of AuCu3NRs in toluene was added, and the ligand exchange was allowed 
to proceed overnight in the dark. The samples were then diluted with 5 mL hexanes and 
centrifuged for 5 min at 7,000 RPM. The supernatant was removed and the particles redispersed 
in 3 mL EtOH via sonication. Particles were then centrifuged at 14,000 RPM for 10 min at 20 
°C. The supernatant was discarded and the particles were redispersed in 3 mL H2O. The particles 
were then centrifuged and redispersed in H2O three times, being dispersed in a final volume of 
0.5 mL. 
Nitrophenol Reduction 
A stock solution of 7 mM p-nitrophenol was prepared using H2O. This solution was then diluted 
120 fold in H2O and degassed under vacuum for 2 h. A solution of 15.8 mg/mL NaBH4 was 
prepared fresh and stored in an ice bath. Into a quartz cuvette, 2 mL of the nitrophenol solution 
was added followed by addition of 100 μL NaBH4, which resulted in a change from clear to 
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yellow, indicating formation of the nitrophenolate anion. The absorbance at 400 nm of this 
solution was ~1.2, and stable for several hours (Fig. S1). To this solution, AuCu3NRs were 
added to a final concentration of 1 or 2 ppm Au. The AuCu3NRs were diluted prior to addition, 
so that 200 μL was added to the solution, dropping the absorbance to ~1.1. Addition of the 
catalyst was defined as time 0 s. The reaction progress was monitored via absorbance at 400 nm, 
with data points taken every 1 s. The reaction was allowed to proceed until the absorbance had 
dropped below 0.2.  
Azide-Alkyne Cycloaddition 
Benzylazide was prepared by SN2 reaction between NaN3 (11 mmol) and benzylbromide (10 
mmol) in 20 mL DMSO. The reaction was allowed to proceed overnight at room temperature 
with vigorous stirring. Then 20 mL H2O was added and the product was extracted three times 
with 95:5 diethyl ether: hexane. The product was washed twice with H2O, once with brine, dried 
over Na2SO4, purified on a silica column, and collected via rotary evaporator. The neat IR of the 
resulting oil confirmed the presence of azide (2100 cm-1). For the alkyne-azide cycloaddition, 
phenylacetylene was dissolved in 1:1 H2O:t-butanol. To this solution, 1.2 eq. benzylazide, and 
0.1 eq. sodium ascorbate was added. This solution was then dispersed in 1 dr. vials containing 
stir bars. To this, AuCu3NRs were added to a final Cu concentration of 0.5 % catalyst loading 
(31 ppm Cu). The reaction was allowed to proceed with magnetic stirring overnight. The reaction 
mixture was extracted with dichloromethane, dried, and collected under rotary evaporation. The 
resulting sample was then dispersed in 1 mL CDCl3 and 1H NMR spectra were acquired. The 
conversion was determined by comparing the integral of the singlet acetylene peak (2.9 ppm) 




Benzonitrile was dissolved in H2O at a concentration of 1 mg/mL. A total of 1 mL of this 
solution was added to 1 dr. vials and AuCu3NRs were added to a final concentration of 47 μM 
metal atoms (0.5 % catalyst loading). The reaction was then allowed to incubate at 75 °C or 95 
°C. Aliquots were taken after 3 h and 24 h on heat. The aliquots were centrifuged for 10 min at 
20 °C and 14,000 RPM to sediment the particles. The supernatant was removed and analyzed by 
UPLC. UPLC measurements were performed using a C18 column, The mobile phase was a 
gradient between 90:10 to 60:40 H2O:acetonitrile (0.1% trifluoroacetic acid) with a flow rate of 
0.1 mL/min. Relative peak areas based on absorbance at 254 nm was used to determine 





Table S1. NMR Peak areas following azide-alkyne cycloaddition 
 
Time (h) Integral at 
2.9 ppma 
Integral at 
















































































































aPeak corresponding to alkynyl proton in phenylacetylene 
bPeak corresponding to vinyl proton in the product, defined as having an area of 1. 
cCalculated as (integral at 7.6 ppm)/(total area) 





















after 24 h 
No Catalyst 25050386 <50000 <0.02 24966032 <50000 <0.02 
PEG-NH2 12603218 409357 0.031 7278057 1238610 0.145 
PEG750 8804162 828996 0.086 4137633 1380175 0.250 
PEG-SH 17635751 442479 0.024 13707896 1533068 0.101 
PEG-COOH 8241617 <50000 <0.02 9346510 1337964 0.125 
PEI10000 8443388 257259 0.030 6642599 1179692 0.151 
PEI600 6577224 455784 0.065 4367036 1206915 0.217 
PEG-NH2d    34230875 226339 <0.02 
PEG750 d    65398610 1225891 <0.02 
PEG-SH d    39334888 599548 <0.02 
PEG-COOH d    36421496 648182 <0.02 
PEI10000 d    52874798 1575178 0.029 
PEI600 d    38560311 1869462 0.046 
aRetention time corresponding to benzonitrile 
bRetention time corresponding to benzamide 
cCalculated as (Area at 1.4 min)/(Total peak area) 





















after 24 h 
No Catalyst 9860902 2575553 0.207 <50000 2793647 >0.98 
PEG-NH2 2793647 1015591 0.267 <50000 12654549 >0.98 
PEG750 4569382 3045214 0.400 <50000 7363029 >0.98 
PEG-SH 7981371 2400009 0.231 <50000 12550753 >0.98 
PEG-COOH 7737616 2085718 0.212 <50000 15718987 >0.98 
PEI10000 3403694 2229391 0.396 <50000 11141310 >0.98 
PEI600 3718736 2838742 0.433 <50000 11141310 >0.98 
aRetention time corresponding to benzonitrile 
bRetention time corresponding to benzamide 




Figure S1. Absorbance at 400 nm over time for NaBH4 reduction of p-nitrophenol without 




Chapter VII. Conclusion 
The surface of metal nanoparticles dictates much of its biological response. Changes to the 
surface can affect its pharmacokinetic profile. Additionally, the surface can be used to load drugs 
and targeted delivery to tumors or microbial infections and the surface can be used as a catalyst 
for organic reactions under extremely mild conditions.  
A major surface consideration is the agglomeration status of nanoparticles in vivo. Blood is an 
extremely complex fluid, and it can induce nanoparticle agglomeration, which may induce 
significant changes in the toxicity and biodistribution of these materials. These changes 
introduce complications to any regulatory mechanisms that will be implemented to deal with 
nanomedicine. Toward this end, Au nanoparticles were synthesized and agglomerated to varying 
degrees. These particles and agglomerates were introduced to whole blood. Darkfield 
microscopy with hyperspectral imaging was used to distinguish between the primary particles 
and agglomerates with minimal samples preparation based on their scattering spectra. 
Additionally, single particle ICP-MS was developed as a complementary method to further 
distinguish particles and agglomerates. These developments represent an important step toward 
the clinical application of nanomaterials, but additional research needs to be performed. 
Specifically, application of these methods to cells will further advance the ability to characterize 
nanomedicines. For these studies, it will be important to investigate a wide range of cell lines, 
the rapid nature of the methods developed here will facilitate the broad investigation of nano-bio 
interactions. Additionally, extraction and characterization of materials following in vivo 
injection, using methods such as these, will be an important step toward the full application of 
these materials.  
 One potential application of noble metal nanomaterials is their use as a drug delivery vehicle for 
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photodynamic therapy of tumors. A photosensitizer was loaded into the PEG coating of Au 
nanocages. The PEG surface coating increased the systems biocompatibility and created an area 
of reduced polarity that could be used to load the extremely hydrophobic photosensitizer. This 
conjugate was tested in mice against implanted tumors, and was found to be more effective than 
the free drug. Ultimately, the conjugate accumulated more efficiently in the tumor than the free 
drug. The drug was progressively unloaded into the tumor interstitium by albumin, and some of 
the drug presumably became embedded in cell membranes. Laser activation of the 
photosensitizer was also found to generate more therapeutic singlet oxygen in the presence of 
nanocages. Photoacoustic tomography was also used to visualize accumulation of the conjugate 
in the tumor site, to better enable guidance of the irradiation. The surface of the conjugate was 
further modified; charge and steric hindrance were used to adjust the release rate of these 
conjugates in a model blood environment. Irradiation was also shown to increase the solution 
temperature and facilitate controllable release of the drug.  
The recent rise in antibiotic-resistant infections has created a growing need for nontraditional 
antimicrobial therapy. Toward this end, daptomycin was loaded into polydopamine coated Au 
nanocages. Photothermal heating was used to release the antibiotic from the construct. After 
loading, an antibody to unique Staphylococcal membrane proteins was conjugated to the surface. 
This construct was shown to bind to both a methicillin resistant and methicillin sensitive S. 
Aureus strain. Incubation of these constructs with either strain, followed by laser irradiation 
demonstrated complete elimination of live bacteria in planktonic culture, which was attributed to 
a synergistic photothermal and chemotherapeutic effect. In the absence of irradiation, little 
difference was observed relative to the negative control. A nontraditional construct such as this 
presents a possible solution to the growing crisis of antibiotic resistance. Several important 
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studies still need to be performed. Most important, the construct must be tested in a biofilm 
model, as biofilms present a significant impediment to antimicrobial therapy relative to 
planktonic cultures. Additionally, optimization of the construct has yet to be accomplished; 
specifically the best antibiotic to use and the targeting ligand has yet to be determined. Further 
conclusive investigation into the polymer’s composition also needs to be performed.  
Surface modifications have made possible the targeted delivery of both hydrophobic and 
hydrophilic drug molecules. The nanoparticle surface can also be extremely catalytically active. 
In theory, the surface can also be used to activate prodrugs in situ. Toward this end, the catalytic 
properties of AuCu3 nanorods were investigated following changes of the surface ligands. Au-
catalyzed reactions were significantly inhibited by thiol anchoring groups, while Cu-catalyzed 
reactions were inhibited by primary amine anchoring groups. The selection of ligand on the 
nanoparticle surface is an important consideration for the design of novel nanoparticle catalysts. 
Further work in this area will include the development of optimal prodrugs for in situ catalysis. 
Additionally, preliminary data suggests the LSPR can increase the surface lability of ligands, 
which may impart controllable catalytic properties to the surface of these types of particles.  
Noble metal nanostructures possess great biomedical potential. There are major concerns that 
much be addressed prior to their implementation, particularly full characterization of these 
systems following injection into an organism. They also have great potential as drug delivery 
vehicles – they can be used to deliver hydrophobic drugs to tumors and hydrophilic drugs to 
bacterial infections. The surface can also be theoretically used to catalyze reactions at the target 
site. Further investigation must be performed to optimize these systems to make the least toxic 
and most effective theranostics agent possible. These materials, however, have the potential to 
enable new and significantly more effective therapeutic and diagnostic modalities.  
